
















The Dissertation Committee for Marta Sans Escofet Certifies that this is the 
approved version of the following Dissertation: 
 
Advancements in Ambient Ionization Mass Spectrometry Towards 

























Advancements in Ambient Ionization Mass Spectrometry Towards 









Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
Doctor of Philosophy 
 
 








I am extremely grateful for all the opportunities and support I have received during 
graduate school. It has been a truly exciting and enlightening experience, and I owe that to 
everyone who has been with me throughout this journey. First of all, I would like to thank 
my parents, Ramon and Joana, and my sister Mireia for always being my number one fans. 
Mom and dad, staying close to you despite being 5,000 miles apart has been a source of 
strength for me every day. Thank you for always being there during my good and bad 
moments and for your advice and words of encouragement. Your relationship inspires me, 
I admire everything you have accomplished together for our family with all your hard work. 
Thank you for teaching me the importance of enjoying everything you do and to live life 
at the fullest. Love you and miss you very much. To my sister Mireia, thank you for always 
believing in me and for being my first teacher when I was still your little baby sister. Thank 
you for making me an auntie to the cutest little boy, Biel. Receiving your pictures and 
videos with him always puts a smile on my face and lightens up my days. I have always 
admired how passionate you are about everything that you do, you have the biggest heart 
in the world, and I love you so very much. To the rest of my family, my grandparents, 
cousins, aunts, and uncles, thank you for all your support and for following my American 
adventures, I love you all. To my 95-year-old grandparent, Paco, thank you for teaching 
me the importance of diligent work from a young age. “Voluntat i constància” (“will and 
persistence”) are your two favorite words. You are the definition of resilience. Your desire 
to continue to learn new things every day is an inspiration to me and many others. Thank 
you for always keeping an interest in everything I do. I admire and love you so much. To 
my childhood friends from home, after all these years growing up together you have 
 vi 
become an extension of my family, I miss and love you all. To Rebe and Claudia, thank 
you sharing my passion for science, for coming to visit, and for bringing with you a piece 
of home. I am so thankful we got to spend last year on the same side of the ocean again 
and share more adventures together. Claudia, I love sharing the PhD life with you, and I 
hope we get to continue our Thanksgiving tradition for many more years. I love you both 
dearly.   
To my graduate advisor and mentor, Professor Livia S. Eberlin, I will never be able 
to thank you enough for everything you have done for me. These past four and a half years 
have gone by so quickly and I have enjoyed them very much. You have had such a positive 
impact on my PhD experience and my development as a scientist; thank you for believing 
in me and always offering your support and guidance. It has been a pleasure to accompany 
you during the beginning of your career as a professor and to witness all the great things 
you have already accomplished with your hard work and dedication. I have learned so 
much from you both professionally and personally and I am so grateful to have you in my 
life. Your commitment and love to your family is inspiring and I feel empowered having 
someone like you to look up to during my future life and career endeavors. I hope that I 
can continue to represent everything you have taught me while I become an independent 
scientist, and that one day I can give it all back to future generations. Thank you, Livia! 
To everyone in the Eberlin lab, I feel incredibly lucky to have gotten the chance to 
share this journey with you all, past and current members, new and older ones. I don’t think 
I will ever find such a welcoming and nice environment to come and work in every day. I 
will miss our daily lunch sessions so much! To Jialing, thank you for everything you have 
taught me and for all your help during my graduate school career. Thank you for always 
taking care of me and treating me like your little sister, I appreciate our relationship very 
much. Clara, I am so thankful that I got to share my graduate experience with you. We 
 vii 
have been together since the first semester, and I will really miss seeing you every day. 
Thank you for always making me laugh, for sharing all your stories with me and for 
listening to mine. I am very proud of everything you have accomplished and cannot wait 
to see what comes next for you; it is going to be awesome. To Alena, Kyana, and Rachel, 
thank you. We have shared so much together; I have seen you go from first year graduate 
students to the amazing scientists you have now become, which makes me feel so proud! 
Thank you for always being there for me. To Anna and Mike, thank you for being the best 
office buddies, you both are hilarious, and I appreciate you so much. Anna, thank you for 
all your help with experiments and data analyses (and for the emotional support), could not 
have done all those droplet images without you! Mike, I will miss our sandwich and taco 
runs for lunch! Mary, my little editor, thank you so much for all your help and for always 
being so kind. To Abby, thank you for your support and honesty, and for all the hugs. 
Sydney, thank you for your positive energy even in the stressful moments, like the once  
we have been experiencing lately! Monica, thank you for being the sweetest person and for 
all your hard work on the MADI project. Keep it up! You will do so great. To Sunil, thank 
you for being such a great and fast learner and for all your great work this past year. To the 
newer members, Praj, Ashish, Meredith, it has been great to spend some time with you and 
I wish you all the best. I would also like to acknowledge John, the other OG! Thank you 
for all your help and productive work all these years, you are such a genius but most 
importantly a great person as well. And of course, thank you to the irreplaceable Angie! 
Thank you for making even the most complicated problems seem easy to solve, and for 
your super positive and vibrant energy. Thank you to the best lab ever, I will miss you all 
very much. 
I have also been very fortunate to have met some great people in the chemistry 
department, my fellow fifth year graduate students, my “bunch of nerds”. I am so glad we 
 viii 
got to share graduate school together and thank you for making it more fun. To Olja, my 
roomie, thank you for being such a loyal friend and for always being there for me. Thank 
you for understanding and sharing my struggles being away and so far from home. I miss 
you already! To Michelle, thank you for being so sweet and for always being ready to have 
fun and unwind. To Josh, Mason, Ryan, Dylan, Jason, you guys are the best and I will miss 
you all! I hope we can all stay in touch and wish you all the best.  
I would also like to thank my committee members for their time and support. Prof. 
Brodbelt, thank you for your guidance and assistance. I really appreciate the relationship 
we have developed throughout these years, and I will miss our tennis sessions! To Prof. 
Tishirani, it has been such an honor to get to collaborate with you and I really appreciate 
you agreeing to participate as a member of my committee. Thank you for being so kind 
and for all your help with our work. To Prof. Crooks, thank you for your time and for being 
so supportive of our group and research, I really appreciate it. I am also very grateful for 
all the great administration and resources at the College of Natural Sciences and the 
department of Chemistry at UT. Betsy Hamblen, thank you for being the best department 
mom and for always helping us get through anything! You are so kind. To Po-Tsan Ku, 
thank you for helping me navigate through the job finding process and for always greeting 
me with encouragement and smiles. To my great collaborators, Bryan Wygant and Prof. 
Mullins, thank you very much for your help! Bryan, thank you for introducing me to Stella 
and for all the hard work that you have put in that project. To Tim Hooper, thank you so 
much for making a lot of our experiments possible with all your hard work developing 
anything and everything that we ask! And thank you for always being so nice and cheerful.  
One of the highlights of my doctoral work has been getting to collaborate with great 
scientists and clinicians at Baylor College of Medicine and at the MD Anderson Cancer 
Research Center and to witness firsthand the excellent work they do every day. To Dr. 
 ix 
Sood, Dr. Liu, Dr. Suliburk, Dr. Carter, among others, thank you so much for all your help 
and guidance with our projects. I have learned so much working with all of you and I am 
extremely grateful for that.  
I would also like to express my gratitude to the funding agencies that have 
supported the work described in this dissertation, the National Institute of Health, the 
National Cancer Institute, the Cancer Prevention and Research Institute of Texas and the 
Welch Foundation. I am also grateful and honored to have received the Excellence in 
Research award from the department of Chemistry and the University Graduate Continuing 
Fellowship from the Office of Graduate Studies at UT.  
And finally, I would like to thank my fiancé, Oscar, for always supporting my 
career aspirations and believing I can do it all. Thank you for following me to Austin, for 
listening to my sciency spiels and being curious about my research, and for always having 
the best advice. You are my rock, your words of encouragements throughout this journey 





Advancements in Ambient Ionization Mass Spectrometry Towards 
Improved Ovarian Cancer Research and Diagnosis 
 
Marta Sans Escofet, PhD 
The University of Texas at Austin, 2020 
 
Supervisor:  Livia Schiavinato Eberlin 
 
Ovarian cancer is a highly aggressive disease accounting for the majority of deaths 
from gynecological malignancies. Investigating the molecular mechanisms driving disease 
development and progression can improve early detection and drive the introduction of 
novel treatment strategies to ameliorate patient outcomes. Enhancing the accuracy and 
efficiency of ovarian cancer surgeries by introducing molecular information to rapidly 
assess tissue samples and guide cancer excision could also offer significant benefits to the 
management of ovarian cancer. Ambient ionization mass spectrometry (MS) methods are 
capable of obtaining biomolecule information directly from tissue samples with minimal 
sample preparation requirements and experimental simplicity, providing a suitable 
platform to conduct these investigations. Desorption electrospray ionization (DESI) was 
introduced in 2004 as the first ambient ionization MS technique and has been widely 
applied to investigate healthy and cancerous human tissue sections towards identifying 
potential cancer molecular markers and developing predictive statistical models towards 
improved cancer diagnosis. Alternative ambient ionization methods utilizing direct liquid 
extraction-based mechanisms have also been developed to improve the analytical 
 xi 
capabilities of ambient ionization MS and expand applications in tissue analysis and cancer 
diagnosis. Overall, this dissertation presents the application and development of ambient 
ionization MS methods for ovarian cancer research and improved diagnostics. First, the 
use of DESI-MS to distinguish between malignant and borderline ovarian tumors, as well 
as determine metabolic markers associated with disease aggressiveness is described. Going 
beyond cancer diagnosis, we next apply DESI-MS to identify trends in metabolic 
composition resulting from the expression of the fatty acid binding protein (FABP4) gene, 
a molecular determinant of ovarian cancer metastasis and residual disease post-surgery. An 
alternative liquid extraction-based ambient ionization MS approach is also described in this 
dissertation to improve spatial control in MS imaging and profiling applications from 
biological tissue sections. The capabilities of this method are tested with various biological 
samples, including ovarian cancer tissue. Finally, we discuss the development of an 
ambient MS technology, the MasSpec Pen, envisioned for nondestructive, rapid, ex vivo 
and in vivo assessment of surgical specimens. We demonstrate the capabilities of this 
system to provide accurate diagnoses from ovarian fresh-frozen specimens ex vivo across 
different sample sets, utilizing various healthy and ovarian cancer tissue types and mass 
spectrometry platforms.  
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Chapter 1: Introduction 
AMBIENT IONIZATION MASS SPECTROMETRY FOR DIRECT TISSUE ANALYSIS AND 
IMPROVED CANCER DIAGNOSIS: FROM BIOMEDICAL RESEARCH TO INTRAOPERATIVE USE 
The powerful capabilities of mass spectrometry (MS) for biomolecule analysis have 
transformed bioanalytical and biomedical research, unwrapping new opportunities in 
biomarker discovery and cancer diagnostics. The development of electrospray ionization 
(ESI) and matrix assisted laser desorption ionization (MALDI) in the early 90’s 
revolutionized the use of MS by facilitating the characterization of intact biomolecules with 
improved analytical performance (1-3). MALDI-MS analyses also provided the capability 
to desorb and ionize analytes from a solid-state sample surface, allowing the investigation 
of heterogenous environments at both cellular and molecular levels directly from tissue 
sections, and driving the field towards molecular imaging applications with MS (4,5). 
Combining the rich molecular and spatial information obtained from tissue MS imaging 
with advanced data modeling and statistics tools has since become an incredibly powerful 
approach to investigate cancer pathogenesis, identify potential molecular markers, and 
develop molecular classifiers for improved cancer diagnosis (6,7). With the introduction 
of ambient ionization techniques in 2004, rich molecular information could now be 
obtained in situ, under ambient conditions, with experimental simplicity and minimal 
sample preparation, thus more suitable for the analysis of biological tissue samples and 
introduction into a clinical workflow (8,9). In the last two decades, ambient ionization MS 
methods have been increasingly used for biomedical and cancer research, with particular 
focus on tissue imaging and spatial profiling (10). New developments and methods aimed 
at improving the analytical and clinical capabilities of ambient MS to facilitate 
implementation in various research and clinical environments have also been pursued 
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(11,12). Nowadays, ambient ionization MS methods are applied or envisioned for use in 
various facets of cancer research and diagnostics, from tissue imaging and molecular 
profiling in basic and translational research studies, to rapid assessment of clinical samples 
for preoperative or intraoperative use, including in vivo use during cancer surgeries (Figure 
1.1).    
Figure 1.1:  Applications and envisioned uses of ambient ionization MS technologies in 
biomedical research and the clinical space.  
Ambient ionization MS technologies have been extensively used to evaluate biological 
samples by biomedical and bioanalytical researchers. The capabilities for direct and in situ 
analysis of biological samples with ambient ionization MS methods provide high 
suitability for introduction into various diagnostic workflows in clinical laboratories. 
Ambient ionization MS technologies for rapid intraoperative evaluation of surgical 
specimens could be incorporated in the frozen section pathology laboratory and the 
operating room for direct ex vivo and in vivo analysis.   
 
 3 
Desorption electrospray ionization (DESI), developed by the Cooks group at 
Purdue University in 2004, was the first and to date most widely used ambient ionization 
MS technique for tissue imaging towards improved cancer diagnosis (8). DESI utilizes a 
spray of charged droplets to desorb and ionize molecules from the surface analyzed (Figure 
1.2A) (13). In the imaging mode, the spray is rastered across the surface of the tissue 
sample, providing molecular information associated to a particular location, or pixel, as 
shown in Figure 1.2B. The spatial resolution or pixel size of the images obtained with 
DESI-MS is commonly between 100-200 µm, allowing to resolve histological features 
within or above those dimensions. Biological sample analysis by this method requires 
minimal sample preparation, only involving the deposition of a frozen section of the tissue 
sample of interest on a glass slide. Using a histologically compatible solvent system for 
DESI-MS analysis, tissue integrity can be preserved to allow subsequent evaluation by 
pathology of the same tissue section analyzed (14). Most suited towards the detection of 
smaller biomolecules (<1500 Da) such as metabolites, fatty acids, and various types of 
lipids, DESI-MS has been widely used to image human tissue samples and investigate 
metabolic aberrations associated with multiple cancer types (10,15-19). Various studies, 
for example, have focused on the diagnosis and stratification of brain cancer with DESI-
MS , allowing identification of cancer subtype, grade, tumor cell concentrations (20,21), 









Figure 1.2:  DESI-MS imaging.  
A spray of charged solvent droplets are directed to the sample surface for desorption and 
ionization of surface analytes (A). In a DESI-MS imaging experiment, spatial coordinates 
are recorded for the data obtained, with each pixel corresponding to a single mass spectrum, 
allowing correlation of spatial and molecular information (B).  
The success of DESI-MS in cancer research has also inspired the development of 
alternative liquid extraction approaches for tissue section analysis and imaging under 
ambient conditions (23). Utilizing a direct liquid extraction- instead of a spray-based 
approach, methods such as liquid microjunction surface sampling (LMJ-SS) (24), liquid 
extraction surface analysis (LESA) (25), and nanospray desorption electrospray ionization 
(nano-DESI) (26), have also been applied for spatial profiling and imaging of tissue 
samples. For example, an LMJ-SS system was recently used to determine hormone levels 
from pituitary tumor tissue sections, demonstrating potential to provide protein biomarker 
information by ambient ionization MS at the time of surgical resection (27). Overall, the 
longer solvent-sample interaction times provided by direct liquid extraction coupled to a 
direct nanospray or an ESI source have led to enhanced ionization efficiency and overall 
sensitivity compared to DESI-MS. In terms of spatial resolution, nano-DESI has allowed 
to resolve spatial features close to cellular dimensions (>10 µm) ) (28,29), while the LMJ-
SSP and LESA have been applied to sample larger areas (600-1000 µm) in biological 
tissues (30). Importantly, the area sampled by liquid extraction techniques is commonly 
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restricted to the diameter of the capillaries or probes used, which is intrinsic to each 
approach and thus results in limited and impractical tunability of the spatial resolution. 
Therefore, methods that would enable to practically and precisely tune spatial resolution in 
liquid extraction ambient ionization MS could improve performance for direct MS 
profiling and imaging by adapting the true pixel size to the desired application. A summary 
of the characteristics and performance metrics for these methods is provided in Table 1.1.    
Table 1.1:  Liquid extraction ambient ionization MS methods for tissue section analysis.  
* A spatial resolution as low as 20 µm has been reported for DESI-MS (31) , but larger 
pixel sizes are more commonly obtained for these experiments. ** Detection of proteins 
by DESI-MS was enhanced by ion mobility (32,33).1 
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discrete droplet 
deposition and re-
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1 The figures in this table are adapted with permission from Laskin J, Lanekoff I. Ambient Mass Spectrometry 
Imaging Using Direct Liquid Extraction Techniques. Anal Chem 2016; 88, 1, 52-73. Copyright © 2016, 
American Chemical Society. 
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Although powerful, the ambient ionization MS methods described above are 
limited to the analysis of thin tissue sections or flat biological surfaces, and currently best 
suited for trained and skilled users in a research laboratory. In the clinical space, the 
capability to provide an easy-to-use MS-based tool capable of acquiring powerful 
molecular information from in vivo or freshly excised tissue specimens during a surgical 
procedure, removing the need for tissue excision and processing, would be highly 
transformative. Towards that end, a new realm of ambient ionization MS methods offering 
the exciting opportunity to provide real-time surgical guidance and tissue diagnosis based 
on molecular information provided by MS analyses has emerged. Envisioned for use by 
surgeons and surgical staff in the operating room, additional considerations such as 
technical simplicity, automation, biocompatibility, and patient safety are of critical 
importance for these methods. The first MS-based technique developed for in vivo, 
intraoperative use is rapid evaporative ionization MS, or the “iKnife”, which combines a 
hand-held electro-cauterization device, a common tool used during surgical operations, 
with MS (34,35). The iKnife technology provides means to transfer and detect ions 
generated through thermal evaporation during tissue electrocauterization, thus relying on 
tissue damage for ion production. In the last ten years, various other approaches for in vivo 
MS analysis have also been developed, utilizing laser, liquid, or solid extraction probes, 
among others, aiming to minimize tissue damage during analysis (36) (Figure 1.3). 
Although still under development, some of these methods have shown promising results 
for direct, rapid, ex vivo cancer diagnosis, and feasibility for in vivo use during human 






Figure 1.3:  Ambient ionization MS hand-held probes developed for in vivo and ex vivo 
use during human surgeries for near-real time tissue assessment and cancer 
diagnosis.  
CRITICAL NEED FOR IMPROVED MOLECULAR CHARACTERIZATION AND CLINICAL 
MANAGEMENT OF OVARIAN CANCER  
 Ambient ionization MS technologies provide a powerful set of tools to improve the 
detection and management of ovarian cancer. Ovarian cancer is the fifth leading cause of 
all cancer-related deaths in women, responsible for the majority of deaths associated with 
gynecological malignancies (39,40). The highly aggressive behavior and commonly late 
detection of this disease result in low 5-year survival rates, averaging at 47%, and reaching 
as low as 30% for metastatic ovarian cancer. Recurrence rates up to 80% have been 
reported, attributed to residual disease after surgery, as well as resistance to platinum-based 
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chemotherapy, among other factors (41). It is estimated that in 2020, about 22,000 new 
cases will be diagnosed in the U.S. (42). Ovarian cancer is highly heterogeneous in 
histology and includes great molecular diversity, with serous carcinoma being the most 
common form. High-grade serous carcinomas (HGSC) are rapidly growing serous 
carcinomas characterized by tumor cells with large and atypical irregular nuclei, as well as 
various genetic aberrations, such as those affecting the BRCA1, BRCA2 and TP53 
pathways (43). HGSC are the most aggressive type, and account for 90% of all serous 
ovarian cancers. Borderline serous tumors (BOT), on the other hand, are benign neoplasms 
with slow proliferation rates and no stromal invasion (44). BOT can develop into malignant 
low-grade serous carcinomas (LGSC), which are significantly rarer than HGSC and present 
with improved clinical prognosis despite responding less frequently to platinum-based 
chemotherapy (45). LGSC are histologically defined by micro-papillary patterns and tumor 
cells with small uniform nuclei (41). While it is well established that ovarian serous 
carcinomas develop through different molecular pathways, further studies are needed to 
understand the mechanisms driving aggressiveness and invasiveness (46). Moreover, a 
large proportion of ovarian serous carcinomas are now believed to originate from precursor 
lesions in the fallopian tubes instead of the ovarian epithelium (47). This new hypothesis 
has resulted in a shift in ovarian cancer research and prevention strategies, raising 
additional questions about the tumorigenesis of this deadly disease (48). 
The primary course of treatment for serous ovarian cancer patients is a combination 
of surgical resection and chemotherapy. Cytoreductive surgery with the objective of 
removing as much tumor volume as possible is critical to maximize patient survival, as 
residual disease post-surgery has been associated with poor patient prognosis and recurrent 
disease (49). Surgical resection is also commonly the first chance to diagnose and stage the 
disease, which is critical to establish a targeted treatment and management plan (50). Thus, 
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providing an accurate diagnostic assessment at the time of surgical intervention as well as 
evaluating the extent of the disease during cytoreduction to minimize residual disease is 
critical to guide patient care. Prior to surgical intervention, the administration of 
chemotherapy can facilitate cytoreductive efforts for advanced and aggressive ovarian 
cancers by decreasing tumor volume and proliferation (51). Yet, the resulting scarring or 
fibrotic tissue can be challenging to distinguish from other tumor and metastatic sites, 
complicating resection and leading to poor surgical outcomes. Current intraoperative 
diagnostic procedures to evaluate ovarian tissue biopsies and guide surgical resection 
involve traditional histopathological evaluation, or frozen section analysis, which is time 
(~30 minutes) and labor-intensive and requires skilled technicians and pathologists to 
produce and interpret results. Thus, this method can prolong operative time, which is costly 
and can subject the patient to increased risks of infection and extended hypoperfusion from 
anesthesia. If a diagnosis cannot be derived intraoperatively, specimens are processed post-
operatively over several days, which entails increased health care costs, and places the 
patient at additional health risks, discomfort and anxiety (52).   
Evaluating the molecular composition of ovarian cancer tissues by ambient 
ionization MS methods for improved molecular characterization and tissue diagnosis can 
be a powerful approach to address current challenges in the clinical management of ovarian 
cancer. Investigating metabolic changes associated with cellular histology and genetic 
expression can provide important insights into the pathogenesis of serous ovarian cancer 
and help determine molecular features associated with disease aggressiveness and 
metastasis. Ambient MS imaging approaches offer suitable capabilities to conduct these 
investigations, allowing correlation of molecular and spatial information, while preserving 
sample integrity for subsequent pathological evaluation. Identification of potential ovarian 
cancer markers by ambient MS methods could also lead to new targets for innovative 
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treatment approaches, thus improving patient survival and decreasing disease recurrence. 
The generation of classification algorithms capable of rapidly (~ 5 min) providing a 
diagnosis based on metabolic data obtained by ambient MS analysis, such as DESI-MS, 
could help introduce detailed molecular information to current workflows for ovarian 
cancer frozen section evaluation, providing complementary guidance for more accurate 
diagnosis and personalized patient care. Translating these diagnostic capabilities to the 
operating room through direct in vivo tissue assessment by MS could be highly 
transformative by providing near-real time diagnostic feedback to expedite surgical 
decision-making. Discrimination of tumor masses and metastatic sites from healthy or 
fibrotic tissue directly through in vivo MS sampling prior to excision could greatly facilitate 
and expedite ovarian cancer cytoreduction, diminishing likelihood of residual disease and 
damage to healthy tissue. Altogether, the use of ambient MS technologies towards 
improved molecular characterization of ovarian cancer tissue samples as well as their 
implementation in the clinical space for ex vivo and in vivo assessment of ovarian tissue 
samples could offer powerful insights into ovarian cancer tumorigenesis and substantial 
improvements over current diagnostic methods to positively impact the management and 
care of ovarian cancer patients. The research projects discussed in this dissertation are 
aimed at addressing current challenges in ovarian cancer research and diagnosis with 
ambient ionization MS technology. 
RESEARCH OBJECTIVES   
My dissertation research has focused on developing ambient ionization MS 
methods for improved characterization of cancer tissue samples and applying them to 
investigate and improve detection of ovarian cancer. The objectives of this research were 
two-fold: (1) utilize DESI-MS imaging to determine metabolic features associated with 
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ovarian cancer aggressiveness and generate statistical models capable of producing 
accurate ovarian cancer diagnoses based on DESI-MS data; and (2) develop alternative 
liquid extraction-based sampling approaches to address current challenges in ambient 
ionization MS methods for both ex vivo and in vivo characterization of cancer tissue 
samples. The studies described in the following five chapters demonstrate the potential of 
ambient ionization MS technology for ovarian cancer research and improved diagnosis.  
Chapter 2 of this dissertation describes the in-depth investigation of ovarian cancer 
tissue samples with DESI-MS imaging. Normal ovarian as well as HGSC and serous BOT 
frozen tissue sections were analyzed to detect metabolic trends correlated to tumor 
development and malignancy. DESI-MS imaging allowed visualization of spatial features 
in the tissue sections corresponding to various cellular environments, such as stroma and 
necrosis. The least absolute shrinkage and selector operator (Lasso) method (53), 
developed by our collaborator at Stanford University, Prof. Tibshirani, was used to 
generate classification models to distinguish between normal, HGSC, and BOT ovarian 
tissue samples and to identify predictive markers of ovarian cancer aggressiveness. Various 
metabolite, fatty acid, and complex glycerophospholipid and sphingolipid species were 
selected as important to characterize normal and cancerous ovarian tissue samples, 
supporting the role of metabolic aberrations in ovarian cancer development and 
aggressiveness and providing additional insights into ovarian carcinogenesis. The 
statistical classifiers generated from DESI-MS imaging data allowed identification of 
ovarian tissue samples with high predictive accuracies (>90%). The results obtained in this 
study suggested DESI-MS as a powerful approach to spatially and molecularly characterize 
ovarian cancer tissue samples, as well as to rapidly provide a cancer diagnosis from frozen 
tissue sections based on altered metabolic features.     
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Going beyond cancer diagnosis and capitalizing on the capabilities of DESI-MS to 
characterize ovarian cancer tissue, Chapter 3 describes the investigation of the effects of 
the fatty acid binding protein gene (FABP4) expression in ovarian cancer metabolism. Dr. 
Anil K. Sood and his research group at the MD Anderson Cancer Research Center 
previously identified the FABP4 gene as a molecular determinant of residual disease in 
ovarian cancer, resulting in overall poorer patient prognosis (49,54). In this study, we 
aimed to improve the understanding of the molecular mechanisms behind the role of the 
FABP4 gene in driving ovarian cancer aggressiveness and metastasis. Frozen human and 
mice tissue samples were provided by the Sood research lab and analyzed by DESI-MS 
imaging in our laboratory. Metabolic features detected from multivariate statistical 
analyses of DESI-MS data, including Lasso and Significance Analysis of Microarrays 
(SAM) (55), were correlated with FABP4 expression levels. Focusing only on data 
obtained from regions of high tumor concentrations revealed a unique set of metabolic 
trends associated with high and low expression of the FABP4 gene, from fatty acid 
unsaturation and oxidation levels to lysophospholipid and cardiolipin abundance. This 
study elucidated certain metabolic determinants of ovarian cancer aggressiveness and 
metastasis beyond histopathological characterization, laying a strong precedent for future 
studies investigating as well as developing novel therapeutic strategies to target these 
metabolic aberrations. 
Chapters 2 and 3 of this dissertation provide powerful examples of the capabilities 
of ambient ionization MS methods, particularly DESI-MS, to analyze and examine the 
metabolic composition of ovarian tissue sections. Chapter 4 describes the development of 
an alternative liquid extraction ambient ionization MS approach for metabolite and lipid 
analysis, providing improved spatial control during direct liquid sampling and extraction 
from biological samples. This method involves the deposition of solvent droplet arrays (~2-
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50 nL) onto sample surfaces by a piezoelectric liquid dispenser, followed by droplet 
aspiration and ionization through a fused capillary emitter for MS analysis. Tuning the 
volume and thus diameter of the droplet deposited with the piezoelectric dispenser allows 
practical and precise control over the area being sampled and the imaging spatial resolution 
(250-650 µm). Direct sampling and aspiration of the droplet in contact with the tissue 
sample through the fused silica capillary enables efficient analyte extraction and ionization 
for MS analysis. The solvent system and experimental parameters were optimized for 
improved metabolite and lipid detection with this approach. This method was tested using 
various biological tissues and samples, including normal and cancerous ovarian samples, 
demonstrating potential for controlled spatial and metabolic profiling of biological samples 
with imaging pixel sizes ranging from 380 to 500 µm. Future work on this technology 
includes design and engineering refinements to allow automation, increased spatial 
resolution and improved sample throughput. Efforts to optimize this method for protein 
analysis from tissue are currently underway, as well as exploring potential additives for 
tuning solvent composition for enhanced chemical coverage. The capability to decouple 
the extraction and ionization processes with this method will also be exploited to 
investigate the mechanisms driving molecular detection with liquid extraction ambient 
ionization MS methods.   
The ambient ionization MS approaches described in the previous chapters can be 
used to investigate tissue samples in the research space and could potentially be introduced 
into a clinical workflow by analyzing excised surgical specimens processed as tissue 
sections. Chapter 5 in this dissertation describes the development and application of an 
innovative ambient ionization MS technology tailored to the analysis of tissue samples in 
vivo and ex vivo directly after excision, removing requirements for frozen tissue section 
preparation. The device, called the MasSpec Pen and developed in our laboratory in 
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collaboration with Prof. Thomas Milner’s laboratory at the University of Texas,  is a 
handheld and biocompatible sampling probe that uses a droplet of water to extract 
molecular information from the surface of a tissue. Following extraction, the droplet is then 
transported to a mass spectrometer for analysis. The sampling and data acquisition process 
can be performed in under 10 seconds, providing metabolic characterization of tissue 
samples in near-real time. Unlike the iKnife technology, molecular sampling and ionization 
rely on direct liquid extraction with a discrete water droplet, which is completely 
nondestructive to the tissue sample analyzed. The MasSpec Pen was utilized to analyze 
banked ex vivo tissue specimens of various cancer types, including ovarian cancer, and 
tested in vivo using murine models of breast cancer. Using the Lasso method, the molecular 
information obtained from the analyses was found to be predictive of tissue and cancer 
type. 
With a high reoccurrence rate of ~80%, associated partly to remaining residual 
disease after surgery, as well as the need for rapid tissue diagnosis during surgery to 
determine an effective treatment plan, the management of ovarian cancer could greatly 
benefit from a technology like the MasSpec Pen to help guide patient care. Initial efforts 
to validate the MasSpec Pen technology for ovarian cancer diagnosis prior to in vivo testing 
in human surgeries are discussed in Chapter 6. In this study, the performance of the 
MasSpec Pen for ex vivo ovarian cancer diagnosis was rigorously evaluated across different 
sample sets, various healthy and cancerous ovarian tissue types, including fallopian tube, 
HGSC, and LGSC samples, and mass spectrometry systems. Overall, high performance 
was obtained, demonstrating the potential and robustness of the metabolic profiles obtained 
by MasSpec Pen analysis to serve as molecular fingerprints for rapid diagnosis of ovarian 
cancer specimens. A pilot clinical study is currently planned to evaluate feasibility for in 
vivo use of this technology in ovarian cancer surgeries.  
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Finally, Chapter 7 provides a concluding summary of this dissertation, as well as a 
discussion on future directions of the research described. A personal perspective on the 
field of ambient ionization MS for cancer research and diagnosis, including current 
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Chapter 2: Metabolic Markers and Statistical Prediction of Serous 
Ovarian Cancer Aggressiveness by Ambient Ionization Mass 
Spectrometry Imaging2 
INTRODUCTION 
Epithelial ovarian cancer is a complex disease that includes great molecular and 
histologic diversity, with serous carcinoma being the most common form (1). Ovarian 
cancer accounts for the majority of deaths for gynecological malignancies due to the 
detection of advanced and aggressive disease at a late stage (2). High-grade serous cancer 
(HGSC) is the most aggressive ovarian epithelial cancer and accounts for 70% of all 
ovarian epithelial cancers diagnosed (3). HGSC is characterized by extensive genetic 
instability, and TP53 mutations are universally found in these tumors (4). Conversely, 
borderline serous ovarian tumors (BOT) or serous tumors of low-malignant potential are 
noninvasive neoplasms with favorable patient prognosis and represent approximately 15% 
of serous ovarian tumors (5). BOTs can progress to malignant low-grade serous carcinoma 
(LGSC), but the clinical outcome is still advantageous in comparison with HGSCs (4, 6). 
HGSC and BOTs present distinct tumor invasion behaviors, with HGSC growing rapidly 
and spreading among healthy tissue, whereas BOTs slowly proliferate without stromal 
invasion. Although histopathologic analysis is routinely employed for diagnosis of serous 
ovarian tumors, sensitive methods that provide molecular information to diagnose and 
stratify patients could serve as complimentary tools for more accurate and personalized 
diagnosis, as well as for the detection of early molecular markers to improve disease 
 
2 
Adapted with permission from Sans M, Gharpure K, Tibshirani R, Zhang J, Liang L, Liu J, et al. Metabolic 
Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass 
Spectrometry Imaging. Cancer Res 2017;77:2903-13. Copyright © 2017, American Association for Cancer 
Research. Sans M performed the experiments, data analyses, and prepared the manuscript. Gharpure K 
assisted in sample collection. Tibshirani R. generated the statistical methods and prediction results. All 
authors contributed editing the manuscript.  
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management (7–9). Moreover, characterization of the molecular differences between 
malignant and borderline serous ovarian tumors could provide new insights to unravel the 
biological mechanisms driving tumor invasion and aggressiveness (10, 11).  
Mass spectrometry imaging techniques have been increasingly used for spatial and 
molecular characterization of cancerous tissues (12–14). In particular, desorption 
electrospray ionization mass spectrometry (DESI-MS) imaging allows simultaneous 
detection of hundreds of lipids and metabolites directly from tissue samples with minimal 
sample preparation (15). DESI-MS employs an electrospray stream to desorb and ionize 
molecular species present on the sample surface (16). When performed in the imaging 
mode, chemical maps displaying the spatial distribution of molecular ions are obtained 
(17). Multivariate statistical analysis of the large spatial and molecular data information 
obtained is essential to derive molecular signatures that are predictive of disease state. 
DESI-MS imaging is powerful for biomarker discovery as it allows visualization of tissue 
heterogeneity and thus unambiguous correlation of histologic features and molecular 
information to build tissue-based molecular classifiers. This methodology has been used to 
investigate diagnostic lipid and metabolic signatures of human cancerous tissues including 
brain (18), breast (19), gastric (20), and others (21–23). Mouse models of human ovarian 
HGSC have been recently investigated using DESI-MS imaging, and differences in 
metabolic species were observed between healthy and tumorous tissues (24). Here, we 
report the use of DESI-MS imaging to investigate the molecular profiles of serous ovarian 
tumors and characterize lipids and metabolites that could potentially serve as markers of 
aggressive disease. Two-dimensional (2D) molecular images allowed correlation between 
molecular signatures and regions with specific histologic features. Classification models 
built using the least absolute shrinkage and selector operator (Lasso) technique (25, 26) 
were tested to predict disease state and tumor aggressiveness. Predictive species selected 
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by the statistical models were tentatively identified by high mass accuracy/high mass 
resolution and tandem mass spectrometry analysis as lipids and metabolites of biological 
relevance. Our results demonstrate the capabilities of DESI-MS for characterizing serous 
ovarian tumors and for the identification of potential predictive markers of disease 
aggressiveness. 
MATERIALS AND METHODS 
Banked human ovarian tissues 
A total of 78 frozen human tissue specimens including 15 normal ovarian tissues, 
15 BOT, and 48 HGSC samples were obtained from the Cooperative Human Tissue 
Network and MD Anderson Tissue Bank under approved IRB protocol. Tissue samples 
were sectioned at 16 µm thick sections using a CryoStar NX50 cryostat (Thermo 
Scientific). After sectioning, the glass slides were stored in a -80 ⁰C freezer. Prior to MS 
imaging, the glass slides were dried for approximately 15 minutes.   
DESI-MS imaging  
A 2D Omni Spray (Prosolia Inc.) coupled to an LTQ-Orbitrap Elite was utilized for 
tissue imaging. DESI-MS imaging was performed in the negative and positive ion modes 
from m/z 100 to 1,500, using a hybrid mass spectrometer that allows for tandem MS 
experiments, high mass accuracy (<5 ppm mass error), and high mass resolution (60,000 
resolving power) measurements. A spatial resolution of 200 µm was used. Ion images were 
assembled using Biomap and MSiReader software. The histologically compatible solvent 
system dimethylformamide: acetonitrile (DMF:ACN) 1:1 (v/v) was used for negative ion 
mode analysis, at a flow rate of 1.2 µL/min (17). For positive ion mode analysis, pure ACN 
was used, at a flow rate of 3 µL/min. The N2 pressure was set to 185 psi. For ion 
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identification, high mass resolution/accuracy measurements using the same tissue sections 
analyzed were conducted using CID and HCD methods, using the Orbitrap for analysis. 
Histopathology and light microscopy 
The same tissue sections analyzed by DESI-MS imaging were subjected afterward 
to a standard hematoxylin and eosin (H&E) staining protocol. Pathologic evaluation was 
performed by Drs. Jinsong Liu and Li Liang using light microscopy. Regions of clear 
diagnosis were assigned and delineated in the glass slides. Light microscopy images of the 
H&E-stained slides were taken using the EVOS FL Auto Cell Imaging System (Invitrogen, 
Thermo Fisher Scientific). Statistical analysis MS data corresponding to the areas of 
interest were extracted from the ion images using MSiReader software. The m/z range was 
discretized by performing hierarchical clustering and cutting the resulting dendrogram at 
distance 0.05. Peaks appearing in more than 10% of the pixels were kept for analysis. For 
two-class classification (normal vs. HGSC, and HGSC vs. BOT), logistic regression was 
performed with Lasso regularization using the "glmnet" package (26) in the R language. 
Regularization parameters were determined by 3-fold cross-validation (CV) analysis. The 
data were randomly divided in a training and validation set of samples, 50–50 per patient 
basis. For three-class classification (normal vs. BOT vs. HGSC), a customized training 
approach was employed as previously described (27). 
RESULTS 
Molecular imaging of serous ovarian cancers  
DESI-MS imaging was performed in the negative and positive ion modes for a total 
of 78 tissue samples, including 15 normal ovarian, 15 BOT, and 48 HGSC tissues obtained 
from two independent tissue banks. A patient demographic table is included in Table A1.1. 
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Characteristic metabolic profiles for HGSC, serous BOT, and normal ovary samples were 
observed in both polarities and presented a remarkable diversity of metabolic species. In 
the negative ion mode, small metabolites, saturated and unsaturated fatty acids, 
sphingolipids (SP), and several classes of glycerophospholipids (GP) such as ceramides 
(Cer), cardiolipins (CL), glycerophosphoethanolamines (PE), glycerophosphoglycerols 
(PG), glycerophosphoserines (PS), and glycerophosphoinositols (PI) were observed 
(Figure 2.1A), whereas additional biologically relevant lipid species, such as 
glycerophosphocholines (PC), triacylgycerols (TG), and sphingomyelins (SM) were seen 
in the positive ion mode (Figure 2.2A).  
 
Figure 2.1:  Analysis by DESI-MSI in the negative ion mode.  
(A) Representative metabolic profiles for high-grade SOC and serous borderline. Top, 
high-grade; bottom, borderline. (B) Representative ion images for high-grade SOC tissue 
samples. (C) Representative ion images for borderline tumor samples. Tumor areas are 
outlined in black on H&E slides. Areas of red intensity within the ion images represent 
highest (100%) and black lowest (0%) relative abundances. Lipid species are described by 
number of fatty-acid chain carbons and double bonds. 
After DESI-MS imaging, the same tissue sections were stained with H&E and 
subjected to detailed pathologic evaluation (17). Specific histologic features characteristic 
of HGSC and serous BOT tissues were observed and annotated for all samples analyzed, 
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as shown in Figures 2.1 and 2.2 for four representative samples for negative and positive 
ion mode, respectively. HGSCs exhibit solid growth or large and complex papillae, with 
heterogeneous nuclei shape and sizes, and extensive stromal invasion (1,4). DESI-MS 
imaging in the negative ion mode allowed visualization of regions with tumor clusters in 
HGSC, as outlined in black for samples HGSC_9 and HGSC_11 in Figure 2.1B. For 
example, high relative abundances of m/z 885.547, m/z 747.516, m/z 724.484, and m/z 
281.248 were observed in regions with high density of tumor cells. In the positive ion 
mode, PC species including PC 36:3, PC 34:1, and PC 32:1 were found at high relative 
abundances in high-grade carcinoma regions, allowing clear visualization of these regions 
in comparison with surrounding stroma. Interestingly, m/z 901.648, tentatively identified 
as ubiquinone or Coenzyme Q10 with a mass error of -1.1 ppm, was noticeably selective 
to the presence of tumor in HGSC samples (Figure 2.2B).  
Conversely, serous BOTs are commonly associated with noninvasive components, 
characterized by increased epithelial proliferation and nuclear atypia, exhibiting multiple 
papillae with ordered branching (5, 6). Serous BOT samples present a distinct histologic 
architecture characterized by tumor growth within the lining of the stroma. Ion images of 
serous BOT samples BOT_4 and BOT_16 are shown in Figures 2.1C and 2.2C. As 
observed for HGSC samples, high relative abundance of PI 18:0/20:4 was seen in the tumor 
region in comparison with stromal areas. Yet, high relative abundances of Cer species such 
as Cer d42:1, Cer d42:2, Cer d40:1, and Cer d34:1 was highly specific to the discrete tumor 
regions in BOT samples. In the positive ion mode, ubiquinone (m/z 901.648) also presented 
higher relative abundances in serous BOT regions. Other species such as PC 36:3 or 36:4 
were also abundant within the tissue slides but not as specific to the BOT tumor areas. On 
the other hand, cholesteryl ester (CE) 18:2 was observed to be more abundant in the 
surrounding stromal regions.  
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Figure 2.2: Analysis by DESI-MSI in the positive ion mode.  
(A) Representative metabolic profiles for high-grade SOC and serous borderline. Top, 
high-grade; bottom, borderline. (B) Representative ion images for high-grade SOC tissue 
samples. (C) Representative ion images for borderline tumor samples. Tumor areas are 
outlined in black on H&E slides. Areas of red intensity within the ion images represent 
highest (100%) and black lowest (0%) relative abundances. Adjacent tissue sections were 
used for negative and positive ion mode analysis. Lipid species are described by number 
of fatty-acid chain carbons and double bonds. 
 
Normal ovarian tissue samples presented stromal regions with heterogeneous 
features such as corpus luteum, follicles, or benign cysts (Figure A1.1). Healthy stromal 
ovarian tissue consistently displayed a lower overall signal intensity for lipid species when 
compared with HGSC tissue samples in the negative ion mode. Moreover, a higher relative 
abundance of PI 20:4/18:1, m/z 885.547, in comparison with PS 18:0/18:1, m/z 788.547, 
was consistently observed in both BOT and HGSC tumors, when compared with normal 
ovarian tissues. However, certain species, such as ascorbic acid, m/z 175.025, were more 
prominent in normal tissue. In the positive ion mode, characteristic mass spectra were 
observed from normal stromal regions, with high relative abundance of PCs such as PC 




Figure 2.3:  Magnified regions for samples HGSC_11 (A), BOT_16 (B), and HGSC_1 
(C), with selected ion images that correlate to and outline the presented 
histologic heterogeneities.  
Lipid species are described by number of fatty-acid chain carbons and double bonds. The 
tumor areas are outlined in black, necrotic areas in red. Areas of red intensity within the 
ion images represent highest (100%) and black lowest (0%) relative abundances. 
Notably, the spatial resolution used for DESI-MS imaging (200 µm) enabled 
visualization of key features of tumor heterogeneity in serous ovarian tumor tissues. Figure 
2.3 shows magnified regions for three tumor samples, with selected ion images that directly 
correlate and clearly outline histologic details of these tissues. For example, necrotic 
regions within the HGSC_1 tissue sample (outlined in red Figure 2.3C) showed a very 
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distinct lipid profile, characterized by high relative abundance of Cer species such as m/z 
682.591 and m/z 600.513 (Figure A1.2). Necrosis is a typical cell injury present in high-
grade carcinomas and was absent in BOT tumors (1,4). In HGSC and BOT samples, the 
molecular composition of tumor regions allowed clear visualization and discrimination of 
cancer and adjacent stromal regions. The distinct molecular compositions associated with 
normal ovarian tissues, and borderline and high-grade tumors strongly suggest lipid and 
metabolite species as potential biomarkers for cancer diagnosis and aggressiveness. 
Statistical prediction and molecular diagnosis of HGSC 
DESI-MS imaging of tissue samples results in a large amount of molecular and 
spatial information (hundreds of molecular ions/hundreds of data points/sample) and thus 
calls for refined statistical evaluation to define what changes in molecular expression are 
significantly different between phenotypes and to build robust statistical classifiers. The 
Lasso method was performed on a random training set of samples to yield a model with 
parsimonious sets of m/z values for discriminating between the classes. A mathematical 
weight for each mass spectral feature was calculated by the Lasso depending on the 
importance that the feature had in characterizing a certain class. The predictive accuracy 
of the model with the selected features was evaluated using an independent validation set 
and presented as agreement (%) with pathologic results.  
To classify HGSC pixels in comparison with normal tissue, MS data were extracted 
from tumor-concentrated regions or stromal areas within the selected tissues slides. First, 
we built a classifier for HGSC using a training subset of samples (8 normal, 23 HGSC). 
Three-fold CV was performed on a pixel by- pixel basis using a total of 20,082 pixels 
evaluated in the negative ion mode, resulting in an overall agreement of 97.1%. The 
statistical model was then applied to the validation set of samples (7 normal, 25 HGSC), 
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which resulted in an overall agreement of 96.5% for 18,671 pixels (Figure 2.4A). The area 
under the receiver operating characteristic curve values (AUC = 0.98 for CV; AUC = 0.97 
for validation set) demonstrate the high performance for normal versus HGSC 
discrimination. Analysis per patient allowed correct classification of 100% of the patients 
in CV, whereas 1 HG sample was misclassified as normal out of the total 25 validation set 
samples (Table A1.2). A subset of 25 m/z values selected by the Lasso as most significant 
contributors to the model were tentatively identified as small metabolites, saturated and 
polyunsaturated fatty acids, and GPs (Table A1.3). The positive ion mode data were also 
analyzed by the Lasso to predict HGSC. Following the same strategy, overall agreements 
of 96.7% (AUC = 0.96) and 95.5% (AUC = 0.95) for CV and validation sets were achieved, 
respectively (Figure 2.4B). The Lasso selected 21 m/z values characteristic for the model, 
the majority of which were identified as PCs, CEs, and TGs (Table A1.3). These results 
demonstrate DESI-MS and Lasso's capabilities of diagnosing the most aggressive form of 
serous ovarian cancers, which is relevant due to the high occurrence and poor prognosis of 
HGSC compared with other subtypes (4). 
Statistical prediction of cancer aggressiveness for HGSC and BOT tissues 
HGSC and BOT tumors present very distinct behaviors including tumor invasion 
and aggressiveness. Investigating the molecular differences between HGSC and BOT 
subtypes can assist in the identification of potential biomarkers of disease aggressiveness. 
Molecular classifiers to predict BOT and HGSC were built using the Lasso for DESI-MS 
data. In the negative ion mode, the classifier was developed using a training set of samples 
(32 samples, 18,190 pixels), resulting in an overall agreement of 93.2% with pathologic 
analysis by CV. The remaining data (31 samples, 13,422 pixels) used to test the molecular 
model yielded 91.8% agreement with evaluation by pathology. Using positive ion mode 
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data, agreements of 90.4% (29 samples, 20,852 pixels) and 97.5% (32 samples, 15,134) 
were obtained for the training and test sets, respectively (Table A1.4). From the species 
selected as predictive markers by the molecular classifier, 41 m/z values were identified as 
metabolites, fatty acids, complex SP, or GP in the negative and positive ion modes (Table 
A1.5).  
 
Figure 2.4:  Lasso per pixel prediction results for normal, HGSC, and BOT classification.  
Negative ion mode (A) and positive ion mode (B). Agreements are calculated based on 
percentage of correctly classified pixels over total pixels classified. See Tables A1.2, A1.4, 
and A1.6 for complete pixel and patient classification results. (C) Weights attributed to 
selected m/z values by the Lasso, represented by nominal mass, for negative ion mode (top) 
and positive ion mode (bottom). Positive weights represent higher relative abundances; 
negative weights represent lower relative abundances. Chemical attribution for selected 
species is provided in Table 2.1. 
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Per patient analysis revealed 3 BOT samples misclassified overall: BOT_2, BOT_6, 
and BOT_13, which were then re-evaluated by pathology (Table A1.4). Remarkably, 
invasive carcinoma features were identified within the tissue sample for BOT_2, which are 
commonly associated with the development of LGSC. The surgical report for BOT_6 
revealed that the patient's contralateral ovary consisted of well-differentiated (low-grade) 
adenocarcinoma, indicative of malignant behavior. Samples BOT_6 and BOT_13 were 
defined by pathology as serous BOT with unusual extensive micropapillary growth patterns 
and architectural complexities, thus supporting the distinct molecular features detected by 
DESI-MS that are not characteristic of the BOT molecular model. 
Statistical prediction of serous ovarian cancers and normal ovarian tissues 
Next, we evaluated the ability of our method to discriminate three classes of ovarian 
tissues: normal, BOT, and HGSC. Lasso was performed on negative ion mode DESI-MS 
data from 15 normal, 15 BOT, and 48 HGSC tissue samples. A customized training 
approach was utilized to provide localized molecular models for predicting each data 
subset, which has been previously applied to MS imaging data (27). A total of 20,225 pixels 
(39 samples) were used for CV, leading to an overall agreement of 92.5%. The remaining 
22,513 pixels (39 samples) were evaluated as an independent validation set with an overall 
88.6% agreement (Figure 2.4A). Positive ion mode analysis from a total of 10 normal, 15 
BOT, and 46 HGSC tissue samples provided an overall agreement of 91.0% in CV (25,839 
pixels) and 96.7% overall accuracy for the validation set of samples (18,249 pixels; Figure 
2.4B). In all the analyses, the highest Lasso error rates were due to misclassification of 
pixels diagnosed as BOT by histopathology as either normal or HGSC, whereas higher 
accuracy was observed for normal and HGSC classes (Table A1.6). Interestingly, the same 
BOT samples misclassified by the two-class comparison between HGSC and BOT were 
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also predicted as carcinomas by the three-class molecular model for normal, BOT and 
HGSC. These results emphasize that metabolic features detected by our method can serve 
as a robust predictive signature of cancer and disease aggressiveness. 
To evaluate the overall discrimination between healthy and tumor samples, per-
pixel results for HGSC and BOT were combined and compared with the results for normal 
tissues. Overall agreements of 95.7% and 96.3% were achieved in the negative ion mode 
for the CV and validation sets, respectively (Figure 2.4A). Positive ion mode data also 
enabled successful discrimination between healthy and tumorous tissues with overall 
agreements of 94.8% for CV and 98.4% for the validation set (Figure 2.4B). The few 
normal pixels classified as HGSC were from samples NL_13 and 14, which presented 
higher stromal cell density compared with the remaining normal samples (Table A1.2). 
Collectively, these results support lipid and metabolites profiles as predictive molecular 
features to distinguish healthy, borderline, and aggressive serous ovarian cancers. 
Molecular markers of ovarian cancer aggressiveness 
The Lasso analysis of normal, HGSCs, and serous BOTs selected subsets of 
molecular features that were highly predictive and characteristic of disease state. An ion 
whose peak abundance is important for characterizing a certain class is given a positive 
weight, whereas ions whose low abundances or absence are important receive a negative 
weight. Note that trends of increased or decreased mass spectral relative abundance and 
2D distributions in tissues were in agreement with the mathematical weight given by the 
Lasso for all of the selected molecular features. Figure 4C shows the statistical weights for 
the selected m/z values for the three-class normal, versus BOT, versus HGSC classification 
model, showing a high diversity of molecular species. Tentative chemical identification of 
the selected ions was performed using high mass accuracy/high mass resolution and 
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tandem MS analyses in comparison with literature reports, lipids and metabolites 
databases, and chemical standards. Table 2.1 provides a list of the m/z values contributing 
to the model and the attributed weights, which were identified as 38 and 21 molecular 
species in the negative mode and positive ion mode, respectively. Attributed molecular 
formulas are included in Table A1.7, with corresponding mass errors for each assigned m/z 
value. Similar m/z values were selected for the two-class molecular model for high-grade 
versus borderline tumors (Table A1.5), supporting the potential role of those metabolic 
species as markers of tumor aggressiveness.  
The selected molecular ions identified include metabolites, fatty acids, and complex 
lipids, which play important biological roles. Within the small metabolites, gluconic acid 
(m/z 195.051) was given a positive weight for HGSC class and a negative weight for BOT 
class. Fragmentation patterns for m/z 195.051 and gluconic acid standard obtained with 
tandem MS analyses for structural confirmation as well as DESI-MS ion images are 
provided in Figure A1.3. Interestingly, the nonoxidized form of gluconic acid, hexose or 
glucose (m/z 215.033), was observed in higher relative abundance in BOT tissues. An ion 
at m/z 174.041, identified as N-acetylaspartic acid (NAA), was selected as an important 
predictive feature for HGSC. Interestingly, NAA has been previously reported as a marker 
of normal brain parenchyma when compared with gliomas (28). Amino acid taurine and 
ascorbic acid were also selected as predictive markers of healthy ovarian tissues when 
compared with tumor tissue, both receiving positive weights for the normal tissue class. 
On the other hand, succinate and malate received negative weights for normal tissue class 
in comparison with serous ovarian tumors. Note that identification of metabolite species 
was performed using DESI-MS tandem MS analyses in comparison with standards and 
literature reports, and high accuracy measurements (<1.7 ppm), although isomeric 
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interferences at the same monoisotopic mass could still occur. Representative tandem MS 
spectra for the metabolites described are provided in Figure A1.4. 
Differences in fatty acid abundances and degrees of saturation were also observed 
between the three tissue subtypes. Polyunsaturated fatty acids, such as FA 20:3 and FA 
22:4, were given positive weights for characterizing the HGSC class. Interestingly, 
monounsaturated fatty acids FA 18:1 and FA 20:1 were given positive weights for 
characterizing serous BOTs, whereas saturated fatty acids (FA 16:0 and FA 18:0) and 
monoacylglycerol (MG 16:0) were given negative weights for serous BOTs. These results 
suggest fatty acid metabolism, including their abundances and degrees of saturation, could 
play a role in serous ovarian tumor proliferation and aggressiveness, as previously shown 
for other cancers types (29, 30). 
Several GP species were also selected as important molecules in characterizing the 
three classes. In the negative ion mode, PG and PI species such as PG 16:0/18:1 or PI 
18:0/18:1 received positive weights by the Lasso almost exclusively for HGSC 
classification. Positive weights for characterizing healthy ovarian tissue were obtained for 
PS species such as m/z 760.515 (PS 16:0/18:1). Furthermore, the molecular model built by 
the Lasso to discriminate between HGSC and healthy tissue (Table A1.3) pinpointed 
additional GP markers such as CL. Positive weights were assigned to CL 72:8 and CL 72:7 
to characterize HGSC, suggesting a role for these lipids in tumor growth and proliferation 
(31). In the positive ion mode, several PC species were selected as predictive markers. For 
example, several C32 PC species were given positive weights for characterization of HGSC 
class, whereas PC34:1 received positive weight for healthy ovarian tissue. For BOT, 
several PC species received negative weights, whereas PC 36:2 provided positive 
correlations for characterizing the serous tumor subtype. The overall positive weights and 
increase in the relative abundances of PC species observed for HGSC class were in 
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agreement with the positive weight attributed to m/z 104.107, identified as the choline head 
group. Notably, previous studies have also reported elevated levels for PC species in human 
epithelial ovarian cancer cells, which was related to tumor proliferation and differentiation 
(32, 33). Representative tandem MS spectra for lipid species detected in the negative ion 
mode and positive ion mode are provided in Figures A1.4 and A1.5, respectively. 
Glycosphingolipids such as Cer were also selected as predictive by our 
classification models. In the negative ion mode for example, Cer d42:3 and Cer d42:2 were 
given positive weights to characterize the healthy ovary class, whereas Cer d42:1 and Cer 
d34:1 received negative weights. On the other hand, Cer d34:1and GlcCer d34:1 received 
positive weights for serous BOT tissue class, whereas Cer d34:2 received a negative 
weight. In the positive ion mode, SM 34:1 received a positive weight for the normal ovarian 
tissue class. Changes in glycosphingolipids expression have been previously reported in 
epithelial ovarian cancer by MALDI-MSI (34). These variations in Cer in normal tissue 
and BOT present interesting insights to the disease, as different fatty acid chain lengths of 
Cer species have been associated to different functions in cancer pathogenesis (35). 
Glycolipids such as TG presented high relative abundances in the mass spectra of 
both tumor subtypes, with distinctive chain lengths and saturation levels characteristic of 
HGSC and BOT. Sterol lipids such as CEs, which are important for cell membrane 
functionality, were selected as predictive markers of HGSC. For example, CE 20:4 was 
attributed a positive weight for HGSC class, whereas CE 18:2 received a negative weight. 
For the normal ovarian tissue class, CE 18:1 received a negative weight by the statistical 
model. The largest weight for the model was attributed to ubiquinone, the fully oxidized 
form of coenzyme Q, one of the electron carriers of the electron transfer chain that is used 
for ATP synthesis and cell signaling for proliferation (36). Ubiquinone presented notably 
increased relative abundances in tumorous areas in comparison with surrounding normal 
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stroma (Figure 2.2), which suggests a potential role for this molecule as a marker for serous 
ovarian cancer.  
Table 2.1:  Identified species selected by the Lasso as significant contributors to the 
molecular model for normal, borderline, and high-grade SOC classification 
with attributed statistical weights.  
Chemical species were tentatively identified by high mass accuracy/high mass resolution 
and tandem MS analyses. Positive weights represent higher relative abundances; negative 
weights represent lower relative abundances. Double negative and double positives 
correspond to greater contributions to the model. Negative ion mode: Lasso weights: "++" 
"- -" ≥ |0.001|; "+" "-" <|0.001|. Positive ion mode: Lasso weights: "++" "- -"  ≥|0.0001|; 
"+" "-" <|0.0001|. Molecular formulas and mass errors are provided in Table A1.7. 
Representative tandem mass spectra for selected m/z species are provided in Figures A1.3-
A1.5. 
 
NEGATIVE ION MODE 
Attribution 
Weights by Lasso 
Detected m/z 
Normal Borderline High-Grade 
Succinate - -  ++ 117.020 
Taurine ++   124.008 
Malate - -   133.014 
Glutamic acid - ++  146.046 
N-acetylaspartic acid - -  ++ 174.041 
Ascorbic acid + -  175.025 
Gluconic acid  - ++ 195.051 
Hexose  ++ - - 215.033 
Phosphatidic acid + - -  226.996 
FA 16:0  -  255.233 
FA 18:2   - 279.233 
FA 18:1 - +  281.248 
FA 18:0  -  283.264 
FA 20:4 +  - 303.233 
FA 20:3  - ++ 305.248 
FA 20:1  ++  309.280 
FA 22:4   + 331.264 
MG 16:0  - -  365.246 
Cer d34:2  - -  570.466 
Cer d34:1 - +  572.481 
Cer d42:3 +   680.575 
Cer d42:2 ++  - 682.590 
Cer d42:1 - -  + 684.607 
GlcCer d34:1  ++  734.535 
PE 36:2   + 742.538 
PG 16:0/18:1 - -  ++ 747.520 
PS 16:0/18:1 ++   760.515 
PG 18:1/18:1   + 773.533 
PG 18:0/18:1   + 775.548 
PS 18:1/18:1 or 18:0/18:2   + 786.528 
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PS 18:0/18:1 ++ -  788.547 
PG 20:4/18:1   + 795.515 
PS 18:0/20:3  +  812.544 
PS 18:0/22:4   ++ 838.56 
PI 18:0/18:2   + 861.552 
PI 18:0/18:1   ++ 863.567 
PI 18:0/20:4 - ++  885.552 
PI 18:0/20:3  - + 887.563 
POSITIVE ION MODE 
Choline group  - ++ 104.107 
DG 36:3  - - + 657.487 
CE 18:2   - - 671.575 
CE 18:1 - -   673.591 
CE 20:4   + 711.548 
SM 34:1 ++   725.558 
PC 32:1   + 770.511 
PC 32:0   + 772.527 
PC 34:1 +  - - 782.569 
PC 34:2  -  796.526 
PC 34:1 + -  798.542 
PC 36:4  - -  820.526 
PC 36:3   ++ 822.542 
PC 36:2  ++  824.558 
PC 38:4   - 848.558 
22:1-Glc-Cholesterol   + 891.704 
TG 52:3  +  895.716 
Ubiquinone - -   901.648 
TG 54:4 -  + 921.729 
TG 56:6   ++ 945.729 
TG 56:4  +  949.759 
Statistical prediction of intratumor heterogeneity 
All the previous analyses described were performed by comparing normal, BOT, 
and HGSC pixels across tissue samples obtained from a total of 78 different patients. To 
evaluate our method performance in detecting tissue heterogeneity within the same patient 
tissue sample, we selected 5 HGSC samples that contained clear regions of stroma tissue 
adjacent to tumor within the same tissue section. Individual statistical classifiers were built 
for each patient using negative ion mode data. Lasso prediction results are presented in 
Table A1.8. Excellent agreements with pathologic classification were observed for all 5 
patients (5,440 pixels), with an overall accuracy of 99.5% obtained for all patients 
combined. To visualize our method's performance in predicting heterogeneous tissue 
Table 2.1 continuation. 
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regions within the same tissue section, we plotted the statistical results for 4 patients 
analyzed, showing pixels classified as HGSC in red and pixels classified as stroma in green 
(Figure 2.5). As observed, high spatial agreement between the predictive images and the 
pathologic diagnosis delineated in the optical images of the H&E stained sections was 
achieved. 
 
Figure 2.5:  Prediction images of tumor and stroma tissue regions by the Lasso for four 
HGSC patients.  
Regions of tumor (red) and stroma (green) are outlined on the optical images of H&E-
stained tissues in the left column. The right column shows the corresponding predictions 
by the Lasso for the areas selected. 
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DISCUSSION 
DESI-MS analysis of serous ovarian tumors allowed a detailed investigation of 
metabolic profiles characteristic of disease state and aggressiveness in the negative and 
positive ion modes. Different metabolic composition and relative abundances allowed clear 
identification of healthy ovarian tissues, HGSC, and serous BOT, within adjacent normal 
stroma and necrotic regions. DESI-MS imaging and pathologic evaluation of the same 
tissue section were essential for study, allowing high specificity for selecting areas of 
interest and extracting molecular information for statistical evaluation. MS imaging 
enabled visualization of features within heterogeneous tumor regions, even for fine 
papillary branches present in serous BOT. This approach is powerful for investigating 
diagnostic molecular signatures as it accounts for cellular heterogeneity and thus increases 
the performance of the tissue-trained statistical classifiers. Here, we report an extensive 
investigation into the molecular profiles for HGSC and serous BOT, identifying 
metabolites, fatty acids, and complex lipids as potential markers to discriminate aggressive 
and noninvasive tumors. 
Alterations in the abundances of lipids and metabolites between healthy ovarian 
and tumorous serous tissues were detected by DESI-MS imaging, which reflect 
abnormalities in cancer cell metabolism. High relative abundance of ascorbic acid (vitamin 
C), a natural oxidant from dietary origin, was observed in normal ovarian tissue. The role 
of vitamin C in maintaining proper functioning of the ovary has been previously described 
in the literature, such as for the development and survival of ovarian follicles (37). Several 
molecules were identified as important predictive markers of disease state and cancer 
aggressiveness, which may become important diagnostic markers and serve as novel 
targets for therapeutic approaches. Gluconic acid, a metabolite that connects the glucose 
and pentose phosphate pathways, was identified as a predictive marker for discrimination 
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between HGSC and serous BOT and is thus a possible marker of ovarian cancer 
aggressiveness. Remarkably, gluconic acid has been previously found to discriminate 
between stages pT2 and pT3 of prostate cancer (38). Succinate and malate, intermediates 
in the citric acid cycle, were also identified as predictive markers of serous ovarian cancers. 
The oncogenic activity of succinate has been previously reported, and accumulation of 
malate has been shown to enhance fatty acid and cholesterol biosynthesis, enabling tumor 
growth (39). 
Alterations in fatty acid and complex lipid metabolism were also detected by our 
approach. Previous studies have outlined the importance of fatty-acid synthesis in tumor 
biology due to their ability to modulate the fluidity of lipid membranes and affect cellular 
machinery (40). Moreover, unsaturated fatty acids have been associated with clinically 
aggressive tumors and were reported to stimulate the proliferation of human breast cancer 
cells, whereas saturated fatty acids induced cell death (29, 30). Our results suggest that 
alterations in fatty-acid unsaturation levels may play a role in serous ovarian cancer 
proliferation and aggressiveness. For example, polyunsaturated fatty acids, such as FA 20:3 
and FA 22:4, were observed at high relative abundances in HGSC tissues and were given 
positive weights by the Lasso for this tissue class. To satisfy the high proliferating 
necessities of tumor cells, GPs are synthesized for continuous membrane production (41). 
During the review of this article, a related study was published aiming to diagnose different 
types of epithelial ovarian cancer based on lipid profiles by DESI-MS (42). Our results 
show good agreement with some of the changes in GPs identified for normal and carcinoma 
differentiation, such as PS 36:1 and PS 34:1, which showcases the potential of DESI-MS 
as a robust tool for tissue characterization. In our study, several PG and PI species were 
identified as predictive markers for tumor aggressiveness, with increased relative 
abundance in HGSC samples. CLs, which are complex GP species present almost 
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exclusively in the inner mitochondrial membrane, were also observed in increased relative 
abundances in HGSC tissue when compared with normal tissue (31). Moreover, increased 
relative abundances of ubiquinone, a component of the mitochondrial respiratory chain, 
was also found to be characteristic of serous ovarian tumors (36). Interestingly, mutations 
in mitochondrial DNA have been reported for human ovarian carcinomas, suggesting that 
alterations in mitochondria play a role in ovarian cancer tumorigenesis (43). 
Another interesting group of lipid molecules identified as potential biomarkers by 
DESI-MS analysis was Cer. Ceramides are SP, which have been studied for their role in 
apoptosis and have been found to be overexpressed in necrotic tissue (35, 44). Here, we 
identified many Cer species with different fatty-acid chain lengths and saturation levels, 
which can help understand many of the underexplored biological functionalities of these 
molecules (35). LGSC, which evolve from BOTs, commonly present more chemo resistant 
responses than high-grade carcinomas (45). Notably, Cer have been investigated for their 
role as potential biomarkers of chemotherapy response, and in this study, high relative 
abundances of Cer species such as Cer d34:1 or GalCer d34:1 were characteristic of BOT 
(35). This finding could be of clinical importance, as it could help understand the 
mechanisms involved in chemotherapy response of serous carcinomas (4). Future studies 
will be pursued to investigate the biological pathways related to the expression of the 
molecules identified, which may help elucidate the pathogenesis of serous ovarian cancers 
and identify novel markers for early detection. 
The classification models generated by the Lasso were successful in interpreting 
the large data sets, identifying molecular predictors of each tissue type as well as providing 
robust statistical classifiers. HGSC was classified with high accuracy in comparison with 
healthy stromal ovarian tissues, for both negative and positive ion mode data (96.4% 
overall agreement). Due to the recent findings proposing the distal end of the fallopian tube 
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as the site of origin of HGSC (4), we plan to analyze fallopian tube molecular profiles to 
investigate the biological processes by which high-grade carcinoma initiates. A three-class 
classification model to differentiate between normal, BOT, and HGSC was also built 
resulting in an overall agreement of 91.9% with pathologic evaluation. Overall, our method 
allowed discrimination between normal tissue and tumorous tissues including BOT and 
HGSC with 96.2% overall agreement. 
Importantly, we also investigated predictive markers of tumor aggressiveness by 
directly comparing borderline and aggressive serous tumors using a two-class molecular 
model. Due to the contrasting biological pathways involved in BOT (which can develop to 
LGSC) and HGSC, both serous ovarian cancers were anticipated to entail distinct 
molecular features (4). The two-class classification models DESI-MS imaging data 
presented an overall accuracy of 93.0% in predicting HGSC and BOT, which demonstrates 
the clinical value of this technique in differentiating tumors with distinct invasive and 
aggressive behaviors. Remarkably, the three BOT samples misclassified as HGSC were re-
evaluated by pathologic analysis and presented unusual histologic features associated with 
the development of low-grade carcinomas. The results suggest that changes in molecular 
composition detected by DESI-MS could be indicative of malignant behavior in borderline 
samples. We plan a follow-up study to investigate more clinically relevant cases as well as 
to further explore the molecular mechanism of development from borderline to malignant 
tumors. 
Proposed priorities to reduce ovarian cancer incidence and improve patient 
outcome include the identification of biomarkers for prevention and early disease detection 
and the development of an integrated molecular view of the disease (7, 46, 47). Our results 
suggest that DESI-MS addresses these concerns by providing molecular information of a 
diverse group of lipids and metabolites that can serve as potential new markers of serous 
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ovarian cancer. Moreover, predictive markers of HGSC and BOT tumors were identified 
that may be used for the development of new therapeutic targets and preventive screening. 
Importantly, the ease and speed by which diagnostic molecular information can be obtained 
by DESI-MS and other relative ambient ionization techniques make this technology 
attractive for clinical use (48). Thus, we suggest DESI-MS as a potential clinical 
technology to integrate metabolic markers with clinical and pathologic approaches to 
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Chapter 3. Investigating the Effects of FABP4 Expression in Ovarian 
Cancer Metabolism3 
INTRODUCTION 
Primary cytoreductive surgery followed by adjuvant chemotherapy is the standard 
treatment for ovarian cancer. Several reports have established a link between residual 
disease after surgery and shorter overall and progression-free survival, as well as poor 
response to adjuvant chemotherapy (1-3). Incomplete resection can result from the 
presence of numerous, dense nodules that simply cannot be removed, distant tumor 
metastasis, location of tumor near critical organs (e.g., porta hepatis), and extensive 
mesenteric involvement. Thus, while a surgeon’s skill is important, residual disease could 
occur because the intrinsic biology of the tumor creates a highly metastatic and infiltrative 
disease pattern, making complete resection infeasible (3,4). A large retrospective study 
showed that initial disease distribution could also affect patient survival despite aggressive 
cytoreductive efforts (5). Considering the impact of residual disease on patient survival, 
many studies are now focusing on the development of predictive models for residual 
disease. However, currently there is little understanding of the biological mechanisms that 
could lead to residual disease in ovarian cancer.  
Previous studies have shown that high expression of fatty acid binding protein 4 
(FABP4) can be a reliable molecular predictor of residual disease in high-grade serous 
ovarian cancer (4). FABP4 is implicated in atherosclerosis, diabetes, inflammatory 
response, and angiogenesis (6-12). In prostate and ovarian cancers, FABP4 acts as a key 
 
3 Adapted with permission from Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, et al. 
FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 2018;9(1):2923. 
Copyright © 2018, Springer Nature. The data presented in this chapter was collected, analyzed and 
interpreted by Sans M. Samples were provided by Dr. Sood’s laboratory at the MD Anderson Cancer 
Research Center along with clinical and molecular data. Gharpure KM, Pradeep S, and Sans M prepared the 
manuscript. All other others contributed in revising the manuscript. 
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mediator between adipocytes and cancer progression (13,14). However, FABP4 regulation 
and the functional implications of FABP4 overexpression in increasing the metastatic 
potential of ovarian cancer cells remain to be investigated. In this study, we contributed to 
the investigation of the underlying tumor biology responsible for the aggressive pattern of 
tumor metastasis using desorption electrospray ionization mass spectrometry (DESI-MS) 
imaging to investigate the downstream effects of FABP4 expression in ovarian cancer 
metabolism. As discussed in Chapter 1, we have previously applied DESI-MS in 
combination with multivariate statistical methods to evaluate and detect metabolic markers 
associated with ovarian cancer aggressiveness (15). Here, we aim to go beyond cancer 
diagnosis and subtyping, and apply this technology to explore changes in the metabolic 
levels detected by DESI-MS associated with the expression of the FABP4 gene.  
MATERIALS AND METHODS 
Tumor samples  
High-grade ovarian tumor samples were obtained from the Cooperative Human 
Tissue Network (CHTN) and the MD Anderson Tissue Bank under an approved IRB 
protocol and written consent was obtained for the use of patient samples for research. The 
details regarding the quality control for the samples obtained from CHTN can be found at 
https://www.chtn.org/quality.html 
In vivo mouse models  
Female athymic nude mice were purchased from Taconic Farms (Hudson, NY) and 
housed in pathogen-free conditions by our collaborators in Dr. Anil K. Sood’s laboratory 
at the University of Texas MD Anderson Cancer Research Center. The mice were cared 
for according to the guidelines of the American Association for Accreditation for 
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Laboratory Animal Care International and the US Public Health Service Policy on Humane 
Care and Use of Laboratory Animals. All in vivo experiments and protocols were approved 
by MD Anderson’s Institutional Animal Care and Use Committee. To establish the tumors, 
1 × 106 cells/mouse A2780 cells, 8 × 105 cells/mouse HeyA8 MDR-Luc cells, or 1 × 106 
cells/mouse Ovcar 5-Luc cells were injected into the ovary. No therapeutic intervention 
was conducted in the experiment in which FABP4-overexpressing cells were injected. For 
all therapeutic experiments, a siRNA dose of 200 μg kg−1 was used, and the treatments 
were started 1 week after cell injections. The mice were divided into two groups: control 
and treatment, 10 mice/group. Mice in the control group received control siRNA 
incorporated into neutral DOPC liposomes. Mice in the treatment group received FABP4 
siRNA incorporated into DOPC liposomes. The doses were given twice weekly 
intraperitoneally. The mice were monitored daily for any toxic effects. Tumor tissues were 
then frozen in optimal cutting temperature media or snap frozen. 
DESI-MS imaging  
DESI-MS imaging was conducted as described previously (15,16). A 2D Omni 
Spray (Prosolia Inc., Indianapolis, IN) coupled to an LTQ-Orbitrap Elite mass spectrometer 
(Thermo Scientific, San Jose, CA) was used for tissue imaging. DESI-MS imaging was 
performed in the negative and positive ion mode from m/z 100–1500, using a hybrid LTQ-
Orbitrap mass spectrometer which allows for tandem MS experiments, high mass accuracy 
(<5 ppm mass error), and high mass resolution (240,000 resolving power) measurements. 
The spatial resolution of the imaging experiments was 200 µm. Spatially accurate ion 
images were assembled using BioMap and MSiReader software. The histologically 
compatible solvent system dimethylformamide:acetonitrile (DMF:ACN) 1:1 (v/v) was 
used for negative ion mode analysis, at a flow rate of 1.2 µl min−1. For positive ion mode 
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analysis, pure ACN was used, at a flow rate of 3 µl/min. The N2 pressure was set to 185 
psi. For ion identification, high mass resolution/accuracy measurements using the same 
tissue sections analyzed were conducted. Tandem MS analyses were performed using both 
the Orbitrap and the linear ion trap for mass analysis. 
Histopathology and light microscopy 
The same tissue sections analyzed by DESI-MS imaging were subjected afterwards 
to standard H&E staining protocol. Light microscopy images of the H&E stained slides 
were taken using the EVOS FL Auto Cell Imaging System (Invitrogen, Thermo Fisher 
Scientific, Waltham, MA, USA). 
Statistical analysis  
MS data corresponding to the areas of interest were extracted using MSiReader 
software. The m per z range was discretized by performing hierarchical clustering and 
cutting the resulting dendrogram at distance 0.05. Peaks appearing in more than 10% of 
the pixels were kept for analysis. Logistic regression was performed with Lasso 
regularization using the “glmnet” package (17) in the R language. Regularization 
parameters were determined by 3-fold cross-validation analysis. The data were randomly 
equally divided into training and validation sets of samples, 50-50 per patient basis. The 
training set was used to build a model by cross-validation (CV) based on assigned statistical 
weights to specific lipid and metabolites important for classification of samples as having 
either high- or low-FABP4 expression. To determine trends in molecular composition, 
Significance Analysis of Microarrays (SAM) was used, providing a list of statistically 
significant m/z features between the high- and low-FABP4 expression groups.  
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RESULTS 
Effect of FABP4 expression on human ovarian cancer tissue metabolites  
To explore the effects of FABP4 on metabolic changes in human ovarian cancer 
tissues, we evaluated metabolic and lipid trends related to FABP4 gene expression by 
DESI-MS imaging. Gene expression levels for each tissue sample were provided by our 
collaborators in Dr. Anil K. Sood’s laboratory at the MD Anderson Cancer Research Center 
using quantitative real-time PCR. In this study, a total of 31 high-grade ovarian cancer 
tissue samples were analyzed by DESI-MSI in both negative and positive ion modes to 
investigate a broad range of lipid and metabolites related to FABP4 expression. Using this 
approach, only the data specific to the tumor region were selected and evaluated, thus 
eliminating the inclusion of stromal lipids and metabolites. 
SAM analysis was conducted to identify statistically significant m/z values (mass 
to charge ratios) detected by DESI-MSI characteristic of low- or high-FABP4 expression. 
Positive SAM scores represent higher relative abundance in samples with low-FABP4-
expression, and negative SAM scores represent higher relative abundance in samples with 
high-FABP4-expression. Negative ion mode data revealed 361 and 289 monoisotopic m/z 
values associated with low or high FABP4 expression, respectively, with false discovery 
rate (FDR) of <3.8%. From these, 238 m/z values were tentatively identified by high mass 
accuracy measurements and tandem MS analysis (Table A2.1) as small metabolites, fatty 
acids (FA), ceramides (Cer), glycerolipids (GL), monoacylglycerophosphates (PA), 
glycerophosphoethanolamines (PE), glycerophosphoglycerols (PG), 
glycerophosphoinositols (PI), glycerophosphoserines (PS), and cardiolipins (CL). 
Molecular formulas detected m/z and mass errors in ppm are provided in Table A2.2 for 
the species identified. Fatty acid and metabolite composition were observed to significantly 
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differ between the two expression groups. For example, higher unsaturation and oxidation 
of fatty acid species was selected as characteristic of high FABP4 expression. A significant 
number of m/z values related to high FABP4 expression corresponded to GL, PE, PG, and 
lysophospholipid species, such as LysoPE, LysoPG, and LysoPI. On the other hand, CL 
species were almost exclusively selected with the low-FABP4-expression type. These 
variations in lipid composition suggest alterations in metabolism and biosynthesis due to 
the changes in the expression of the FABP4 gene. 
We then applied the Lasso (Least absolute shrinkage and selector operator) (17) 
method to evaluate if predictive statistical models could be built to classify samples as 
having low- or high-FABP4 expression based on metabolite composition (Table 3.1). The 
samples were randomly divided into a training and validation set of samples (50:50). 
Results based on negative ion mode data yielded an overall agreement of 81.6% and 0.79 
area under the curve (AUC) value for the training set performance. The remaining 
independent set of samples were classified with an overall agreement of 56.1% and AUC 
value of 0.60. In positive ion mode data, an overall agreement of 74.2% for CV (AUC = 
0.73) and 61.7% agreement for the validation set (AUC = 0.58) were achieved. To improve 
prediction of FABP4 expression, positive and negative ion mode data were combined to 
build a comprehensive model. Using this approach, 66.7% of high-FABP4 patients and 







Table 3.1:  Confusion matrix showing lasso classification of high-grade serous cancer 
samples into high and low FABP4 expression based on DESI-MS lipid and 
metabolite data in negative, positive and combined polarities.  
Results are shown for pixels and patient classification both for the training set (cross-
validation) and validation set. Agreement is calculated comparing lasso prediction to 
FABP4 expression provided by qRT-PCR. AUC – Area Under the Curve.   
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Evaluating lipid and metabolite changes due to FABP4 expression from in vivo mouse 
models   
To further investigate direct changes in lipid and metabolite levels due to the 
changes in FABP4 expression, we analyzed in vivo tissues from high-grade ovarian cancer 
mouse models. Using DESI-MS imaging, we compared tumor tissues of FABP4 siRNA 
group (low FABP4 expression, n = 3) to control siRNA samples (high FABP4 expression, 
n = 3). SAM analysis revealed 627 monoisotopic m/z values characteristic of FABP4 
silencing, with FDR < 5.5%. From the selected m/z values, a total of 184 species (59 
increased in low FABP4, 125 increased in high FABP4) were identified as metabolites, FA 
and complex lipids, with attributed SAM scores associated to FABP4 expression (Table 
A2.3). Overall, the majority of the lipid classes received negative SAM scores, thus being 
associated to high FABP4 expression. For example, FA and monoacylglycerophosphates 
(PA) were selected exclusively for characterization of the control siRNA samples. On the 
other hand, Cer species were associated with low expression of the FABP4 gene. These 
trends were also reflected by the relative abundances observed in the ion images as shown 
in Figure 3.1, where all the lipid species shown except for the Cer d42:1 displayed higher 
relative abundances within the high FABP4 samples. Remarkably, comparison between 
the metabolic species selected by SAM analysis for both human and mouse samples 
resulted in a total of 76 common m/z values related to high or low FABP4 expression (Table 
3.2). Among these, various FA species were associated with high expression of the FABP4 
gene in both the mice and human samples. Interestingly, common GL and PI species for 
both animal samples were specific to the high FABP4 class, while Cer species were 
characteristic of tissues with low FABP4 expression. Differences in FA chain length and 
saturation level were also observed within the same GP class. For example, longer FA 
chain in PE and lysoPE species were associated with high FABP4 expression, while longer 
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FA chain in PS lipids were characteristic to tissue samples with lower FABP4 expression. 
These similar metabolic trends observed in both human and mice samples strongly suggest 
and corroborate the effects of the FABP4 gene in metabolism and biosynthesis. 
Figure 3.1:  DESI-MS ion images of in vivo tumor samples from control siRNA and 
FABP4 siRNA treatment groups.  
Areas of red intensity within the ion images represent highest (100%) and black lowest 
(0%) relative abundances. Lipid species are described by head group, number of fatty-acid 














Table 3.2:  Lipid and metabolite species related to low and high expression of the FABP4 
gene in both human and mice samples based on SAM analysis from DESI-
MS imaging data.  
siFABP4 - LOW FABP4 
EXPRESSION 










Metabolites  Metabolites  Fatty Acids  
Succinate C4H5O4 Taurine C2H6NO3S FA 18:3 C18H29O2 
Glutathione C10H16N3O6S Xanthine C5H3O2N4 FA 18:2 C18H31O2 
Glycerophosphoethanolamines Glycerophosphoethanolamines FA 18:1 C18H33O2 
LysoPE 18:1 C24H45NO8P LysoPE 16:0 C21H43NO6P FA 18:0 C18H35O2 
PE 18:1/18:1 C41H77NO8P LysoPE 18:0 C23H47NO7P FA 19:0 C19H37O2 
PE 22:6/16:0 C43H73NO8P PE P-18:0/18:4 C41H73NO7P FA 20:5 C20H29O2 
Glycerophosphoglycerols PE P-38:4 C43H77NO7P FA 20:4 C20H31O2 
PG 18:0/18:1 C42H80O10P PE 20:4/18:1 C43H75NO8P FA 18:2 C18H32O2Cl 
PG 18:0/18:0 C42H82O10P PE 40:5 C45H79NO8P FA 18:1 C18H34O2Cl 
PG 42:7 C48H80O10P PE 22:4/18:0 C45H81NO8P FA hydroxy 20:4 C20H31O3 
Ceramides Glycerophosphoglycerols FA 22:6 C22H31O2 
Cer d18/16:0 C34H69NO3Cl LysoPG 18:2 C24H44O9P FA 22:5 C22H33O2 
Cer m18:1/22:0 C40H79NO2Cl LysoPG 18:1 C24H46O9P FA 22:4 C22H35O2 
Cer m42:1 C42H83NO2Cl LysoPG 22:6 C28H44O9P FA 22:3 C22H37O2 
Cer d42:1 C42H83NO3Cl PG 16:0/18:1 C40H76O10P FA 20:4 C20H32O2Cl 
Cer d42:0 C42H85NO3Cl PG 18:2/18:2 C42H74O10P FA 24:5 C24H37O2 
Cer d18:1/26:1 C44H85NO3Cl PG 18:2/18:1 C42H76O10P FA 24:4 C24H39O2 
Cer d18:1/26:0 C44H87NO3Cl PG 18:1/18:1 C42H78O10P FA 22:4 C22H36O2Cl 
Cardiolipins  PG 20:4/20:4 C46H74O10P Glycerophosphoinositols 
CL 70:7 C79H138O17P2 Cardiolipins  LysoPI 18:0 C27H52O12P 
CL 70:6 C79H140O17P2 CL 72:4 C81H148O17P2 LysoPI 20:4 C29H48O12P 
CL 74:10 C83H140O17P2 Glycerolipids  PI 20:3/17:1 C46H80O13P 
CL 74:9 C83H142O17P2 MG 18:0/0:0 C21H40O4Cl PI 18:1/20:4 C47H80O13P 
Glycerophosphoserines DG 36:3/0:0 C39H70O5Cl PI 18:0/20:4 C47H82O13P 
PS P-36:2  C42H77NO9P DG 36:2/0:0 C39H72O5Cl PI 18:0/20:3 C47H84O13P 
PS P-36:1 C42H79NO9P Glycerophosphoserines PI 18:0/22:6 C49H82O13P 
PS 18:0/18:1 C42H79NO10P PS 18:1/18:2 C42H75NO10P PI 18:0/22:4 C49H86O13P 
PS 40:2 C46H85O10NP PS 18:0/20:4 C44H77O10NP   
PS 40:1 C46H87O10NP PS 39:4 C45H79NO10P   
PS 18:1/24:1 C48H89O10NP     




The integration of DESI-MS imaging with multivariate statistical analyses offers 
the powerful capability to carefully evaluate changes in lipid and metabolite levels 
associated with other molecular and histological features in a tissue sample. Metabolic 
changes in ovarian cancer have been studied before (18,19). However, without spatial 
information, it is difficult to determine whether the metabolic alterations are occurring in 
the tumor or stromal compartment. To focus on the tumor compartment, we employed 
DESI-MS imaging, which allowed us to identify the chemical species present in the tissue 
as well as their spatial distribution. Analysis of the data, specific to tumor compartment of 
patient samples revealed that a unique metabolic profile is associated with the expression 
of FABP4. Higher unsaturation and oxidation of fatty acids and lysophospholipids were 
observed in higher relative abundance in samples with higher FABP4 expression. Several 
studies have suggested that unsaturated fatty acids play a key role in pathways leading to 
tumor progression by activating the beta catenin pathway, downregulating PTEN or 
increasing cancer cell adhesion (19-22). Fatty acid oxidation has also been shown to 
increase metastasis in breast and ovarian cancer models (14,23). Lysophospholipids have 
also been known to stimulate cancer cell migration and they are also considered as potential 
biomarkers for ovarian cancer (24,25). High expression of FABP4 can thus regulate 
various metabolites and protein pathways that can lead to aggressive metastasis of ovarian 
cancer. This data elucidating the key metabolic determinants of ovarian cancer metastasis 
thus lay a strong foundation for future studies which can focus on the development of 
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Chapter 4. Spatially Controlled Molecular Analysis of Biological 
Samples Using Nanodroplet Arrays and Direct Droplet Aspiration4  
INTRODUCTION 
Mass spectrometry (MS) imaging and spatial profiling allows untargeted and label-
free chemical and spatial characterization of hundreds of molecular species from biological 
samples (1,2). Secondary ion mass spectrometry (SIMS) and matrix assisted laser 
desorption ionization (MALDI) are the most well-established techniques for MS imaging 
and profiling of biological samples under vacuum (3-7). Ambient ionization MS techniques 
offer an alternative approach for direct and in situ  analysis of biological samples with 
minimal sample preparation requirements and at atmospheric pressure conditions (8). 
Within the ambient ionization MS techniques, liquid extraction MS approaches rely on the 
use of solvent to extract molecular information from a sample surface, allowing low sample 
abrasiveness and tunable analyte extraction for tissue imaging and analysis (9). A variety 
of methods using liquid extraction have been employed to directly analyze biological tissue 
samples (9,10), including spray-based methods such as desorption electrospray ionization 
(DESI) (11,12), as shown in Chapter 2 and 3 of this dissertation, and direct liquid extraction 
methods such as liquid microjunction surface sampling probe (LMJ-SSP) (13), liquid 
extraction surface analysis (LESA) (14,15), nanospray desorption electrospray ionization 
(nano-DESI) (16,17), and the Single-Probe (18). The range of molecular species detectable 
by each method is commonly dictated by their extraction and ionization mechanisms, 
generally most effective at analyzing small molecules, such as lipids and metabolites. 
Direct liquid extraction methods allow longer solvent-sample interaction times and are 
 
4 Adapted with permission from Sans M, Krieger A, Wygant, B. R., Garza, K.Y M, et al. Spatially controlled 
Molecular Analysis of Biological Samples using Nanodroplet Arrays and Direct Aspiration. J. Am. Soc. 
Mass Spectrom. 2020;31,2,418-428. Copyright © 2020, American Chemical Society. Sans M performed all 
experiments and data analyses and prepared the manuscript. Krieger A, Wygant, B.R, and Garza, K.Y.M 
assisted with experiments and data analysis. All authors reviewed the manuscript.  
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often coupled to a direct nanospray or an ESI source for enhanced ionization efficiency 
and overall sensitivity.  
Mass spectrometry imaging by liquid extraction techniques can be performed at 
various spatial resolutions. High spatial resolution imaging has been demonstrated by 
nano-DESI (>10µm) (19,20), and the Single Probe (~8.5 µm) (18), while other methods, 
such as LESA and the LMJ-SSP, allow direct sampling of larger tissue regions with a 
spatial resolution of ~600-1000 µm (21). Spatial resolution in liquid extraction techniques 
is generally related to the size of the sampling area and/or probe, which is intrinsic to each 
individual approach. For example, in LMJ-SSP, nano-DESI, and the Single-Probe, the 
spatial resolution is often restricted to the diameter of the capillaries used to generate the 
micro junction or liquid bridge, while in LESA, the spatial resolution is determined by the 
diameter of the sampling tip (9). Although feasible, the ability to precisely control and tune 
the spatial resolution of these methods for different applications can be impractical and 
requires change in hardware such as the sampling probe used. Moreover, precisely 
determining the dimension of the sampling area, and the spatial resolution, can be 
challenging. Several experimental approaches have been proposed to measure spatial 
resolution, either by using standardized grids, measuring the probe trace across a surface, 
resolving a feature of known dimensions, or evaluating relative changes in the abundance 
of a specific m/z feature as the a probe is rastered across the surface (2,18,19,22). 
Therefore, methods that would enable practical and precise tuning, control, and accurate 
measurements of the spatial resolution in liquid extraction techniques could improve their 
applicability and performance for direct MS profiling and imaging. 
Here, we report the development of an alternative approach for spatially controlled 
imaging and spatially controlled analysis of metabolites and lipids from biological tissue 
samples. This method allows precise tuning and deposition of arrays of solvent droplets 
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(~2-50 nL) onto sample surfaces using a piezoelectric liquid handling dispenser, followed 
by droplet aspiration and ionization through a fused capillary emitter for MS analysis. The 
spatial resolution is directly controlled by the diameter of the droplet in contact with the 
tissue sample, which can be precisely tuned with the piezoelectric dispenser. Efficient 
analyte extraction and transport is achieved by directly and entirely sampling the droplet 
through the fused silica capillary. In the imaging mode, arrays of droplets can be formed 
to cover areas of interest for molecular analysis. Here, we apply this method to image tissue 
samples with high spatial control using different droplet sizes (390, 420, and 500 µm), as 
well as profiling of human cells. Overall, our results demonstrate this approach is valuable 
for spatial profiling of biological tissue and imaging at tunable and well-controlled spatial 
resolution.    
MATERIALS AND METHODS 
System design 
A multi-channel piezoelectric dispenser consisting of a print head assembly, which 
can hold four 2 mL fluid reservoirs and four piezoelectric microdispensing devices (MJ-
AT-01-80, MicroFab, TX) was used.  For these experiments, only one microdispensing 
device was used at a time. A pneumatic line was used to transfer solvent from the reservoir 
to the dispensing tip. The print head assembly was mounted on a 3-dimensional positioner 
(CH Instruments, TX) that had a 50 mm range in the x, y, and z directions, with a resolution 
of 0.1 micrometers.(23)  
A blunt, platinum-coated fused silica capillary (OD 360 µm – ID 100µm, New 
Objective Inc., MA) cut at a length between 12 to 15mm comprised the nanospray emitter. 
The angle and position of the conductive emitter were controlled using an arm coupled to 
a rotation and XYZ mount (Newport Corporation, CA). Voltage was supplied to the emitter 
 68 
via a voltage pin in the arm holder connected to the emitter clasp. A bent extended DESI 
transfer tube was used for analyte transfer from the emitter to the MS. The arm was 
mounted on a 2D moving stage (Prosolia Inc., IN). Two Dino Lite Microscope cameras 
(AnMo Electronics Corporation, Taiwan) were used to assist careful alignment of the 
emitter. 
Microscope glass slide treatment 
Glass slides were treated with dichlorodimethylsilane to produce hydrophobic 
substrates for tissue mounting. To produce the hydrophobic substrates, glass slides were 
soaked in a 50:3 solution of n-hexane (95%+, Fisher) and dichlorodimethylsilane (99%+, 
Acros Organics) for 5 minutes, before being soaked in only n-hexane for an additional 5 
minutes. They were then dried at 60°C for 1 hour in a vacuum oven to dry and cure. 
Tissue and biological sample analysis 
Mouse brain tissue samples were purchased from Bioreclamation IVT. Normal and 
tumor ovarian and brain human tissues were acquired from the Cooperative Human Tissue 
Network under approved IRB protocol. Samples were kept frozen at -80 °C prior to 
analysis and sectioned onto the treated glass slides at 16 µm using a CryoStar NX50 
cryostat (Thermo Fisher Scientific). For diagnosis and slide annotation, tissue samples 
were stained with a standard hematoxylin & eosin (H&E) staining procedure and evaluated 
by expert pathologists. Ovarian cell pellets were obtained from the MD Anderson Tissue 
Bank and kept frozen at -80 °C. Sample aliquots (10-20 µL) were deposited onto 
microscope slides and allowed to dry before analysis.  
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Mouse brain homogenate 
Mouse brain homogenates were prepared by thawing and thoroughly mixing a 
whole mouse brain organ with a cordless microtube homogenizer (Cole-Parmer, IL). The 
resulting tissue mixture was added into a peel-away mold (Thermo Scientific, MA) and 
frozen overnight at -80 °C. The frozen mouse brain homogenate was then sectioned at 16 
µm using a CryoStar NX50 cryostat (Thermo Fisher Scientific) and mounted onto 
microscope glass slides.   
Imaging workflow and data analysis 
For tissue section analysis, a line of consecutive dimethylformamide (DMF) 
droplets was dispensed across the entire length of the tissue section, stepping the dispenser 
head in the y-direction after each droplet. After the vertical array was deposited on the 
tissue sample, the sample slide was placed in the slide holder of the 2D moving stage. After 
droplet deposition, the droplet array was aligned to the capillary emitter, allowing 
sequential transfer of individual droplets to the MS. Note that with this configuration, slight 
changes in the total contact time between the droplet and the sample surface (extraction 
time), occurred between the first and subsequent droplets (<30 sec between first and last) 
(Figure A3.1). A washing step using pure methanol to flush the capillary emitter was 
incorporated between each line of droplets. Mass analysis was performed using a Q 
Exactive Orbitrap (Thermo Fisher Scientific, CA) in the negative ion mode from m/z 100 
to 1,500, at 70,0000 mass resolving power. The resulting raw data for each droplet was 
averaged (2-3 scans) using Thermo Xcalibur software and extracted as a xlsx file format. 
Note that the number of averaged scans was kept consistent for each droplet analyzed 
within a sample. Existing software for image plotting was not compatible to the data format 
obtained from these experiments, and instead ion images were built in R Studio by plotting 
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the absolute abundance of an ion of interest in two dimensions, with every pixel 
corresponding to an individual droplet. The gtools, readxl, rowr, grDevices and viridis 
packages in R were used. The source code and associated documentation can be found in 
the GitHub repository (https://bitbucket.org/eberlinlab/madi-image/src/master/). Tandem 
mass spectrometry analysis was performed for identification during analysis using high-
energy collisional dissociation (HCD). Cosine similarity analysis was performed in the 
CRAN R language.  
DESI-MS analysis 
DESI-MS analyses of mouse brain tissue samples were performed for comparison 
purposes. A 2D Omni Spray (Prosolia Inc., IN) coupled to a Q Exactive mass spectrometer 
(Thermo Scientific, CA) was used. DESI-MS was performed in the negative ion mode from 
m/z 100 to 1500, at 70,000 resolving power. Pure DMF and DMF: acetonitrile (ACN) were 
used as the solvent systems, at a flow rate of 1.5 µL/min to achieve a matching spatial 
resolution of 500 µm.  
RESULTS  
Design and development 
To provide controllable and precise spatial resolution for ambient ionization MS 
profiling and imaging, we used a piezoelectric picoliter dispenser for accurate deposition 
of individual solvent droplets onto tissue samples, coupled to effective analyte transfer 
from tissue samples to the MS for sensitive analysis. The piezoelectric picoliter dispenser 
system utilizes pneumatic lines to transport solvent to the dispensing tips (Figure 4.1A). 
For these experiments, a single dispensing tip was used. Single droplets of sub-nanoliter 
volume (500 pL for DMF, Figure A3.2) were dispensed by controlling the voltage 
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differential applied to a set of electrodes attached to a piezoelectric material bonded to a 
glass micropipette. Dispensing multiple droplets on the sample in the same location results 
in a droplet of increased volume and diameter. The diameter of the resulting droplets in 
contact with the tissue sample was thus effectively controlled by adjusting the number of 
droplets dispensed per spot. The position of the piezoelectric tip was carefully controlled 
by a 3-dimensional positioner, allowing precise deposition of droplet arrays. 
Utilizing a single piezoelectric tip, we deposited a line of consecutive solvent 
droplets onto the tissue surface in the y-direction (Figure 4.1B). Deposited droplets were 
then aspirated to the MS using a fused silica capillary (OD 360 µm, ID 100 µm) aligned to 
the MS inlet. Positioning and angle of the capillary was controlled using an arm coupled 
to an XYZ and a rotation mount, as shown in Figure 4.1C and Figure A3.3. An extended 
transfer tube was used to enable a wider range of motion in the y-direction. Taking 
advantage of the differential between the ambient pressure (~1.0 bar) and the fore vacuum 
pressure provided by the front end of the mass spectrometer (1.6-1.9 mbar), droplets were 
sequentially aspirated after being placed in contact with the distal end of the emitter, while 
the proximal end of the emitter was inserted into the transfer tube. In this way, the droplet 
was directly introduced into the MS system, thus minimizing sample loss. The fused silica 
emitter was platinum coated at the distal end to allow the application of a voltage bias 
between the MS inlet and the end of the capillary, while the proximal end of the emitter 
was not coated to prevent electrical arcing or discharge. The voltage cord was connected 








Figure 4.1:  System design and development.  
A picoliter dispenser was used to deposit individual solvent droplets in the y-direction onto 
tissue samples for MS imaging (A). The printhead assembly was coupled to a 3-
dimensional positioner to allow accurate positioning of the solvent droplets onto the tissue 
section, which was held static on a slide holder.  Line of DMF droplets after being deposited 
onto a mouse brain sample by the picoliter dispenser deposited (B). After dispensing a line 
of droplets, the tissue sample is mounted on a 2D moving stage, where a capillary emitter 
aligned with the MS inlet is used to individually transport and ionize droplets containing 
solvated analytes extracted from the tissue surface (C).  
 
Metabolite and lipid analysis in the negative ion mode 
Several solvent systems commonly used for metabolite and lipid extraction and 
analysis by solvent based ambient ionization MS techniques were tested in the negative ion 
mode, including DMF, water, ethanol, methanol, and ACN (24). Properties of the solvent 
systems investigated can be found in Table A3.1. Similar molecular species were detected 
with all the solvent systems tested, although qualitative changes in the metabolite and lipid 
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profiles were observed (Figure A3.4). DMF was selected as the solvent system for further 
analysis in the negative ion mode for its high lipid solubility, high surface tension, low 
vapor pressure, and limited adhesion to tissue sections. The high surface tension of DMF 
(37 mN/m) allowed the formation of droplets at high contact angles, even on the mildly 
hydrophilic surfaces of tissue sections, facilitating aspiration by the capillary emitter. To 
correlate droplet dispensing volume with droplet size, and thus spatial resolution, DMF 
droplets containing between 5 (2.5 nL) and 100 individual drops (50 nL) were dispensed 
at a rate of approximately 1 droplet per second on mouse brain homogenate tissue sections. 
Optical images were used to measure the diameter of the droplets deposited onto tissues, 
which ranged from 250 to 650 µm at the volumes tested. Importantly, highly reproducible 
diameters were measured between droplet replicates (RSD=1.5%, n=161), with a clear 
correlation between the number of dispensed droplets and overall supported droplet 
diameter (Figure 4.2, Table A3.2). The droplet diameters were also observed to stay 
consistent and monodispersed following droplet dispensing for tens of seconds until 
significant evaporation is observed, as shown in Figure A3.5 for droplets of 20, 15 and 10 
nL volumes. These results demonstrate that reliable and tunable droplet deposition can be 
achieved using the piezoelectric system, providing precise control over the area sampled, 











Figure 4.2:  Correlation between dispensed DMF droplet volume and spatial resolution 
(droplet diameter µm) for MS imaging (A,B).  
See Table A3.2 for additional metrics. Optical images of mouse brain tissue sections with 







Next, various parameters of the system, such as fused silica capillary positioning, 
inlet temperature, and source voltage, were optimized with the goal of maximizing transfer 
of the deposited droplet from the tissue to the mass spectrometer and mass spectral intensity 
of analytes. Optimization was performed by dispensing replicate arrays of 20 nL droplets 
onto mouse brain homogenate sections, and subsequently analyzing them at different 
parameters (n=7-10 replicates for each parameter). First, silica capillary positioning was 
evaluated. Optimal transfer of the deposited droplets to the mass spectrometer was 
achieved by placing the silica capillary approximately 1-2 millimeters inside the extended 
transfer tube, aligned to the center of the tube orifice, and angled approximately 60-70° 
degrees relative to the sample surface. At this geometry, maximal droplet aspiration and 
transfer was observed, with minimal solvent remaining at the tissue surface. Optimal inlet 
temperature was then determined by varying the inlet temperature from 200-400°C. As 
observed in Figure 4.3A, the total ion count (TIC) values increased at higher temperatures, 
reaching maximum values at 350 °C, followed by a decrease in abundance at 400 °C. These 
results suggest that increasing inlet temperature enhances ionization efficiency likely by 
facilitating solvent evaporation. A similar trend in ion abundance as a function of inlet 
temperature was also observed by selecting several species commonly detected in the mass 
spectra, and separately plotting the sum of absolute abundances according to molecular 
type: metabolites (small carbohydrates and amino acids), fatty acids, and lipids (including 
sphingolipids and glycerophospholipids) (Figure 4.3B). Next, we evaluated the effect of 
source voltage (0.25 – 1.75 kV) on the ion intensity detected. Higher TIC values were 
observed at an applied voltage between 1.25 – 1.5 kV (Figure 4.3C), while a drop in TIC 
values was detected at 1.75 kV. Interestingly, optimal voltage values appeared to differ 
between distinct molecular classes (Figure 4.3D). For example, while lipid species present 
qualitatively higher ion abundances at high potentials (> 1.25 kV), fatty acids and 
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metabolite species were detected at lower ion counts, suggesting that smaller molecules 
may become unstable at higher electric fields. Note that the application of an external 
electric field was not necessary to produce detectable ion signals for larger (>100 nL) 
droplets. For the remaining experiments described, a voltage of 1.5 kV and inlet 
temperature of 350 °C were selected as optimal parameters for the analysis of metabolites, 
fatty acids, and other lipids by this method.  
Monitoring the effects of inlet temperature and source voltage on performance and 
signal detected provide insights into the ionization process of this approach. We 
hypothesize that droplet formation, desolvation, and charge separation occur following a 
similar mechanism as in electrospray ionization (ESI) or nanospray (25), assisted by the 
pressure drop and temperature increase between the atmospheric environment and the inlet 
tube, as well as the application of a voltage differential. As shown in Figure A3.6, similar 
mass spectra profiles in terms of species detected and their relative abundances were 
observed by this method and ESI analysis of a mouse lipid extract solution, supporting the 











Figure 4.3:  Optimization of the inlet temperature applied to the capillary emitter (A,B) 
and applied source voltage (C,D).  
Effect on method performance was evaluated based on total ion current (A,B) and absolute 
abundance of metabolites (m/z 124.006 and 174.041), fatty acids (m/z 281.248 and 
303.233), and lipids (m/z 600.515, 654.568, 747.521, 766.545, 790.540, 834.530, 888.625) 







MS imaging of mouse brain tissue samples 
To demonstrate the imaging capabilities and spatial control of this approach, serial 
sections of mouse brain tissue samples were analyzed using various droplet sizes, including 
387 ± 12 µm (~10 nL), 424 ± 11 µm (~15 nL) and 496 ± 12 µm (~20 nL) (Table A3.3). 
Row and column spacing was added between the droplets to avoid overlap in sampling, 
resulting in pixel sizes of 500x460 µm, 550x510 µm, and 600x560 µm, respectively. DMF 
droplets were dispensed as individual lines in the y-direction (top to bottom) at a rate of 
approximately 1 s per droplet, and analyzed sequentially at an average of 4 s of data 
acquisition per droplet, resulting in a total dispensing and analysis time per line of 
approximately 90 s, as shown in Figure A3.1. The effect of extraction time (3-90 s) in the 
magnitude of the TIC detected was also evaluated. As shown in Figure A3.7, no statistically 
significant differences were observed in TIC between the various extraction times in the 
time scale described (ANOVA p-value = 0.079,). Importantly, the time of analysis per line 
was notably below droplet evaporation time (>160 sec for 10nL, >190 sec for 15 nL, and 
>250 sec for 20nL). Each of the images were acquired in under 1 h, including the time 
added for the washing cycles and for transferring the glass slide between the dispensing 
and 2D moving stages in between lines. During analysis, spikes in the ion current 
corresponding to the individually analyzed droplets were observed in the resulting ion 
chromatograms (Figure A3.8). The mass spectra obtained from different regions of the 
tissue presented high relative abundance of several metabolites, fatty acids, and lipid 
species characteristic of white and grey matter of mouse brain tissue (Figure 4.4B)(26,27). 
A list of the most abundant m/z ratios detected, and their corresponding molecular 
attributions assigned based on high mass accuracy and MS/MS measurements during 
discrete droplet sampling (Figure A3.9) is provided in Table A3.4.  The spatial distribution 
of the ions detected were also characteristic of brain tissue, with high relative abundances 
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of sulfatide species such as ST 18:0 (m/z 806.548) and ST 24:1 (m/z 888.625) in white 
matter, and other lipid species including PG 34:1 (m/z 747.520) and PE 40:6 (m/z 790.540) 
in grey matter (Figure 4.4B). Reproducible spatial distributions of lipid species detected 
were observed at the three different spatial resolutions explored, with improved definition 
of white matter features at higher spatial resolutions. Note that detection of similar lipid 
species has been reported in spatially resolved LESA-MS experiments of mouse brain 
tissue sections in the negative ion mode, although using different solvent systems (27,28). 
When comparing the these results to the  mass spectra obtained by DESI from mouse brain 
tissue sections using the same DMF solvent, similar species were also detected, although 
at different relative abundances (for more discussion, please see additional results in 
Appendix A3, Figure A3.10 and Figure A3.11). 
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Figure 4.4:  Ion images obtained using different droplet sizes from serial mouse brain 
tissue sections and optical images with grey and white matter regions outlined 
and shaded in grey and white, respectively (A). Representative mass spectra 
obtained from grey (top) and white matter regions (bottom) (B).  





Analysis and imaging of cancerous tissue samples  
We next used this platform to analyze normal and cancerous human ovarian tissue 
samples (n=5) using droplets of 491 ± 10 µm in diameter (20 nL), resulting in 600x560 µm 
pixel sizes. Heterogeneous distributions for a variety of different ions tentatively identified 
as deprotonated or chlorinated Cer, PE, PC, PG, PI, and diacylglycerol (DG) species (Table 
A3.5), among others, were observed, and their distribution correlated to histological 
differences within the tumor tissue samples, including stromal, tumor, and necrotic areas 
(Figure 4.5A). As reported in previous studies, an overall higher abundance of lipid species 
was detected from areas corresponding to high tumor cell concentrations (delineated in 
black), compared to the surrounding connective tissue (29,30). Figure 4.5B shows 
representative mass spectra obtained from high-grade serous carcinoma (SC), low-grade 
SC ovarian samples, and normal ovarian tissue. Rich metabolic profiles were obtained, 
with qualitative differences in species and abundances between the mass spectra obtained 
for each tissue type. For example, a higher abundance of PI species, such as m/z 885.553, 
was detected from high-grade SC tissue, while Cer, PE, and PC species were observed at 
a higher relative abundance from spectra obtained from low-grade SC tissue. A lower 
diversity of lipid species, such as PE and PC, were observed from normal ovarian tissue 
mass spectra. Yet, PE P-38:5 (m/z 748.531) was detected at higher relative abundances in 
normal ovarian tissue compared to cancer tissue. In addition, high relative abundance of 
lactosylceramide (LacCer) species, such as LacCer d38:1 (m/z 980.685) or LacCer d42:2 
(m/z 1006.699) were observed in the mass spectral profiles obtained from necrotic tissue 






Figure 4.5:  MS imaging of ovarian carcinoma samples (A). Representative mass spectra 
from high-grade serous carcinoma (top), low-grade serous carcinoma 
(middle), and normal ovarian tissue (bottom) (B).  




We then applied the system to image a glioblastoma and a normal human brain 
tissue section (600x560 µm pixel size). Heterogeneous spatial distribution and distinct lipid 
profiles were observed in the ion images obtained from the glioblastoma tissue, 
corresponding to tumor and necrotic tissue regions as determined by pathological 
evaluation of the H&E stained tissue (Figure 4.6A, top). For example, ceramide species 
were detected at higher relative abundances from necrotic regions, while other lipids, such 
as PG 34:1 (m/z 747.520) or ST 36:1 (m/z 806.548) were detected at higher relative 
abundances within the tumor region. A depletion of a variety of lipid species, such as PI 
36:2, PI 38:4, PS 40:6, or PE 40:6, among others, were observed in the glioblastoma tumor 
area when compared to normal brain tissue, similar to what has been reported (32,33). Ion 
images from normal brain tissue allowed visualization of white matter regions, 
characterized by the distribution of sulfatide species (e.g. ST 24:1, ST 24:1(OH), ST 
24:0(OH), and ST 26:1) within the branching architectures of the tissue sample (Figure 
4.6A, bottom). Other species, such as PE P-24:1 at m/z 700.529, displayed a homogeneous 
distribution throughout the entire tissue section, while PS 40:6 (m/z 834.529) was observed 
at higher relative abundance within the grey matter region, complementary to the 
distribution of sulfatides in the white matter. Representative mass spectra profiles obtained 
from regions identified as glioblastoma tissue, and grey and white matter from normal 
brain, are shown in Figure 4.6B, including tentative identification of several ions (Table 
A3.6). Overall, these results demonstrated that this discrete droplet sampling approach can 
be used to obtain molecular information characteristic of normal and cancerous tissues 






Figure 4.6:  MS imaging of a glioblastoma tumor sample (top) and normal brain tissue 
(bottom) (A). Representative mass spectra from glioblastoma tissue (top), 
grey matter (middle) and white matter (bottom) normal brain tissue (B). 




Analysis of human ovarian cell samples 
In addition to tissue imaging, we tested the use of this method to analyze human 
ovarian cells deposited and dried onto a glass slide. Figure A3.13 shows representative 
mass spectra obtained from tumor ovarian cells (control) and two replicates of a genetically 
modified strain of human ovarian tumor cells, with the overexpression of the fatty acid 
binding protein (FABP4) gene. Rich molecular information, including various metabolites, 
fatty acid and lipid species were detected. Notably, a higher relative abundance of fatty 
acid species, such as m/z 281.249 (fatty acid – FA 18:1), m/z 303.324 (FA 20:4), and m/z 
327.234 (FA 22:6) were detected in from the cell lines with FABP4 overexpression when 
compared to control tumor cells, which corroborates previous studies, and as discussed in 
Chapter 3 of this dissertation (34). A variety of lipid species, such as Cer, PG, and PI 
species were also detected in the spectra from the m/z 500 to 1000 range. These results 
showcase the capabilities of this approach to provide metabolic profiles representative of 
cell composition from cell samples dried on a glass slide.  
Evaluation of method performance as a tool for imaging and analysis of biological 
samples 
To evaluate method reproducibility, cosine analyses were performed on data 
acquired from mouse brain and human cancerous tissue samples. Cosine analysis compares 
mass spectra based on both the m/z values detected as well as their relative abundances, 
providing similarity values ranging from 0 (dissimilar or orthogonal vectors) to 1 (identical 
or parallel vectors). Average cosine values of 0.89 ± 0.09 (n=15) and 0.95 ± 0.05 (n=6) 
were obtained by comparing mass spectra acquired from grey matter pixels in three mouse 
brain tissue serial sections, and from pixels corresponding to a homogeneous ovarian tumor 
region from two serial sections, respectively (Table A3.7). To provide additional 
reproducibility metrics, the ratio between the ion abundances at m/z 834.530 and m/z 
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885.550, two abundant features in grey matter mass spectra, was evaluated from three serial 
sections, achieving consistent values with an RSD of 11.3% (n=15) (Table A3.8), which 
are comparable to what has been reported for DESI-MS (RSD = 8.0%, n=5)(35).  
Carryover is a common performance concern caused by the presence of residual 
analyte from a previous run or analysis, thus affecting the accuracy and precision of 
measurements, in a variety of bioanalytical techniques, including MS (36,37). As our 
approach utilizes a silica capillary to transport solvated analytes to the MS inlet, potential 
adherence of residual analyte to the capillary inner wall could be a source of carryover. To 
prevent this, the silica capillary was washed after each line of droplets analyzed during an 
image. Using this approach, changes in the ion abundance between droplets in each vertical 
line were observed to correlate to tissue type and histology (i.e. brain white matter, grey 
matter, tumor, necrosis or connective tissue) (Figure A3.14), thus suggesting that washing 
between each line of droplets was sufficient to prevent significant carryover that could 
affect accurate localization of species in the resulting data and ion image. For example, the 
extracted ion chromatogram of m/z 904.618 was localized to the white matter branches of 
the brain tissue, independently of droplet number in the line dispensed, while the extracted 
ion chromatogram of m/z 700.529 stayed relatively consistent along the line analyzed. 
These changes in abundance in the tissue region analyzed agree with the histologic features 
of the tissue section, as previously discussed for their corresponding ion images in Figure 
6a. These results suggest that carryover within a line of droplets does not play a significant 
role in the ion signal detected, and spatially accurate molecular information can be obtained 




In this study, we described the design of a liquid extraction ambient ionization MS 
method for spatially controlled profiling and imaging of biological tissue samples. The 
system includes a piezoelectric picoliter solvent dispenser that enables controlled 
deposition of solvent droplets for accurate tuning of imaging spatial resolution. A similar 
aspiration mechanism has been previously described by the scanning mass spectrometry 
(SMS) probe, used to resolve chemical microenvironments within a large droplet (~100 
µL)(38). In our system, a fused silica capillary was used to directly aspirate entire discrete 
droplets of small volume (2-50 nL) after analyte extraction from tissue surfaces. We 
optimized this method for the detection of metabolite and lipid information in the negative 
ion mode directly from biological samples, detecting a variety of small molecules, FAs, 
GPs, SPs, and sulfoglycolipids, such as STs. We demonstrated that this system can be used 
to image various tissue types, such as mouse brain, and normal and cancerous human 
ovarian and brain, yielding ion images and molecular information that are representative 
of histological differences present in the tissue samples (i.e. white vs grey matter, tumor vs 
normal areas) in a reproducible manner.  
While other liquid extraction techniques such as LESA-MS, LMJ-SSP, and nano-
DESI follow similar operational principles for direct profiling and imaging of biological 
tissue sections (9), the method we describe here is an alternative approach employing a 
microarray of solvent droplets and direct nanospray from a fused silica capillary (<5 
seconds per spot) for direct tissue analysis. Different from LMJ-SSP and nano-DESI, 
which utilize a liquid microjunction through which a solvent flow is continuously delivered 
to a sample surface, the approach we described employs discrete solvent droplet deposited 
by a piezoelectric dispenser to perform liquid extraction from biological samples. The 
discrete droplets employed in this study are of considerably less volume (<100 nL) to those 
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used during LESA analyses (~1000-2000 nL) and are directly aspirated using a fused silica 
capillary instead of being robotically introduced onto a microfabricated chip for infusion 
(14). Despite the moderate resolution reported in this study (390 µm droplet size, 500x460 
µm pixel size), which is lower than nano-DESI but comparable to what has been reported 
for LESA and LMJ-SSP, the ability to quantitatively tune spatial resolution in an automated 
way with a piezoelectric picoliter solvent dispenser is appealing for biological sample 
profiling and tissue imaging applications. Refinements in the design and engineering of the 
system will be pursued to improve spatial resolution and speed for MS imaging. Mounting 
the dispensing device to the 2D moving stage to sequentially dispense and analyze each 
droplet individually should prevent the need for spacing between droplets, allow aspiration 
of smaller DMF droplets, as well as exploring droplets of more volatile chemical 
composition. Further, this modification will also facilitate automation and improve sample 
throughput by circumventing manual transfer of the glass slides between the dispenser 
stage and the MS. Moving to dispenser stage in a spot by spot fashion instead of continuous 
rastering of the 2D stage will also highly increase sample throughput. Experiments using 
various solvent systems through the multi-channel dispensers as well as the incorporation 
of chemically reactive additives into the extraction solvents will be explored to expand 
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Chapter 5. Nondestructive Tissue Analysis for Ex Vivo and In Vivo 
Cancer Diagnosis Using a Handheld Mass Spectrometry System5 
INTRODUCTION 
Tissue assessment and diagnosis are critical in the clinical management of cancer 
patients. Tissue diagnosis is particularly important during surgical excision of solid cancers 
for surgical margin evaluation. Many women diagnosed with breast cancer, for example, 
undergo breast conserving surgery, which involves removing the lesion of interest with a 
rim of normal tissue and preserving the rest of the breast. One of the greatest challenges a 
breast cancer surgeon faces is determining the delicate boundary between cancerous and 
normal tissues to achieve negative margins for invasive and carcinoma in situ while 
optimizing aesthetic outcomes (1). Similarly, optimal surgical treatment of lung 
carcinomas includes complete local resection of the primary tumor (2) because adverse 
patient outcome is strongly associated with residual tumor at the bronchial resection margin 
(3). For high-grade serous ovarian cancer (HGSC) patients, postoperative residual disease 
after surgical debulking is also negatively associated with progression-free survival and 
response to adjuvant chemotherapy (4). Thus, accurate negative margin assessment and 
complete tumor excision are highly desirable across cancer surgeries because they offer 
the greatest potential for prolonged disease-free and overall survival (1, 5–7). 
Intraoperative assessment of the extent of tumor involvement can be challenging 
through conventional histopathologic analysis of frozen sections. Frozen section 
preparation is time- and labor-intensive and requires skilled technicians and pathologists 
 
5 Adapted with permissions from Zhang J, Rector J, Lin JQ, Young JH, Sans M, Katta N, et al. Nondestructive 
tissue analysis for ex vivo and in vivo cancer diagnosis using a handheld mass spectrometry system. Sci Transl 
Med 2017;9:eaan3968. Copyright © 2017, American Association for the Advancement of Science. Authors 
contributed to design and development, data collection, statistical analysis and interpretation, and manuscript 
preparation. Sans M contributed to data collection and interpretation, and preparation of materials for the 
manuscript. 
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to produce and interpret the results. Moreover, freezing artifacts can negatively interfere 
with tissue structure and cell morphology, thus complicating pathological interpretation. 
Logistically, intraoperative frozen section analysis prolongs operative time, subjecting the 
patient to increased risks related to extended anesthesia. Therefore, margin specimens are 
frequently processed postoperatively as permanent specimens. However, when positive 
margins are found during the final pathologic evaluation, the patient is subjected to 
additional surgical procedures for re-excision of the involved margin, which increases 
health care costs and places the patient at risk for additional surgical complications, 
discomfort, and anxiety (1, 8). 
Molecular analysis of cancer tissues offers the exciting opportunity to incorporate 
cancer-specific biomarkers into clinical decision-making for improved cancer detection 
and diagnosis. Several molecular imaging technologies have been developed and advanced 
to preclinical and clinical phases for ex vivo and in vivo tissue diagnosis. 
Immunohistochemistry protocols targeting protein biomarkers are routinely used in 
diagnostic pathology for postoperative evaluation of ex vivo tissue sections and typing of 
neoplasms (9). Gene sequencing technologies are powerful for postoperative identification 
of specific genetic mutations and chromosomal translocations in ex vivo tissue samples 
(10). Intraoperative real-time techniques including fluorescent probes that target tumor 
cells are currently being implemented for in vivo tumor and surgical margin visualization 
(11). Emerging optical technologies including Raman spectroscopy and stimulated Raman 
scattering microscopy have been recently applied for intraoperative diagnosis of brain 
cancers (12, 13). Mass spectrometry (MS) imaging approaches have been successfully 
applied for molecular imaging of cancer tissues (14–17). 
Within the last decade, several ambient ionization MS techniques have been 
developed for rapid molecular diagnosis of cancer tissues and have shown exceptional 
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potential for clinical use (18). Desorption electrospray ionization MS imaging (DESI-
MSI), for example, has been use for ex vivo cancer diagnosis and surgical margin 
evaluation of tissue sections and tissue smears (19, 20). Yet, technical incompatibilities 
including the use of a spray of organic solvents, high-pressure nebulizing gas, and high 
voltage have prevented the use of DESI-MSI for fresh tissue and in vivo analyses. A few 
approaches for direct MS analysis of cancer tissue specimens have been developed (18). 
Rapid evaporative ionization MS, or the iKnife, combines an electrocauterization device 
with MS for direct tissue analysis and classification and has been successfully used 
intraoperatively for in vivo cancer diagnosis (21, 22). Ultraviolet and infrared lasers have 
also been coupled with MS for characterization of cancer tissues (23, 24). Although these 
approaches offer the advantage of incorporating common surgical methods into an MS-
based diagnostic workflow, these technologies rely on tissue damage to produce molecular 
ions or are operationally constrained to a specific surgical modality.  
Here, we describe the development and application of an automated, 
biocompatible, disposable handheld device, the MasSpec Pen, for direct, real-time 
nondestructive sampling and molecular diagnosis of tissues. We tested the MasSpec Pen 
for ex vivo molecular evaluation of human normal and cancerous tissue samples from 253 
patients. The mass spectra obtained presented rich molecular information including 
diagnostic metabolites, lipids, and proteins. Statistical analysis using the least absolute 
shrinkage and selector operator (Lasso) technique allowed prediction of cancer with high 
sensitivity and specificity (25). In a tumor bearing mouse model, we demonstrate that this 
technology is suited for in vivo use and diagnosis of breast cancer during surgery. 
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MATERIALS AND METHODS 
Study design 
The objective of this study was to evaluate the potential of an MS based probe to 
nondestructively analyze and diagnose cancer in human tissue samples. Here, we 
investigated the molecular profiles of human tissue samples obtained from 281 patients 
including normal and cancer breast, lung, thyroid, and ovary tissues. All patient samples 
were obtained from the CHTN (Cooperative Human Tissue Network), Asterand 
Bioscience, and the Baylor College of Medicine Tissue Bank under approved Institutional 
Review Board protocol. The mass spectra obtained using the MasSpec Pen in tissue 
samples were normalized, background subtracted, and analyzed using a statistical 
technique to build classification models. Expert, board-certified pathologists evaluated the 
H&E-stained tissue sections obtained from the tissue samples analyzed. The pathologists 
were blind to any information about the acquisition from MS analysis. Samples were 
excluded from statistical analysis if they were determined by the pathologist to have 
substantial heterogeneity in cell composition, which included 28 samples, resulting in a 
final sample set of 253 samples. The in vivo animal model experiments were conducted 
under approved Institutional Animal Care and Use Committee protocol. 
Design and engineering of the MasSpec Pen 
A three-dimensional (3D) printer (Model uPrint SE Plus) was used to print the key 
component, a polydimethylsiloxane (PDMS) (Dow Corning) probe tip. The pen tips were 
fabricated by casting an elastomer from a negative mold designed using SolidWorks 
computer-aided design software and then dissolving the mold away. PTFE tubing (ID, 1/32 
inch; outer diameter, 1/16 inch; Cole-Parmer) was directly inserted into the probe tip for 
experiments.  
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Mass spectrometry data acquisition 
All experiments were performed on a Q Exactive Hybrid Quadrupole- Orbitrap 
mass spectrometer (Thermo Fisher Scientific). Full scan was carried out at the range of m/z 
120 to 1800, using a resolving power of 140,000, a capillary temperature of 350°C, and an 
S-lens radio frequency level of 100. Wild-type mouse brains were purchased from 
Bioreclamation IVT. Human tissue samples were obtained frozen and stored in a −80°C 
freezer until analysis, when they were thawed at room temperature. The tissues were placed 
on a glass slide and analyzed by the MasSpec Pen using the experimental steps described. 
After experiments, the tissue regions analyzed were annotated and frozen, and 16-mm 
tissue sections were prepared using a CryoStar NX50 cryostat. Additional tissue sections 
at different regions of the tissue piece were obtained for the MasSpec Pen analysis. Tissue 
sections were H&E-stained and evaluated by histopathology after analysis. 
In vivo mouse experiments 
BT474 HER2+ cells were grown for 24 hours and injected subcutaneously into the 
right flank of the mouse (total injection of 100 ml) in Dr. Anna G. Sorace’s laboratory at 
the University of Texas at Austin. Tumors were monitored weekly for growth until they 
reached 0.7 to 1.0 cm in diameter (average of 250 mm3). In vivo experiments were 
performed during surgical resection of tumors using murine animal models while the mice 
were under anesthesia (2% isoflurane and 98%O2). A surgical blade was used to open a 
flap of skin, leaving an estimated space of 1 to 2 cm around the tumors, and then, the skin 
flap was dissected from the surface of the tumor. The skin was flapped to expose the tumor 
and adjacent normal tissues, which were analyzed in several regions using the MasSpec 
Pen. Pieces of the tumor were then resected using a scalpel and analyzed ex vivo. Tumor 
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tissue pieces analyzed by the MasSpec Pen were annotated, flash-frozen, sectioned, and 
subjected to H&E staining for diagnosis. 
Statistical analysis 
Averages of three mass spectra obtained during each 10-s MasSpec Pen analysis 
were used to build molecular databases. The Xcalibur raw data were converted to Microsoft 
Excel spreadsheet format. The full mass range of the spectra was partitioned into bins by 
rounding m/z values to the nearest hundredth. All mass spectra were first normalized 
according to total ion count or to the absolute intensity of m/z 885.55 to account for slight 
fluctuations in signal intensities that may occur between experiments. Then, background 
peaks and peaks not appearing in at least 10% of the samples analyzed were excluded to 
reduce random noise. For each tissue sample type (breast, thyroid, lung, and ovary), the 
data were imported to R programming language. PCA was performed by centering the 
preprocessed data to mean zero and computing principal components using the prcomp 
function in R. The first three principal components were visualized with the rgl and pca3d 
packages for R. For tissue classification, the Lasso method was applied using the glmnet 
package in the CRAN R language library. Models generated using the Lasso are simpler to 
interpret than other regularization methods because it yields “sparse” models (models that 
involve only a subset of the features). A mathematical weight for each statistically 
informative feature is calculated by the Lasso depending on the importance that the mass 
spectral feature has in characterizing a certain class (cancer versus normal or a cancer 
subtype versus normal). Classification was performed using a leave one- out cross-
validation approach to assess the predictive accuracy within the training set. Performance 
of trained classifiers was measured by sensitivity, specificity, accuracy, and AUC. 
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RESULTS 
Optimization of the MasSpec Pen design and operation 
We designed the MasSpec Pen (Figure 5.1A) as an automated and biocompatible 
handheld sampling probe that allows gentle and time- and volume-controlled extraction of 
molecules from a tissue sample using a discrete water droplet. Several prototypes of the 
system were engineered with the goal of minimizing tissue damage, maximizing tissue-
analyte extraction, and maximizing solvent transfer to the mass spectrometer. The 
optimized system contains three primary components: (i) a syringe pump that is 
programmed to deliver a defined water volume (4 to 10 ml) to the sampling probe; (ii) 
small diameter [inner diameter (ID), 800 mm] polytetrafluoroethylene (PTFE) tubing 
conduits, which are integrated to a fast (8ms) two-way pinch valves for controlled solvent 
transport from the pump to the tissue and from the tissue to the mass spectrometer; and (iii) 
a handheld pen-sized probe for direct sampling of biological tissues. 
The main component of the handheld pen-sized probe is a 3D printed PDMS tip 
(Figure 5.1B). The probe tip is designed with three ports: an incoming port that delivers a 
single water droplet to the probe tip (conduit 1), a central port for gas (N2, CO2, or air) 
delivery (conduit 2), and an outgoing port to transport molecular constituents in the water 
droplet from the tissue to the mass spectrometer (conduit 3). At the probe tip, all ports 
combine into a small reservoir where a single water droplet is retained and exposed to the 
tissue sample for a controlled amount of time (3 s), allowing efficient analyte extraction. 
After the 3-s extraction period, the MasSpec Pen is removed from the tissue. 
Concomitantly, conduit 3 is opened, allowing vacuum extraction of the droplet to the mass 
spectrometer, whereas positive pressure from a low-pressure gas delivery (<10 psi) is 
provided through conduit 2 (Figure 5.1C). The gas provided by the second tube does not 
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participate in the extraction process but is used instead to prevent the collapse of the system 
due to the vacuum used and to assist solvent transport from the tissue to the mass 
spectrometer. A subsequent flush step cleans the system; this is not used for extraction of 
biomolecules from tissues because there is no contact with the tissue during this period. 
Conduit 3 is directly connected to the transfer tube of a high–mass resolution Orbitrap mass 
spectrometer so that the negative pressure of the mass spectrometer vacuum system drives 
the movement of the droplet from the reservoir to the mass spectrometer for ionization and 
mass analysis. This setup simplifies the operational steps and precludes the use of 
ionization sources, although various connection and ionization methods could be coupled 
to our system. 
The diameter of the reservoir at the probe tip determines the volume of solvent 
exposed to the tissue and the spatial resolution of the device. Using current tooling, we 
have designed MasSpec Pen tips with sampling sizes ranging from 1.5 to 5.0 mm, which 
is determined by the reservoir diameter. At a 2.77-mm reservoir diameter, a solvent volume 
of 10 ml is retained in the reservoir and contacts the tissue sample for a defined time period, 
whereas 4.4 ml is retained in a reservoir with a 1.5-mm diameter. Contact times of 1, 3, 
and 5 s between the droplet and the tissue sample were evaluated (Figure A4.1). The 3-s 
contact time was selected for all the experiments because it allowed ease of operation by 
the user and yielded mass spectra with sufficient total ion intensity. A tube length of 1.5 m 
was used for all the conduits to allow free handheld use of the device by an operator without 
geometrical or spatial constraints. 
The tip design using three conduit tubes and high-speed actuated pinch valves 
allowed precise control of droplet motion and showed excellent performance and 
robustness. The entire process from sampling to mass spectral acquisition is completed in 
10 s or less and is automated using an Arduino microcontroller so that each acquisition and 
 100 
analysis is individually triggered through a one-step click using a foot pedal. System 
automation ensures that each solvent droplet is delivered separately to the inlet, yielding 
several mass spectra that are averaged for a final molecular profile of the sample. 
Controlled droplet delivery allowed the mass spectrometer to operate without any evident 
performance degradation. After each use, the MasSpec Pen was cleaned through a rapid 
and automated cleaning flush or by replacing the disposable tip. Contamination of the mass 
spectrometer was evaluated by installing commercially heated ESI source and acquiring 
mass spectra after the MasSpec Pen analysis. No lipid contamination was observed other 


















Figure 5.1: Schematic representation of the MasSpec Pen system and operational steps.  
The pen-sized handheld device is directly integrated into a laboratory-built MS interface 
through PTFE tubing (A). The integrated MS interface houses the pinch valves, 
microcontroller, and tubing to connect the system to the mass spectrometer inlet. The 
system is triggered by the user through a foot pedal. The MasSpec Pen (handheld device) 
is designed with a PDMS tip and three PTFE conduits, which provide incoming water (1) 
and gas (2) to the tip and an outgoing conduit for the water droplet (3) (B). The tip contacts 
the tissue for analysis. Inset shows the three conduits (1 to 3) and solvent reservoir (4) 
within the tip. When the system is triggered (t = 0 s) by using the foot pedal, the syringe 
pump delivers a controlled volume of water to the reservoir. The discrete water droplet 
interacts with the tissue to extract the molecules (t = 2 s). After 3 s of extraction, the vacuum 
and the gas conduits are concomitantly opened (arrows) to transport the droplet from the 









Nondestructive molecular analysis of tissue samples 
The MasSpec Pen was designed to operate directly on tissue specimens 
independently of tissue stiffness and morphology. We tested the performance of the 
MasSpec Pen to analyze soft tissue samples (0.1 to 5 g) from different organs including 
mouse brain and human breast, thyroid, lung, and ovary tissues. Tissue analyses were 
performed under ambient conditions through a simple one-step experiment, following the 
same operational steps described previously. The MasSpec Pen tip was gently brought into 
contact with the surface of the tissue sample for a period of 3 s during which extraction 
took place. The mass spectra obtained for a region of gray matter probed from a piece of 
fresh mouse brain tissue were reproducible (RSD= 4.6%; n = 10). MasSpec Pen analyses 
of human tissue samples provided similar rich molecular information, especially of tissues 
composed of epithelial and cancerous cells. Noncancerous tissue specimens that were 
mostly composed of soft connective tissue such as stroma provided less abundant mass 
spectra. Many of the normal breast tissue samples analyzed presented abundant fat content, 
which is immiscible with water and thus yielded lower total ion counts in the mass spectra 
when compared to breast cancer tissues or normal breast cancer glands. 
Visual and microscopic inspection of the tissue samples after the MasSpec Pen 
analysis revealed no detectable damage to the tissue morphology in the region probed. 
Figure 5.2A shows optical images obtained from a lung tissue sample before, during, and 
after the MasSpec Pen analysis. No observable damage to the tissue was seen at the region 
analyzed, and rich mass spectra were obtained (Figure 5.2B). The automated and time-
controlled operational steps of the MasSpec Pen prevent tissue damage because the tissue 
is only exposed to the small water droplet and not to the vacuum used to transport the 
droplet from the reservoir to the mass spectrometer. These results provide evidence that 
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Figure 5.2: Nondestructive molecular analysis of human tissue samples using the 
MasSpec Pen.  
Optical images show a lung adenocarcinoma tissue sample before, during, and after the 
MasSpec Pen analysis. A magnification of the tissue specimen (inset) shows no 
macroscopic damage to the tissue region analyzed by the MasSpec Pen. (A) Negative ion 
mode mass spectrum obtained for the tissue region analyzed including the identification of 
the most abundant molecular ions (B). 
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Molecular diagnosis and statistical prediction of cancer in human tissues  
We next evaluated whether the molecular information obtained from human tissue 
samples using the MasSpec Pen was diagnostic and predictive of disease state. We 
analyzed a total of 253 human tissue specimens using the MasSpec Pen, including 95 lung 
samples (47 normal and 48 cancer samples including 17 adenocarcinoma, 17 squamous 
cell carcinoma, and 14 cancer samples of other histologic subtypes), 57 ovary samples (29 
normal and 28 HGSC samples), 56 thyroid samples (27 normal, 11 FTA, and 18 PTC 
samples), and 45 breast samples (29 normal and 16 ductal carcinoma samples). Patient 
demographic information is provided in Table A4.1. After the MasSpec Pen analysis, the 
region analyzed was demarcated and registered through a series of optical images. Parallel 
pieces of the samples were frozen, sectioned at the demarcated region, hematoxylin and 
eosin (H&E)–stained, and evaluated by histopathology to derive a diagnosis. Only samples 
with a predominant cell composition and clear diagnosis were used to build molecular 
databases. The histologically validated mass spectra obtained for the cancerous samples 
presented molecular species identified as several lipids and metabolites previously 
described as potential disease markers using ambient ionization MS techniques. For the 
lung cancer tissue, characteristic molecular markers such as PI(36:1) (as m/z 863.565), 
PG(36:2) (m/z 773.542), PG(34:1) (m/z 747.514), and FA(18:1) (m/z 281.249) were 
observed (Figure 5.2B). For the normal lung, m/z 885.550, identified as PI(38:4), and m/z 
744.552, identified as PE(36:1), were observed. The mass spectra obtained for breast 
cancer tissue presented diagnostic lipid markers previously described by DESI MSI (26, 
27), including m/z 885.550, identified as PI(38:4), m/z 863.565, identified as PI(36:1), m/z 
773.542, identified as PG(36:2), and several FA such as m/z 303.233, identified as 
FA(20:4), and m/z 281.249, identified as FA(18:1). PCA performed on the data obtained 
 105 
from the 253 human tissue samples analyzed showed separation between cancer and 
normal tissues for each organ (Figure 5.3). 
 
Figure 5.3: PCA of the data obtained from human tissue samples using the MasSpec 
Pen.  
A total of 253 patient tissue samples were analyzed including breast (n = 45), thyroid (n = 
56), ovary (n = 57), and lung (n = 96) cancer and normal tissue samples. 3D PCA (PC1, 
PC2, and PC3) score plots are shown for each tissue type. The first three PCs explain the 








To evaluate whether the MasSpec Pen molecular signatures are predictive of cancer 
and normal tissues, we applied the Lasso method to build classification models using the 
histologically validated mass spectral database. The performance of the model was 
evaluated through a leave-one-patient-out cross-validation approach and was measured by 
sensitivity and specificity for cancer, as well as accuracy and the area under the curve 
(AUC) (Table 5.1). For breast cancer (n = 45), 87.5% sensitivity, 100% specificity (AUC 
= 1.0), and an overall accuracy of 95.6% were achieved, which is comparable to the results 
reported using DESI-MSI (98.2% accuracy; n = 126) (27), the iKnife (95.5%accuracy; n = 
10) (22), and matrix-assisted laser desorption/ionization imaging of lipids and proteins 
(94.1%accuracy; n = 68) (28). For HGSC (n = 57), 100% sensitivity, 89.7% specificity, 
and 94.7% accuracy were achieved (AUC = 0.98), which is also similar to classification 
results obtained by DESI-MSI (97.1% accuracy; n = 31, results described in Chapter 2) 
(29). For lung cancer (n = 96), 97.9% sensitivity, 95.7% specificity, and 96.8% accuracy 
were achieved (AUC = 0.97). When predicting on the basis of lung cancer histologic 
subtypes, 93.8 and 92.2% accuracy was achieved for squamous cell carcinoma and 
adenocarcinoma, respectively. Thyroid tumor samples investigated included benign FTA 
and malignant PTC samples. A classifier for each was built, yielding 94.7% accuracy for 
FTA and 97.8% accuracy for PTC. Overall, 96.4% sensitivity, 96.2% specificity, and 
96.3% accuracy were achieved for all four types of cancer investigated. These results 
demonstrate that the molecular information obtained from human tissue samples by the 
MasSpec Pen can be used to identify cancer and indicate that the statistical classifiers built 





Table 5.1: Human tissue sample details and results obtained using the MasSpec Pen. 
Pathological diagnosis, number of patient samples, and the Lasso prediction sensitivity, 
specificity, accuracy, and AUC obtained using a leave-one-out cross-validation approach 
are shown. Lasso prediction results for lung are shown for normal versus all cancer tissues 
(first row), followed by normal versus lung adenocarcinoma (middle row) and normal 
versus squamous cell carcinoma (last row). Lasso prediction results for thyroid are shown 
for normal versus malignant papillary carcinoma and normal versus benign follicular 
adenoma.  
 




 Diagnosis Histologic type  Sensitivity Specificity Accuracy AUC 
Breast Normal  29 87.5% 100.0% 95.6% 1.00 
 Cancer Ductal carcinoma 16     
Lung Normal  47 97.9% 95.7% 96.8% 0.97 
 Cancer Adenocarcinoma 17 88.2% 93.6% 92.2% 0.98 
  Squamous cell 17 88.2% 95.7% 93.8% 0.93 
  Others 14 - - - - 
Ovary Normal  29 100.0% 89.7% 94.7% 0.98 
 Cancer High-grade serous 28     




18 94.4% 100.0% 97.8% 0.99 










Intrasample analysis of histologically distinct and cancer margin tissue regions  
We evaluated the ability of the MasSpec Pen to identify histologically distinct 
regions in a single human tissue sample that contained regions of HGSC adjacent to normal 
ovarian stroma tissue. Five regions of the tissue sample were analyzed consecutively using 
a MasSpec Pen with a 1.5-mm probe tip diameter, as demarcated in the optical image 
shown in Figure 5.4A. A tissue section of the sample including the regions analyzed by the 
MasSpec Pen was subjected to H&E staining and evaluated by histopathology. Regions 1 
and 2 were diagnosed by histopathology as normal stroma, whereas regions 4 and 5 were 
diagnosed as HGSC. Region 3 was in the margin between the cancer and normal stroma 
tissue regions, presenting ~50% tumor tissue and ~50% normal stroma tissue (Figure 5.4A, 
inset). Figure 5.4B shows the mass spectra obtained for regions 1, 3, and 5. The spectra 
obtained for region 5, HGSC, presented characteristic lipid markers detected in the HGSC 
tissues analyzed ex vivo to build our statistical classifier. The mass spectra obtained for 
region 1, diagnosed as normal ovarian stroma tissue, presented less abundant molecular 
ions as also observed for the other stroma tissues analyzed ex vivo. Region 3 presented 
molecular profiles characteristic of HGSC with lower total abundance due to the 
contribution of normal stroma tissue present within the region analyzed. The mass spectra 
obtained for the five regions were then evaluated by our ovarian cancer molecular classifier 
as an independent validation set. Our classifier correctly identified regions 1 and 2 as 
normal and regions 3 to 5 as cancer (Figure  5.4C). Similar results were obtained for a 
different tissue sample with histologically distinct regions (Figure A4.2). These results 
show that the molecular information obtained by the MasSpec Pen can be used to detect 




Figure 5.4:  MasSpec Pen analysis of an HGSC tissue sample with mixed histologic 
composition.  
Optical image shows the tissue sample that was analyzed at the demarcated regions (1 to 
5) using a 1.5-mm-diameter MasSpec Pen. After the MasSpec Pen analysis, the tissue 
sample was frozen, sectioned, and H&E-stained. An optical image of the H&E-stained 
tissue section obtained at region 3 is shown (inset), presenting a mixed histologic 
composition including cancer and adjacent normal stroma tissue (A). The MasSpec Pen 
negative ion mode mass spectra are shown for regions 1 (normal stroma; average of n = 3 
mass spectra), 3 (mixture of normal stroma and cancer; average of n = 3 mass spectra), and 
5 (cancer; average of n=3 mass spectra) (B). Table listing the pathologic diagnosis of the 






In vivo analysis of a murine model of human breast cancer during surgery  
The MasSpec Pen was designed with biocompatible materials to ensure full 
compatibility as an in vivo molecular diagnostic tool. We tested the MasSpec Pen for in 
vivo tissue analysis using a murine model of human breast cancer. BT474 human epidermal 
growth factor receptor 2–positive (HER2+) breast cancer cells were implanted 
subcutaneously in nude athymic mice (n = 3). Under anesthesia, the skin overlying the 
tumors was dissected away, and several tissue regions were analyzed following the same 
automated experimental steps described previously, including multiple positions of the top 
of the tumor, the core of the tumor after partial tumor resection, and adjacent normal soft 
connective tissue. Figure 5.5A shows an optical image of the animal under anesthesia 
before initiation of surgery, before analysis (after surgical removal of the skin), during the 
MasSpec Pen analysis, and after the analysis. The mass spectra obtained for the tumor 
regions presented many molecular species observed in human breast tissue, with a 
distinctive profile from what was obtained for adjacent normal soft connective tissue 
regions (Figure 5.5B). Using optical microscopy, no observable macroscopic or 
microscopic damage to the tissue regions analyzed were detected due to MasSpec Pen 
analyses, as evident from the optical images obtained of the H&E-stained tissue sections 
(Figure A4.2). Further, no apparent effects to the health of the animals were observed due 
to the MasSpec Pen analysis during surgery. After in vivo analysis, freshly excised tumor 
specimens were also analyzed ex vivo, yielding mass spectra with common lipid species to 
those observed during in vivo analysis despite variations in relative abundances, which are 
likely due to the reanalysis process of the same tissue region (Figure A4.3). These results 





Figure 5.5: Intraoperative analysis of tumor and normal tissues in a murine model.  
Experiments were performed in vivo in mice under anesthesia. Optical images show the 
animal under anesthesia and before, during, and after the MasSpec Pen analysis (A). 
Representative negative ion mode mass spectra show distinct molecular profiles from 






We developed the MasSpec Pen as an automated and biocompatible handheld 
sampling probe that allows gentle and time- and volume-controlled extraction of molecules 
from a tissue sample using a discrete water droplet. Our results provide evidence that the 
MasSpec Pen is suited for rapid ex vivo and in vivo cancer diagnosis of tissue samples. The 
mass spectra obtained from the analysis 253 human tissue samples presented rich 
molecular information that is diagnostic of disease state. The chemical extraction process 
used is gentle so that the tissue is undamaged after molecular analysis. Statistical classifiers 
built from the mass spectra obtained provided high sensitivity and specificity for cancer 
detection (>96%), including prediction of histologic subtypes of lung cancer and benign 
and malignant thyroid tumors. Experiments performed in animal models demonstrate that 
this technology is suitable for in vivo molecular evaluation of cancer and normal tissues 
without causing observable tissue harm or evident stress to the animal. The MasSpec Pen 
provides rich mass spectra from biological samples characterized by a variety of singly and 
doubly charged ions of lipids and metabolites and multiply charged protein ions, similar to 
those obtained by DESI-MSI and ESI methods. A liquid-solid chemical extraction process 
is used to sample molecules from the tissue using a water droplet, without assistance from 
a gas or a strong electric field. Our results show that by depositing a discrete water droplet 
onto a tissue sample for a determined amount of time, efficient extraction of biomolecules 
is achieved while tissue integrity is preserved. The extraction process is similar to that 
reported for liquid extraction surface analysis (30), liquid microjunction surface sampling 
probe (31), and nanoDESI (32), although the latter two techniques use a continuous flow 
of solvent onto a sample surface, whereas the MasSpec Pen uses a single water droplet for 
extraction. In our current system, the water droplet containing analytes is transported as a 
liquid sample to the mass spectrometer and directly introduced to an extended transfer tube, 
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which is connected to the heated inlet. Vaporization and ionization occur in the inlet region 
of the mass spectrometer, similar to what has been observed in solvent-assisted inlet 
ionization (33). Additional means of ionization such as electric field or laser assistance 
were not applied, although various connection methods and ionization sources (ESI, 
atmospheric pressure chemical ionization, atmospheric pressure photoionization, and 
others) could be adapted for our system.  
Biocompatibility has been recognized as a key functional requirement of next-
generation medical devices (34). The MasSpec Pen was designed as a simple, disposable 
device made with biocompatible materials and chemicals for contact with living tissues. 
The probe tip material, the conduit tubes, and the chemical used were PDMS, PTFE, and 
water, respectively. PDMS and PTFE are widely recognized as biocompatible materials 
and have a long history of utilization in medical devices including catheters and long-term 
implants (35). Our experiments demonstrate that the low volume (10 µl or less) of high-
purity water used caused no effect to the tissues analyzed in vivo and ex vivo. The MasSpec 
Pen has shown good compatibility for contact with living tissues, which should enable in 
vivo use.  
We designed the MasSpec Pen as an automatic and user-friendly device that could 
be used during routine medical diagnosis. A drawback of many ambient ionization MS 
methods is the need for geometrical optimization and alignment between the source, the 
sample, and the mass spectrometer inlet to achieve good ion transmission. On the other 
hand, the MasSpec Pen operates in a geometry-free manner independently of sample 
stiffness and morphology and does not require optimization because all of the components 
required for solvent delivery, tissue sampling, and solvent retrieval are incorporated within 
the tip. The 1.5-m tube transport systems enable free motion and ease of use to the operator. 
The high-speed electronically and time-controlled pinch valves allowed precise control of 
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droplet motion and showed excellent performance, robustness, and reproducibility in the 
results obtained.  
Our results suggest that the MasSpec Pen may provide the performance required 
for near real-time nondestructive molecular diagnosis of tissues in vivo and ex vivo. 
Intraoperative diagnosis and surgical margin evaluation continue to be research focuses of 
clinical ambient ionization MS, with efforts used to develop devices for in vivo diagnosis 
(18). For example, a sampling probe using a DESI-MSI source to produce a continuous 
high-pressure spray of microdroplets has been proposed for tissue analysis (36), but it has 
not been demonstrated for cancer diagnosis or in vivo use. Ultraviolet and infrared laser 
approaches have been reported for tissue analysis through ablation processes (23, 24). A 
resonant infrared laser ablation system was used to analyze a cancer tissue sample ex vivo 
and human finger skin in vivo (24). To date, the iKnife has been the most successful MS 
based technique demonstrated for in vivo, intraoperative diagnosis (21, 22). Yet, the 
electrocauterization process used by the iKnife is necessary for ion generation for MS 
analysis, resulting in thermal and mechanical damage of the analyzed tissue. Further, 
surgical modalities other than electrocauterization are used in oncologic surgeries, such as 
ultrasonic surgical aspiration, cold knife and mechanical stapled excisions, and laser 
surgery. Different from laser and electrocauterization approaches, an advantage of the 
proposed water-based MasSpec Pen technology is its nondestructive nature, which allows 
diagnosis of cancerous tissues without damage to normal tissues. Because the MasSpec 
Pen performs molecular diagnosis independently of any dissection tools, it has the potential 
to be used in many surgical modalities. Intraoperatively, we envision the MasSpec Pen to 
be used in conjunction with a surgical resection tool, depending on the oncologic surgery 
and the preference of the medical professional. Because surgeons routinely exchange 
handheld surgical instruments during surgery, with assistance from surgical technologists, 
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we expect the MasSpec Pen to be adapted into routine surgical workflows. Clinically, the 
MasSpec Pen could be suitable for pre- and postsurgical procedures that require diagnosis 
of ex vivo samples (fresh tissues, tissue sections, or biopsies) commonly examined by 
pathologists.  
Our results show that the molecular information obtained using the MasSpec Pen 
is diagnostic of disease and can be used for rapid tissue classification, cancer diagnosis, 
and subtyping. We tested the MasSpec Pen using 253 patient tissue samples including the 
normal and tumorous breast, ovary, lung, and thyroid tissues. The mass spectra presented 
rich molecular profiles characterized by a variety of potential cancer biomarkers. The 
statistical classifiers built using machine learning algorithms and the histologically 
validated molecular information provided an overall sensitivity of 96.4%, specificity of 
96.2%, and accuracy of 96.3% for cancer. Our classifiers allowed the identification of 
different histologic types of lung cancers and benign and malignant thyroid tumors when 
compared to normal tissue samples and correctly predicted ovarian cancer diagnosis in an 
independent test sample with mixed histologic features. Yet, as with any technology that 
relies on machine learning and statistical modeling of large data sets to provide predictive 
diagnosis, larger sample sets are needed to increase the training set size, improve the 
predictive accuracy of our classifiers including information on tumor cell concentration, 
and expand the histologic and molecular subtypes of neoplasms and normal tissues. 
Rigorous validation studies of the statistical results using large independent held-out test 
sets are necessary to determine possible overfitting of our statistical models and to more 
conclusively determine the overall performance of the method.  
Here, we demonstrated that the MasSpec Pen is effective for in vivo diagnosis of 
cancer regions during murine oncological surgery. The entire procedure from triggering 
the system to data analysis is performed under 10 s, and further improvements are 
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envisioned. Compared with the time necessary for intraoperative pathologic frozen section 
analysis of excised species (~30 min) or postoperative final pathologic evaluation (several 
days), the time required for the MasSpec Pen analysis could expedite surgical procedures, 
diagnosis, and treatment. Our results demonstrate that the molecular information obtained 
using a 1.5-mm sampling size allows accurate identification of cancer in marginal tumor 
regions of mixed histologic composition, although further validation of these results with 
larger independent sample sets is needed. We are currently exploring other machining 
methods to increase sampling resolution; however, the 1.5-mm sampling size relates well 
with the degree of precision achieved during surgical resection.  
We envision that the MasSpec Pen will become a valuable clinical technology for 
near real-time in vivo and ex vivo cancer diagnosis. Emerging technologies including 
fluorescence-guided surgery (11), Raman spectroscopy (12), optical coherence 
tomography (37), reflectance spectroscopy (38), and stimulated Raman scattering 
microscopy (13) have been proposed for cancer diagnosis and surgical guidance. Although 
powerful, many of these methods rely on injection of exogenous labels that target specific 
cell types for tumor visualization, require tissue excision and processing for analysis, suffer 
from moderate tissue specificity, or provide limited biochemical information. The 
approach we propose here leverages on the unparalleled sensitivity and specificity provided 
by MS for untargeted molecular evaluation and on its biocompatibility for disease 
diagnosis and clinical use. Yet, many challenges exist in translating and integrating new 
technologies into the workflow of a complex surgical and clinical environment (39). 
Integration of the MasSpecPen into laparoscopic and robotic surgical systems for 
minimally invasive procedures and improved communication and visualization tools will 
facilitate its inclusion in clinical workflows. Similarly, size- and cost-effective mass 
spectrometers with sufficient analytical performance for molecular evaluation are needed 
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for dedicated surgical use. Advances in building and validating databases for tissue 
identification, as well as automated computational methods for real time output of 
predictive results, are also necessary for broad use. Further work will require careful 
evaluation of the long-term benefits to patients to determine the value of new technologies 
in clinical practice. We expect that the excellent performance and simple design and 
operation of the MasSpec Pen, combined with its clinically desirable features, may enable 
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Chapter 6. Performance of the MasSpec Pen for Rapid Diagnosis of 
Ovarian Cancer6 
INTRODUCTION 
Ovarian cancer is a highly lethal disease and the fifth leading cause of all cancer-
related deaths in women (1, 2). Accurate diagnosis and stratification of ovarian cancer is 
important to develop personalized treatment approaches (3). High-grade serous carcinomas 
(HGSC) and low-grade serous carcinomas (LGSC) are common subtypes of ovarian 
cancers, with the latter accounting for just a small proportion of cases. HGSCs show 
aggressive features including rapid growth and invasive behavior, whereas LGSCs follow 
a more indolent course (4). Cytoreductive surgery in combination with chemotherapy is 
the primary course of treatment for HGSC and essential to maximize patient survival. 
However, the timing of cytoreductive surgery is of debate (5, 6). Patients likely to undergo 
complete resection commonly undergo surgery followed by chemotherapy, whereas 
patients likely to undergo incomplete resection are directed to neoadjuvant chemotherapy 
before surgery. In both scenarios, differentiation of tumor from normal tissue is critical to 
maximize cancer excision, although intraoperative identification through gross inspection 
can be difficult. For example, differentiation of tumor from scarring or fibrotic tissues 
resulting from neoadjuvant chemotherapy is challenging from metastatic sites, often 
requiring unnecessary resection of healthy tissue (7). Histopathologic analysis of tissue 
sections is commonly employed to diagnose surgical specimens, either intraoperatively 
 
6 Adapted from Sans M, Zhang J, Lin JQ, Feider CL, Giese N, Breen MT, et al. Performance of the 
MasSpec Pen for Rapid Diagnosis of Ovarian Cancer. Clin Chem 2019;65:674-83. Copyright © 
2019, American Association for Clinical Chemistry. Sans M and Zhang J collected all the data 
presented in this manuscript. Sans M and Lin JQ performed statistical analysis. Sans M analyzed 
and interpreted the results, prepared all the materials, and wrote the manuscript. All authors 
contributed in revising the manuscript.   
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through frozen section analysis, or postoperatively through permanent tissue sections. 
Despite its relatively rapid turnaround (approximately 30 min), intraoperative frozen 
section evaluation results can be limited owing to freezing artifacts affecting tissue 
histology. Further, frozen section evaluation of multiple tissue specimens can be 
impractical, because numerous areas of concern are often identified during surgery. 
Postoperative tissue analysis is time consuming (approximately 1 week) and places the 
patient at additional health risks, discomfort, and anxiety (8). Thus, new technologies that 
allow rapid and accurate intraoperative tissue evaluation could improve diagnosis during 
cytoreductive surgery and the overall management of ovarian cancer patients (9, 10). 
Mass spectrometry (MS) technologies have shown potential for clinical use and 
cancer diagnosis (11–23). Ambient ionization MS techniques are suitable for rapid and in 
situ analysis of biological tissues because of their operational simplicity at atmospheric 
pressure and minimal sample preparation requirements (24). Several ambient ionization 
techniques have been suggested and tested for intraoperative cancer diagnosis and surgical 
margin evaluation either through ex vivo tissue sections and tissue smears analyses (12–
18), or in vivo (19–23). Desorption electrospray ionization-MS imaging, for example, has 
been applied for ex vivo analysis of metabolic profiles of borderline ovarian tumor, HGSC, 
and normal ovarian tissue sections, allowing cancer diagnosis and subtyping (25, 26). The 
rapid evaporative ionization MS technique was recently used for in vivo ovarian cancer 
diagnosis (27). Our team has previously described the development of a handheld device, 
named the MasSpec Pen, for ex vivo and in vivo nondestructive molecular analysis and 
diagnosis of tissues, discussed in Chapter 5 (21). In that study, we tested the MasSpec Pen 
for molecular evaluation and diagnosis of 253 human tissue samples (normal and cancer 
ovarian, lung, thyroid, and breast). For ovarian cancer (n = 29 normal and n = 28 HGSC), 
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a clinical sensitivity of 100%, specificity of 89.7%, and overall accuracy of 94.7% were 
achieved using leave-one-out cross-validation analysis. 
Biocompatibility and the nondestructive nature of the MasSpec Pen analyses are 
clinically attractive and could facilitate translation into clinical use. Nevertheless, testing 
of the statistical classifiers using different sample cohorts is critical to evaluate model 
overfitting and validate its performance. Analysis of other histological subtypes, such as 
LGSC, is also desirable to evaluate potential for ovarian cancer diagnosis. Moreover, 
distinguishing ovarian cancer from surrounding healthy peritoneum tissue where ovarian 
cancer often spreads could improve surgical resection (28). Because fallopian tubes (FTs) 
have been proposed as the most likely site of HGSC origin, evaluation of FT tissue is also 
relevant (5,29). Finally, performance assessment using different mass spectrometers would 
demonstrate broad applicability of the technology. In particular, smaller, lower-cost, and 
lower-performance mass spectrometers, such as a linear ion trap (LIT), could ease 
technology translation into the clinical space (30–33). Yet, LIT exhibits lower mass 
resolving powers than orbitrap systems, which could potentially prevent accurate tissue 
diagnosis. To address these questions, here we evaluated the MasSpec Pen for ovarian 
cancer diagnosis across different sample sets, tissue types, and MS systems. Training, 
validation, and test sample sets were used to evaluate the predictive performance and 
molecular information obtained. LGSC, FT, and peritoneum samples were analyzed to 
explore the MasSpec Pen capabilities for cancer subtyping and differentiation from other 
healthy tissues in the abdominal cavity. Lastly, performance using a LIT mass analyzer 
was investigated to test method versatility across systems. 
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MATERIALS AND METHODS 
Human tissue samples 
In total, 160 deidentified ovarian frozen tissue samples were obtained from the 
Cooperative Human Tissue Network (CHTN; Table 5.1). Samples were requested by the 
research team and collected from different tissue banks within the CHTN network in 3 
different batches, the first in the fall of 2015, the second in the fall of 2017, and the third 
in spring of 2018. Samples were selected following criteria based on tissue diagnosis 
(HGSC or LGSC) by gross anatomy and pathological evaluation, and specimen size (>200 
mg). FT and peritoneum tissues (32 samples, 29 patients) were received as deidentified 
frozen specimens from the MD Anderson and CHTN Tissue Banks, or prospectively 
collected as fresh specimens during endometriosis surgery performed by MB (under 
approved IRB protocol#: 2017–08-0087) at the Seton Medical Center (Austin, TX; Table 
A5.1). Patients undergoing endometriosis surgery were consented. Information on disease 
severity (other than grade for ovarian cancer) and alternative diagnoses were not 
considered in our study. Samples were analyzed at room temperature in random order. The 
analyzed area of the tissue was demarcated and registered through optical images. The 
same demarcated tissue or a parallel piece was frozen and sectioned at 10–16 µm using a 
CryoStar NX50 cryostat (Thermo Fisher Scientific), stained by standard hematoxylin and 
eosin procedure, and evaluated by expert pathologists (not blinded from previous clinical 
information) to confirm diagnosis of the analyzed area. Of note, the final diagnoses were 
performed after MasSpec Pen analyses (Figure 6.1). Only samples with clear diagnosis (n 




Table 6.1:  Patient demographic information.  
Ovarian tissue samples were obtained from the CHTN Tissue Bank under approved IRB 
protocol. Samples were acquired as three independent sample sets (set 1 (n=57), set 2 
(n=39), set 3 (n=64)). 
 
Parameter Normal High-grade SC Low-Grade SC 
Sample Set 1 
Number of Patients (N) 29 28 - 
Median Age, Years 50 62 - 
Age Range, Years (31,80) (30,83) - 
Number of Patients by Race 
(22, 7, 0, 0, 0) (25,2,0,0,1) - 
(White, Black, Asian, Hispanic, Unknown) 
Sample Set 2 
Number of Patients (N) 14 11 14 
Median Age, Years 57 61 57.5 
Age Range, Years (34,82) (47,76) (18,82) 
Number of Patients by Race 
(10,3,1,0,0) (6,1,0,0,4) (14,0,0,0,0) 
(White, Black, Asian, Hispanic, Unknown) 
Sample Set 3 
Number of Patients (N) 35 29 - 
Median Age, Years 53 65 - 
Age Range, Years (23,86) (44,85) - 
Number of Patients by Race 
(22, 11, 0, 1, 1) (24,2,1,0,2) - 







Figure 6.1: Tissue samples were analyzed with the MasSpec Pen using a discrete water 
droplet to extract molecular information after 3 seconds of contact time. 
Mass spectra were obtained using an orbitrap and a linear ion trap mass analyzer. For 
pathological evaluation, tissue samples were stamped post-analysis, frozen, sectioned and 
hematoxylin and eosin (H&E) stained.  
MasSpec Pen analysis 
The MasSpec Pen with a 2.7-mm pen tip diameter was used for analysis, using the 
same procedures and system previously described in Chapter 5 of this dissertation (21). 
The MasSpec Pen uses a water droplet to extract molecules from tissues upon contact, 
which are then analyzed by an orbitrap mass spectrometer and statistical classifiers, 
resulting in a total analysis time of approximately 10 s. A new MasSpec Pen device was 
used for each of the tissue analyses described in this study to prevent any potential 
carryover between samples. Experiments were performed on a Q Exactive Orbitrap and an 
LTQ mass spectrometer (Thermo Fisher Scientific). Orbitrap analyses were performed 
from m/z 120–1800 at a resolving power of 140000 at m/z 200. Ion trap analysis analyses 
were performed from m/z 120 to 1000, at a capillary temperature of 350°C, and tube lens 
and capillary voltages of -110 V and -35 V, respectively. Note that while orbitrap 
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experiments were performed from m/z 120-1800, ion trap measurements were restricted to 
m/z 120-1000 due to the presence of background ions at higher mass ranges (m/z >1000). 
The m/z restriction was unavoidable, as the interfering ions are constantly observed in the 
mass spectra at m/z >1000 of the specific ion trap mass spectrometer that was available and 
used for this study. Tandem MS of selected ions was performed during MasSpec Pen 
analyses using high-energy collisional dissociation in the Q Exactive. Of note, the MasSpec 
Pen orbitrap analysis of sample set 1 (n = 57) and the resulting data were previously 
described (21), whereas all the remaining samples and analyses were new to this study. 
Statistical analysis 
Three mass spectra were averaged for each sample. The orbitrap and ion trap data 
were binned to m/z 0.01 and m/z 1, respectively, and normalized to the median absolute 
intensity. Note that other normalization methods, including normalizing by the total ion 
count and the ion count at m/z 885.551, were tested in this study, with median normalization 
providing the best performance.  Background peaks and others not appearing in at least 
10% of the samples analyzed were excluded. The Lasso method was applied to the 
preprocessed data using the glmnet package in the CRAN R language library (34). Five 
unique molecular models were built to differentiate between the tissue types from training 
sets of samples, by assigning mathematical weights to each statistically informative feature 
depending on its importance in characterizing a certain class. For HGSC and ovarian cancer 
prediction, data from sample sets 1 and 2 were randomly split between training and 
validation sets. Predictive accuracy within the training set was assessed by leave one-out 
CV. Those models were then used to predict on the validation set as well as on an 
independent test set (set 3) of samples. Classification performance was measured by 
sensitivity, specificity and accuracy. The “pROC” R package was used to select an optimal 
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threshold from the ROC curve (35). Cosine similarity analysis was performed in the CRAN 
R language using average mass spectra for each tissue type analyzed in each sample set.  
RESULTS 
MasSpec Pen analysis of ovarian tissue samples using an orbitrap mass analyzer 
In our previous study described in Chapter 5, we analyzed a sample set including 
normal ovarian and HGSC tissue using the MasSpec Pen coupled to an orbitrap mass 
spectrometer (21). Here, 2 additional sample sets were obtained and analyzed using the 
same approach (Table 6.1). Figure 6.2 shows representative MasSpec Pen mass spectra 
from the 3 different tissue types from the second sample set. A variety of small metabolites, 
such as glutamate (m/z 146.045), ascorbate (m/z 175.025), and glutathione (m/z 306.077), 
as well as complex glyocerophospholipid (GP) species, such as 
glycerophosphoethanolamine (PE) P-18:0 20:4 (m/z 750.546), glycerophosphoserine (PS) 
18:0 18:1 (m/z 788.546), and glycerophosphoinositol (PI) 18:0 20:4 (m/z 885.551), were 
detected. Identification and corresponding mass errors are provided in Table A5.2for 
species tentatively assigned using high mass accuracy and tandem MS/MS measurements. 
Representative MasSpec Pen MS/MS spectra of ovarian tissue samples are shown in Figure 
A5.2. The molecular profiles obtained from normal and HGSC from the second and the 
third sample sets presented similar trends to those previously observed from tissues 
analyzed in the first sample set (see Figure A5.3). In particular, mass spectra from normal 
ovarian tissue were characterized by high relative abundance of ascorbate and other small 
metabolites, whereas GP species appeared at higher relative abundances in the mass spectra 
from HGSC tissues (Figure 6.2). The mass spectra obtained from LGSC also presented a 
rich variety of GP species at higher relative abundances than in the mass spectra from 
normal tissues. Further, when comparing LGSC to HGSC, qualitative changes in the 
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relative abundances were observed between the mass spectra of the 2 cancer subtypes 
(Figure 6.2). For example, higher relative abundances of plasmalogen PE species, such as 
m/z 722.514 and m/z 750.546, were observed in the mass spectra from LGSC, whereas 
glutamate and glycerophosphatidic acid (PA) 18:0 18:1 (m/z 701.514) were at higher 
relative abundances in HGSC tissue. Cosine analysis was performed to evaluate the 
similarity in the mass spectra between the 3 sample sets for the same tissue class. Note that 
cosine analysis provided similarity values ranging from 0 (dissimilar) to 1 (identical). 
Similarity values of 0.76 ± 0.06 and 0.80 ± 0.06 were achieved from HGSC and normal 





Figure 6.2: Representative MasSpec Pen mass spectra of high-grade serous carcinoma 
(top), low-grade serous carcinoma (middle, background subtracted) and 
normal ovarian tissue (bottom) obtained with an orbitrap mass analyzer.  
Optical image of the stained parallel tissue section analyzed is provided. Tentative 
identifications are shown for selected ions. X:Y represents number of carbon atoms double 
bonds in the fatty acid chains.  
Statistical prediction of ovarian cancer using training, validation, and test sample 
sets 
Next, we evaluated if the molecular information obtained from MasSpec Pen 
analysis using the orbitrap mass spectrometer was predictive of normal, LGSC, and HGSC 
across different sample sets. In our previous study (21), a classifier for HGSC diagnosis 
was built from a sample set 1, a single sample batch, and evaluated using leave-one out 
cross-validation only. Here, the histologically validated mass spectra obtained from the 
second set of samples were combined with the first sample set data to improve and validate 
the statistical classifiers (n = 43 normal, n = 36 HGSC). First, the combined data set was 
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randomly split into a training set (n = 32 normal, n = 28 HGSC) to build the statistical 
model, and a validation set (n = 11 normal, n = 8 HGSC) to evaluate performance and test 
for possible overfitting. Using the training set, 100% clinical sensitivity, 96.8% clinical 
specificity, and 98.3% accuracy was achieved, which are an improvement over previously 
published results of 100% clinical sensitivity, 89.7% specificity, and 94.7% overall 
accuracy. In the validation set, 100% clinical sensitivity, specificity, and accuracy were 
obtained (Figure 6.3). Using our previous model (built on sample set 1 alone) to predict on 
sample set 2, we achieved 100% clinical sensitivity, 75% specificity, and 90.9% overall 
accuracy (Table A5.3), which was an overall lower performance than what we achieved by 
including samples from different batches in the training sample set. Note that tissue 
samples were grouped based on tissue type and, as such, the effect of sample source (or 
tissue bank) on method performance was not evaluated. 
Next, a statistical classifier to discriminate between normal and serous cancer (SC) 
samples was also built by combining the HGSC and LGSC samples into a single class (n 
= 43 normal, n = 43 cancer). Similarly, the model exhibited high performance in both 
training (93.9% clinical sensitivity, 96.9% specificity, and 95.4% accuracy) and validation 
sample sets (100% clinical sensitivity, 90% specificity, and 95.0% accuracy). To further 
test the performance of the statistical models (HGSC vs normal and SC vs normal), 
prediction was performed on the third sample set (Figure 6.3). Results are reported for 
samples of clear diagnosis by pathology (n = 28 normal, n = 24 HGSC), corresponding to 
91.7% clinical sensitivity, 92.9% specificity, and 92.3% overall accuracy, with 4 out of 52 
samples misclassified.  
A 3-class statistical model was also created to differentiate between normal ovarian, 
HGSC, and LGSC tissues. Because of the limited LGSC sample size (n = 7), the model 
was built using cross-validation on the entire data set. Despite the introduction of the new 
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LGSC subtype, all HGSC and normal ovarian samples were correctly classified (n = 79, 
100% accuracy). For LGSC classification, an accuracy of 71.4% was achieved, with 2 out 
of the 7 samples misclassified as HGSC. Collectively, the 3-class model showed strong 
overall performance for cancer diagnosis, resulting in an overall accuracy of 97.7%. A 
summary of all results, including confusion matrices, classification performance, and 
number of metabolic species included in the models are provided in Tables A5.3 and A5.4 
Among the species selected to generate the statistical models, ascorbate (m/z 
175.024) and taurine (m/z 124.006) were selected as important for the discrimination of 
normal tissue, and lactate (m/z 201.038), glutathione (m/z 306.077), and the PI 18:0 20:4 
(m/z 885.551) were characteristic of HGSC and the combined cancer class. For the 3-class 
model, PE P-18:0 20:4 at m/z 750.546 was given a positive weight for the characterization 
of LGSC, in agreement with the trends in relative abundances observed in the 
representative mass spectra shown in Figure 6.2. Gluconate (m/z 195.051) and glutamate 













Figure 6.3:  Lasso classification performance for ovarian cancer prediction based on 
MasSpec Pen data for the training, validation and test sets.  
Results are shown in terms of sensitivity, specificity and overall accuracy. Confusion 
matrices with per patient prediction are shown in Table A5.3. 
Distinguishing ovarian cancer from healthy FT and peritoneum tissue 
FT (n = 15) and peritoneum (n = 17) tissue samples were also analyzed with the 
MasSpec Pen and compared to ovarian cancer tissues. Mass spectra obtained from 
peritoneum tissue were commonly characterized by fatty acid (FA) species, detected both 
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as monomers, such as FA 18:1 (m/z 281.247), and dimers, such as FA 18:0 –16:0 (m/z 
537.487). Chlorinated triacylglyceride (TG) species were also detected at higher mass 
range, such as TG 52:3 (m/z 891.720), reflecting on the fat content characteristic of 
peritoneal and omental tissues. High abundance of complex lipids, such as PI, PE, and PS 
species, were observed from the lipid and metabolite profiles obtained from FT samples 
(Figure 6.4A). A list of tentatively identified species with mass errors is provided in Table 
A5.5. 
Molecular models to discriminate peritoneum and FT tissue from ovarian cancer 
samples from batch 1 and 2 were built by leave-one-out cross-validation analysis (Figure 
6.4B). A detailed summary of all classification results, including the number of metabolic 
species included in the models, is provided in Table A5.6. All peritoneum (n = 15) and FT 
(n = 11) samples were correctly classified when compared to HGSC and ovarian SC 
samples (100% clinical specificity). Clinical sensitivity values of 88.9% and 90.7% were 
achieved for HGSC (n = 36) and SC overall (n = 43) vs FT samples, respectively. When 
compared to peritoneum samples, lower clinical sensitivities were achieved for HG 
(80.0%) and SC (83.7%). Interestingly, many of the features selected by the models to 
characterize HGSC and ovarian SC tissue from FT and peritoneum tissue were similar to 
those used for discrimination against normal ovarian tissue, such as lactate, glutamate, or 
PI 38:4. Yet, ascorbate was given a positive weight for ovarian cancer classification. 
Hexose (m/z 215.031) was selected as predictive of both FT and peritoneum samples, 
whereas a species at m/z 267.073, tentatively identified as inosine, a purine nucleoside, was 
only associated to FT tissue. 
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Figure 6.4:  Differentiating ovarian cancer tissue from healthy peritoneum and fallopian 
tube tissue samples.  
Representative mass spectra profile obtained from MasSpec Pen analysis of peritoneum 
(top) and fallopian tube (bottom) tissue. Tentative identifications are shown for selective 
ions (A). Lasso results for peritoneum (top) and fallopian tube (bottom) vs HGSC and 
cancer tissue differentiation (B). 
Validation of the MasSpec Pen using and ion trap mass analyzer 
The MasSpec Pen was coupled to a LIT and used to evaluate a subset of HGSC and 
normal ovarian samples (n = 20 normal, 20 HGSC). Note that the LIT provides lower 
performance for mass analysis with limited resolving power (1600 at m/z 885.7) and mass 
accuracy when compared to the resolving power (72000 at m/z 885.547) and mass accuracy 
(< 5 ppm) achieved with orbitrap mass analyzers. Figure 6.5A shows that the mass spectra 
obtained for the same HGSC sample analyzed by both systems are highly comparable, 
although a higher number of resolved lipid species were detected by orbitrap analysis, as 
anticipated. Distinctive metabolic profiles for HGSC and normal ovarian samples were 
obtained by MasSpec Pen and LIT analysis (Figure A5.4). Similar to the orbitrap data, 
 136 
HGSC mass spectra were characterized by the high relative abundance of GP species, 
whereas normal samples displayed considerably lower lipid abundance and higher relative 
abundances of small metabolites.  
Statistical classifiers were built to evaluate the predictive performance for HGSC 
diagnosis based on LIT data. The data was randomly split into a training (n = 30) and 
validation sets (n = 10), yielding excellent classification performance, with 100% clinical 
sensitivity, specificity, and accuracy in both sets (Figure 6.5B). For adequate comparison, 
a new model was built using orbitrap data from the same set of samples analyzed using the 
LIT (n = 40). High specificity was achieved in both the training (93.3%) and validation 
sets (100%) by the new orbitrap model, whereas lower clinical sensitivity was observed for 
the training (86.7%) and validation (80.0%) sets, respectively, with 3 HGSC samples 
misclassified as normal. Note that these 3 samples had been correctly classified by the 
model built using orbitrap data acquired from the larger training set (n = 60). A detailed 






Figure 6.5:  Representative mass spectra profile obtained from the same HGSC sample by 
ion trap (top, profile mode) and orbitrap (bottom, centroid mode) analysis. 
Tentative identifications are shown for selected ions (A). Lasso results for 
HGSC prediction comparing performance between the models built from 
orbitrap and ion trap data acquired from the same sample set (n=40) (B). 
DISCUSSION 
Validation of the diagnostic capabilities of the MasSpec Pen is paramount for 
potential clinical translation. Utilizing a cohort of 138 histologically validated ovarian 
cancer and normal tissue samples, we demonstrate here the predictive power of the 
statistical models built from MasSpec Pen analyses. Machine learning and classification 
algorithms are not parametrically constrained and thus are more susceptible to overfitting 
than other more traditional methods (36). Overfitting occurs when a model uses spurious 
correlations within a single data set rather than relationships within the population. Here, 
statistical validation and evaluation of model overfitting were performed using training (to 
fit the model), validation (to provide an unbiased evaluation while tuning parameters such 
as data normalization methods), and test (to provide an unbiased evaluation of a final 
model) sets of samples. Improved performance was achieved for HGSC diagnosis using a 
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new training set that combines samples from different batches, compared to what we have 
previously reported using a single sample batch (21). These results show that including 
samples from different batches in the training set helps improve the predictive power of 
the classifiers. High prediction accuracies were also observed in both the validation and 
test sets, indicating that the model was not overfitting to the training set. Similar results 
were obtained for the normal vs SC classifier, demonstrating that the MasSpec Pen and 
machine learning provide robust predictive models for ovarian cancer diagnosis.  
Discrimination between LGSC and HGSC tissue was also explored. Owing to the 
lower clinical occurrence of LGSC, sample availability was limited. Nevertheless, trends 
in lipid and metabolite composition between the 2 cancer types were and reflected by the 
moderate classification accuracy achieved. Collection of additional LGSC tissues is 
ongoing to continue MasSpec Pen validation for ovarian cancer subtyping. Four molecular 
models were also built to discriminate HGSC and SC from healthy FT and peritoneum 
samples, yielding 100% clinical specificity and sensitivity from 80.6% to 90.7% for cancer 
diagnosis. Assessment of the mass spectra from the cancer samples misclassified as FT 
revealed unusually high abundance of m/z 215.031, weighted toward FT classification, and 
an overall low lipid abundance in samples misclassified as peritoneum. Interestingly, 3 out 
of the 7 cancer tissues misclassified as peritoneum were obtained from ovarian cancer 
metastasis to the omentum. Segregation of primary or metastatic samples will be evaluated 
to investigate differences in molecular information that may be correlated to 
misclassification, as well as refinement of the statistical models. Nonetheless, the overall 
accuracies (>86%) achieved demonstrate the MasSpec Pen potential to differentiate SC 
from surrounding normal ovarian and abdominal healthy tissues.  
The features chosen by the lasso models as predictive for ovarian cancer diagnosis 
and subtyping were identified as biologically relevant species. For example, ascorbic acid, 
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which has an important role in normal ovarian functions (37), was selected as important 
for normal ovarian tissue characterization, whereas GP lipids, such as PI 18:0 20:4, were 
at high relative abundance in cancer tissue and selected as predictive markers. Gluconate 
and glutamate were selected as important for the discrimination of LGSC and HGSC 
samples. Similar trends and species have also been reported using desorption electrospray 
ionization MS (26). Moreover, increased abundance of glutamate has been reported 
previously in invasive ovarian carcinomas compared to borderline tumors by gas 
chromatography and MS analyses (38). Another interesting feature selected was inosine at 
m/z 267.073, which was associated with FT tissue. Inosine is rapidly metabolized from 
adenosine, a nucleoside known to modulate neurotransmission and contractile responses in 
the FTs (39) and has been previously detected in oviduct cells (40).  
Smaller and lower-cost equipment could facilitate translation of MS technologies 
to the clinic (30). LIT mass spectrometers are attractive for clinical use due to their 
scalability, tolerance for higher operating pressure, and lower cost (31). However, LIT 
analyzers provide limited mass resolution, which could potentially compromise 
performance. To demonstrate that the MasSpec Pen can be compatible with a mass 
spectrometer platform other than an orbitrap, and to further investigate how classification 
performance is affected by collecting data with lower performance mass analyzers, we 
coupled the MasSpec Pen to a LIT system. Using a smaller sample set than what 
collectively explored for orbitrap analysis, we achieved 100% accuracy for HGSC 
classification in training and validation. The higher performance achieved compared to the 
orbitrap data could be related to the absence of batch effects in the LIT data and will be 
further investigated. Overall, similarities between the detected metabolic profiles and 
statistical models observed between orbitrap and LIT data support the validity and 
robustness of the predictive molecular species and further support that the MasSpec Pen 
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provides consistent molecular analysis across MS systems. More testing of the LIT and 
other mass spectrometers is needed across multiple sample sets and cancer subtypes.  
In conclusion, our study demonstrates high performance and versatility of the 
MasSpec Pen technology and statistical models across different sample sets and MS 
platforms, as well as feasibility for cancer subtyping. The MasSpec Pen leverages on its 
nondestructive nature for direct and gentle analysis of tissues and the sensitivity, 
specificity, and speed provided by MS for untargeted and accurate molecular diagnosis. 
Further, its simple design, ease of operation, and biocompatibility are attractive for clinical 
use. Thus, we envision the MasSpec Pen to be employed in the operating room (OR) for in 
vivo and/or ex vivo use in conjunction with standard surgical tools. Yet, this study 
represents a first step toward validating the performance of the MasSpec Pen for ovarian 
cancer diagnosis. Several challenges still need to be addressed and further validation 
pursued to demonstrate the usefulness of the MasSpec Pen in its envisioned application in 
the OR. Although our experiments performed on ex vivo tissues obtained from tissue banks 
yield diagnostic molecular results, in vivo and freshly excised tissues in the OR may present 
slightly different molecular profiles. Moreover, extensive analyses of benign ovarian 
disease and tissues with varied histologic composition are needed to further demonstrate 
its value in more complex surgical pathology cases. As such, in vivo OR experiments 
utilizing the MasSpec Pen for ovarian cancer diagnosis are currently planned to further 
evaluate its diagnostic capabilities. Performance evaluation across different institutions, 
instrumentation, and users are also envisioned to further validate our results and evaluate 
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Chapter 7: Conclusions and Perspectives  
Investigating metabolic trends in ovarian cancer tissue can provide powerful 
insights into the mechanisms driving disease development and progression and the 
opportunity to introduce molecular information into routine clinical diagnoses. The 
unparalleled analytical specificity and sensitivity of MS, together with the clinically fitting 
features of ambient ionization, such as minimal sample requirements and experimental 
simplicity, offer highly suitable capabilities to achieve these objectives. The studies 
described in this dissertation demonstrate the versatility of ambient ionization MS methods 
to analyze cancer tissue ex vivo as thin tissue sections or fresh-frozen specimens and 
showcase feasibility for in vivo analyses from viable tissue. The continued technical 
development of these technologies to address current challenges in ambient ionization MS 
as well as improve robustness and ease-of-use can further advance performance to pursue 
additional clinically relevant areas in ovarian cancer research. Additional factors, including 
successful validation in pilot and trial studies to evaluate clinical impact and meet 
regulatory standards, will need to be considered to achieve implementation of these 
technologies for clinical use.   
DESI-MS imaging has been widely applied to distinguish between healthy and 
diseased tissue, as well as to differentiate between various cancer subtypes, determining 
potential metabolic markers associated with each particular tissue type. Future studies 
should focus in critical oncological areas that can truly benefit from the high diagnostic 
accuracy and efficiency provided by DESI-MS and multivariate statistical analyses, such 
as those cases not solvable with current tools available to pathologists, or those that 
represent a great burden to process and diagnose. Moreover, going beyond cancer diagnosis 
and predicting patient prognosis, including surgical outcome, treatment response, or 
progression-free survival rates might offer a higher impact to the care and management of 
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ovarian cancer patients. Investigating molecular features associated with clinical response 
could also have large implications in understanding resistance and sensitivity to current 
treatment strategies, such as chemo and immunotherapies, currently a critical problem in 
ovarian cancer treatment. Importantly, correlating DESI-MS lipid data to protein and 
genetic molecular changes could provide additional mechanistic information into the 
development of tumorigenic pathways in ovarian cancer. To facilitate routine use by non-
experts in clinical laboratories and pathology rooms, advances in DESI-MS technology to 
ameliorate ease of method optimization and robustness, as well as reduce user-
dependability, will also be crucial.  
Alternative methods for ambient ionization MS tissue section analysis, such as the 
one described in Chapter 4, can address current analytical limitations in spatially controlled 
metabolic profiling and molecular coverage by exploiting the capabilities to easily tune 
droplet volume and composition, including the introduction of chemical additives for 
enhanced molecular detection and on-tissue derivatization. These approaches could be of 
high relevance for improved protein and peptide detection from tissue samples by ambient 
ionization MS technology. Future testing and refining of this method for characterization 
of biological tissue samples will determine its overall potential impact in ovarian cancer 
research. Importantly, this method also provides a suitable platform for an in-depth 
investigation of the mechanisms driving molecular extraction and ionization in liquid 
extraction ambient MS technologies. Even though various ambient ionization MS methods 
employ liquid extraction mechanisms to interrogate tissue samples, such as DESI-MS and 
the MasSpec Pen, little is known about the parameters and conditions driving the sampling 
and detection of molecular ions in these experiments. Conducting an investigation to 
separately study extraction and ionization events using the method described in Chapter 4 
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of this dissertation will ultimately provide important insights to advance and optimize these 
technologies for detection of molecular species from tissue samples.  
The development of ambient ionization MS methods capable of providing 
distinctive molecular profiles of various cancer types in vivo, such as ovarian cancer, opens 
a new set of applications previously considered unattainable with MS technology. It is truly 
striking that a technique such as the MasSpec Pen is capable of extracting sufficient 
molecules from a tissue sample using only a droplet of water in under 10 seconds, and that 
this information can be used to generate robust statistical models with machine learning 
algorithms to predict cancer diagnosis. Importantly, the ease-of-use of this technology, 
including the handheld device and automated platform, enables surgeons and other 
clinicians to easily introduce the MasSpec Pen into their clinical workflow. This 
technology could help improve the accuracy and efficiency of ovarian cancer cytoreductive 
surgeries, minimizing residual disease and improving patient outcome. After 
demonstrating adequate capabilities for ex vivo use, as described in Chapters 5 and 6, 
testing of this technology during human surgeries is currently underway and planned to 
continue through multiple pilot clinical studies, and will be imperative to validate 
performance and pursue implementation for clinical use. The opportunity to evaluate viable 
tissue with vascular and dynamic biological activity, commonly also accompanied by 
blood and other bodily fluids at the surface analyzed, is an invaluable experience to gather 
powerful observations to direct future refinements and developments towards improved 
clinical use. The optimization of MS instrumentation to allow for routine analysis of 
surgical specimens, such as adapting the MasSpec Pen to miniaturized mass spectrometers 
and developing robust ion optics interfaces, will also facilitate testing and translating the 
MasSpec Pen and other technologies to various clinical practices.   
 147 
Importantly, most of the findings and data interpretations discussed in this 
dissertation were generated based on evaluations and results provided by advanced 
statistical and computational methods, such as those developed by our collaborator Prof. 
Tibshirani. Thus, careful interpretation of the outputs provided by these analyses is 
extremely important, understanding the underlying assumptions and thus the limitations, if 
any, of the resulting conclusions. Moreover, rigorous testing and validation of the results 
should be performed to ensure unbiased observations, and with the ultimate goal of 
reaching a conclusion representative of the whole population. Preprocessing of MS data 
prior to data analysis can be challenging yet is paramount to ensure reliable and accurate 
results. The development, optimization, and standardization of data handling methods for 
MS will enable widespread use by researchers and clinical professionals and facilitate 
comparisons between results obtained by different institutions and laboratories. 
Improvements in open-source data analysis and visualization tools that provide informative 
interpretations from the highly complex and large MS imaging datasets are also needed to 
assist in data evaluation. The further advancement of methods for data preprocessing, 
modeling, and prediction will only continue to improve the capabilities of MS for tissue 
characterization and diagnosis. 
All-inclusive, the studies described in this dissertation suggest that ambient 
ionization MS technology can provide powerful information to address various 
applications in ovarian cancer research and diagnosis. Continued technical development of 
these technologies will facilitate widespread use in bioanalytical laboratories and reveal 
new applications in cancer research. To achieve implementation as a routine diagnostic 
tool for rapid and direct assessment of tissue samples, additional considerations need to be 
addressed. Apart from testing feasibility with clinical samples in the same environments 
envisioned for ex vivo and in vivo use, careful validation with current standard of care will 
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be crucial to evaluate the need and ultimate impact of these approaches. Thus, collaboration 
and partnership with clinicians and hospitals to provide the required infrastructure and 
logistics to conduct rigorous validation studies will be of highest importance. Adapting the 
operation and capabilities of these methods to facilitate use by pathologists and surgeons, 
mimicking other technologies routinely employed in the frozen section or operating room, 
and developing a user-friendly platform that can provide straight-forward information in a 
timely and robust matter will also need to be pursued. Ultimately, the incorporation of MS 
technology as a routine tool used for cancer diagnosis and surgical guidance will rely on 
regulatory approval by federal and international organizations as medical devices and/or 
in vitro diagnostics. With MS-based clinical diagnostics being a relatively new field, 
guidance from regulatory experts will be highly valuable to continue the development and 
testing of these technologies and to define future studies required to achieve clearance. It 
goes without saying that the implementation of MS technology, foreign to most surgical 
and oncological practices, for routine cancer diagnosis will be no easy task, but the 
potential benefits that these methods can provide to cancer patients, clinicians, and to the 





APPENDIX A1. METABOLIC MARKERS AND STATISTICAL PREDICTION OF SEROUS 
OVARIAN CANCER AGGRESSIVENESS BY AMBIENT IONIZATION MASS SPECTROMETRY 
IMAGING 
Table A1.1:  Patient demographic table.  
Tissue samples were obtained from the Cooperative Human Tissue Network (CHTN) and 
from the MD Anderson Cancer Center Tissue Bank.  
 
 Patient Group 
Parameter Normal Borderline High-grade 
Number of Patients (N) 15 15 48 
Median Age, Years 53 48 64 
Age Range, Years (39,77) (23,78) (43,84) 
Number of Patients by Race 
(White, Black, Asian, Unknown) 
(10,4,0,1) (11,2,0,2) (38,6,1,3) 
Tissue Bank CHTN CHTN 
CHTN (N=24) 






Figure A1.1: Representative DESI mass spectrum for normal ovarian tissue sections.  
Negative ion mode (A). Positive ion mode (B). DESI-MS representative ion images. 
Adjacent tissue sections were used for negative and positive ion mode analysis (C). Corpus 
luteum areas are outlined in black. Areas of red intensity within the ion images represent 
highest (100%) and black lowest (0%) relative abundances. PI: glycerophosphoinositol 
PG: glycerophosphoglycerol CL: PC: glycerophosphocholine DG: Diacylglyceride. Lipid 







Figure A1.2: Representative negative ion images characteristic for HG tumorous and 
necrotic regions for sample HGSC_1.  
PI 38:4, PG 34:1 and CL 72:7 were found overexpressed in the cancer regions, while 
necrosis was characterized by higher relative abundances for Cer d42:2, Cer d36:1 (mass 
error = 1.8 ppm) and Cer d34:1. Tumor regions are outlined in black, necrosis in red. Areas 
of red intensity within the ion images represent highest (100%) and black lowest (0%) 
relative abundances. PI: glycerophosphoinositol PG: glycerophosphoglycerol CL: 
cardiolipin Cer: ceramide. Lipid species are described by number of fatty acid chain 












Table A1.2: Lasso results based on pixel and patient analysis for normal vs high-grade 
SOC classification, for negative and positive ion polarities.  
Negative (Normal N=15, High-grade N=48). Positive (Normal N=10, High-grade N=46). 
Results show agreements for CV (cross-validation) and validation sets. Rows represent 
classification based on pathological evaluation, columns represent classification based on 
LASSO prediction. Agreements per pixels are calculated based on percentage of correctly 
classified pixels over total pixels classified. Per patient analysis by the Lasso is based on 
classification results for the majority of pixels from the patient. AUC (area under the 
curve).  
 













Normal 5554 44 99.2 
97.1 0.98 High-
Grade 
532 13952 96.3 
Validation 
Normal 5377 151 97.3 
96.5 0.97 High-
Grade 




Normal 8 0 100 
100.0 - High-
Grade 
0 23 100 
Validation 
Normal 7 0 100 
96.5 - High-
Grade 
1 24 96.9 




Normal 3946 272 93.6 
96.7 0.96 High-
Grade 
376 14798 97.5 
Validation 
Normal 3684 200 94.9 
95.5 0.95 High-
Grade 




Normal 5 0 100 
100.0 - High-
Grade 
0 23 100 
Validation 
Normal 5 0 100 
89.3 - High-
Grade 




Table A1.3: Identified species selected by the Lasso as significant contributors to high-
grade versus normal discrimination with attributed weights.  
Weights attributed with respect to high-grade classification: positive weights represent an 
increase in relative abundances in high-grade tissue samples in comparison to normal tissue 
samples, while negative weights represent lower relative abundances in high-grade tissue 
samples in comparison to normal tissue samples.  Tentative molecular formulas and 
chemical identification were attributed by high mass accuracy/high mass resolution and 
tandem MS analyses. Molecular formulas correspond to ionized molecule. Double negative 
and double positives correspond to greater contributions to the model. Negative ion mode: 
Lasso weights: ‘++’ ‘- -’ ≥ │0.001│; ‘+’ ‘-’ <│0.001│. Positive ion mode: Lasso weights: 
‘++’ ‘- -’ ≥ │0.0001│; ‘+’ ‘-’ <│0.0001│.  
 
NEGATIVE ION MODE 






Succinate ++ 117.020 C4H5O4 -1.7 
Malate ++ 133.014 C4H5O5 -1.5 
N-acetylaspartic acid ++ 174.041 C6H8NO5 0.1 
Ascorbic acid - 175.025 C6H7O6 0.1 
Didehydro-D-gluconic 
acid 
- 226.996 C6H8O7Cl 0.9 
FA 16:0 + 255.233 C16H31O2 0.8 
FA 18:2 - 279.233 C18H31O2 -1.1 
FA 20:4 + 303.233 C20H31O2 -1.0 
FA 20:3 + 305.248 C20H33O2 -1.0 
FA 22:4 + 331.264 C22H35O2 -1.2 
PE (18:1/1:0) - - 528.273 C26H43NO8P -0.8 
Cer d34:1 + 572.481 C34H67NO3Cl 1.2 
DG 28:4 - - 679.508 C41H72O5Cl -0.3 
Cer d42:3 - 680.575 C42H79NO3Cl -0.6 
Cer d42:2 - - 682.590 C42H81NO3Cl 1.5 
Cer d42:1 ++ 684.607 C42H83NO3Cl -0.1 
CL 72:8 + 723.479 C81H140O17P2 -0.4 
CL 72:7 + 724.484 C81H142O17P2 3.6 
PG 16:0/18:1 ++ 747.520 C40H76O10P -1.9 
PS 16:0/18:1 - - 760.515 C40H75NO10P -2.0 
PG 18:1/18:1 ++ 773.533 C42H78O10P 0.9 
PS 18:0/18:1 - 788.547 C42H79NO10P -2.4 
PI 18:0/18:2 + 861.552 C45H82O13P -2.1 
PI 18:0/18:1 ++ 863.567 C45H84O13P -1.5 
PI 18:0/20:4 + 885.552 C47H82O13P -2.1 
POSITIVE ION MODE 






Choline group + 104.107 C5H14NO 2.9 
Aminopentanoic acid ++ 156.042 C5H11NO2K -1.3 
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Hexacosanedioic acid - 465.335 C26H50O4K -1.3 
PC 21:4 ++ 610.291 C29H50NO8PK -0.7 
DG 34:2 - - 631.471 C37H68O5K -1.1 
DG 34:1 - - 633.486 C37H70O5K -1.4 
CE 18:2 - - 671.575 C45H76O2Na -2.2 
DG 28:4 - - 683.503 C41H72O5K -2.0 
CE 20:3 ++ 697.589 C47H78O2Na 0.1 
CE 20:4 ++ 711.548 C47H76O2K -0.4 
SM 34:1 - - 725.558 C39H79N2O6PNa -1.4 
PC 32:1 ++ 770.511 C40H78NO8PK -1.6 
PC 32:0 ++ 772.527 C40H80NO8PK -1.9 
PC 34:1 - - 798.542 C42H82NO8PK -1.5 
PC 36:4 - 804.555 C44H80NO8PNa -4.4 
PC 36:3 ++ 822.542 C44H82NO8PK -0.9 
PC 38:5 + 846.539 C46H82NO8PK 2.8 
22:1-Glc-Cholesterol ++ 891.708 C57H95O7 -1.3 
Ubiquinone ++ 901.648 C59H90O4K -1.1 
TG 54:4 ++ 921.729 C57H102O6K 2.1 

















Table A1.4: Lasso results based on pixel and patient analysis for borderline vs high-grade 
SOC classification, for negative and positive ion polarities.  
Negative (Borderline N=15, High-grade N=48). Positive (Borderline N=15, High-grade 
N=46). Results show agreements for CV (cross-validation) and validation sets. Rows 
represent classification based on pathological evaluation; columns represent classification 
based on LASSO prediction. Agreements per pixels are calculated based on percentage of 
correctly classified pixels over total pixels classified. Per patient analysis by the Lasso is 
based on classification results for the majority of pixels from the patient. AUC (area under 
the curve).  
 













Borderline 2573 144 94.7 
93.2 0.97 High-
Grade 
1098 14375 92.9 
Validation 
Borderline 973 295 76.8 
91.8 0.93 High-
Grade 




Borderline 9 1 90.0 
93.8 - High-
Grade 
1 21 95.5 
Validation 
Borderline 4 1 80.0 
93.9 - High-
Grade 
1 25 96.0 




Borderline 1484 494 75.0 
90.4 0.92 High-
Grade 
1508 17366 92.0 
Validation 
Borderline 1421 69 95.4 
97.5 0.99 High-
Grade 




Borderline 7 2 77.8 
93.1 - High-
Grade 
0 20 100 
Validation 
Borderline 6 0 100 
96.9 - High-
Grade 






Table A1.5: Identified species selected by the Lasso as significant contributors to high-
grade versus borderline discrimination with attributed weights.  
Weights attributed with respect to high-grade classification: positive weights represent an 
increase in relative abundances in high-grade tissue samples in comparison to borderline, 
while negative weights represent lower relative abundances in high-grade tissue samples 
in comparison to borderline. Tentative molecular formulas and chemical identification 
were attributed by high mass accuracy/high mass resolution and tandem MS analyses. 
Molecular formulas correspond to ionized molecule. Double negative and double positives 
correspond to greater contributions to the model. Negative ion mode: Lasso weights: ‘++’ 
‘- -’ ≥ │0.001│; ‘+’ ‘-’ <│0.001│. Positive ion mode: Lasso weights: ‘++’ ‘- -’ ≥ 




NEGATIVE ION  MODE 







Succinate ++ C4H5O4 117.020 -1.7 
Glutamic acid - - C5H8NO4 146.046 -0.7 
N-acetyl-aspartic acid ++ C6H8NO5 174.041 0.1 
Ascorbic acid + C6H7O6 175.025 0.1 
Gluconic acid ++ C6H11O7 195.051 0.5 
Hexose - - C6H12O6Cl 215.033 0.9 
FA 16:0 ++ C16H31O2 255.233 0.8 
FA 18:1 - C18H33O2 281.248 -0.7 
FA 20:4 - C20H31O2 303.233 -1.0 
FA 20:3 ++ C20H33O2 305.248 -1.0 
FA 20:2 - - C20H35O2 307.264 -0.7 
FA 20:1 - C20H37O2 309.280 -0.3 
FA 22:4 ++ C22H35O2 331.264 -1.2 
MG 16:0 + C19H38O4Cl 365.246 -1.6 
PE 18:1/1:0 + C24H45NO8P 506.288 -1.8 
Cer d34:1 - C34H67ClNO3 572.481 1.2 
DG 34:1 ++ C37H70O5Cl 629.491 0.8 
Cer d40:1 + C40H79NO3Cl 656.575 0.3 
Cer d41:1 ++ C41H81NO3Cl 670.589 2.4 
CL 72:7 - C81H142O17P2 724.484 3.6 
GlcCer d34:1 - - C40H77NO8Cl 734.535 -0.7 
PE 18:1/18:1 ++ C41H78NO8P 742.538 1.9 
PE 38:4 + C43H77NO8P 766.538 1.3 
PS 18:1/18:1 or 
18:0/18:2 
- C42H77NO10P 786.528 -1.5 
PS 18:0/18:1 - C42H79NO10P 788.547 -2.4 
PG 20:4/18:1 ++ C44H76O10P 795.515 -3.0 
PS 38:4 + C44H77NO10P 810.528 -1.5 
PS 18:0/20:3 - - C44H79NO10P 812.544 -1.2 
PS 40:6 - - C46H77O10NP 834.527 -2.4 
PS 22:4/18:0 ++ C46H81NO10P 838.560 0.5 
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PI 18:0/18:2 + C45H82O13P 861.552 -2.1 
PI 18:0/18:1 ++ C45H85O13P 863.567 -1.5 
PI 18:0/20:4 - C47H83O13P 885.552 -2.1 
PI 18:0/20:3 + C47H84O13P 887.563 -3.4 










choline group ++ C5H14NO 104.107 2.9 
DG 36:3 ++ C41H72O5K 657.487 -2.4 
CE 18:2 - - C45H76O2Na 671.575 -2.2 
PC 34:1 - - C42H82NO13PNa 782.569 -2.0 
PC 34:2 ++ C42H80NO8PK 796.526 -1.1 
PC 36:4 ++ C44H80NO8PK 820.526 -1.3 

















Table A1.6: Lasso results based on pixel and patient analysis for normal, high-grade and 
borderline classification, for negative and positive ion polarities.  
Results show agreements for CV (cross-validation) and validation sets. Rows represent 
classification based on pathological reports, columns represent classification based on 
molecular model. Agreements are calculated based on percentage of correctly classified 
pixels over total pixels classified. Patients are assigned as normal, borderline or high-grade 












Negative Ion Mode – Per Pixel  
CV 
Normal 6751 36 343 94.7 Normal 94.7 
Borderline 254 1690 288 75.7 
Tumor 96.2 
High-Grade 242 347 10274 94.6 
Val 
Normal 3185 0 811 79.7 Normal 79.7 
Borderline 0 1111 642 63.4 
Tumor 100 
High-Grade 7 1112 15645 93.3 
Negative Ion Mode – Per Patient 
CV 
Normal 8 0 1 88.9 Normal 88.9 
Borderline 0 7 2 77.8 
Tumor 100 
High-Grade 0 0 21 100 
Val 
Normal 5 0 1 83.3 Normal 83.3 
Borderline 0 5 1 83.3 
Tumor 100 
High-Grade 0 2 25 92.6 
Positive Ion Mode – Per Pixel  
CV 
Normal 4229 544 214 84.8 Normal 84.8 
Borderline 308 1224 446 61.9 
Tumor 97.2 
High-Grade 285 521 18068 95.7 
Val 
Normal 3074 23 18 98.7 Normal 98.7 
Borderline 26 1155 309 77.5 
Tumor 98.4 
High-Grade 215 14 13415 98.3 
Positive Ion Mode – Per Patient 
CV 
Normal 5 1 0 83.3 Normal 83.3 
Borderline 2 6 1 66.7 
Tumor 93.1 
High-Grade 0 0 20 100 
Val 
Normal 4 0 0 100 Normal 100 
Borderline 0 5 1 83.3 
Tumor 96.9 
High-Grade 1 0 25 96.1 
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Table A1.7: Chemical identity and molecular formula tentatively attributed by high mass 
accuracy/high mass resolution and tandem MS analyses for identified species 
selected by the Lasso as significant contributors to high-grade, borderline and 
normal classification.  
Weights to the model are provided in Table A2.1. 
 

















Succinate 117.020 C4H5O4 -1.7 Choline group 104.1067 C5H14NO 2.9 
Taurine 124.008 C2H6NO3S -0.8 DG 36:3 657.4871 C39H70O5K -2.4 
Malate 133.014 C4H5O5 -1.5 CE 18:2 671.5753 C45H76O2Na -2.2 
Glutamic acid 146.046 C5H8NO4 -0.7 CE 18:1 673.5906 C45H78O2Na -1.8 
N-acetylaspartic acid 174.041 C6H8NO5 0.1 CE 20:4 711.5480 C47H76O2K -0.4 
Ascorbic acid 175.025 C6H7O6 0.1 SM 34:1 725.5578 C39H79N2O6PNa -1.4 
Gluconic acid 195.051 C6H11O7 0.5 PC 32:1 770.5109 C40H78NO8PK -1.6 
Glucose 215.033 C6H12O6Cl 0.9 PC 32:0 772.5268 C40H80NO8PK -1.9 
Didehydro-gluconic 
acid 
226.996 C6H8O7Cl 0.9 PC 34:1 782.5686 C42H82NO8PNa -2.0 
FA 16:0 255.233 C16H31O2 0.8 PC 34:2 796.5262 C42H80NO8PK -1.1 
FA 18:2 279.233 C18H31O2 -1.1 PC 34:1 798.5422 C42H82NO8PK -1.5 
FA 18:1 281.248 C18H33O2 -0.7 PC 36:4 820.5264 C44H80NO8PK -1.3 
FA 18:0 283.264 C18H35O2 -1.1 PC 36:3 822.5417 C44H82NO8PK -0.9 
FA 20:4 303.233 C20H31O2 -1.0 PC 36:2 824.5581 C44H84NO8PK -1.8 
FA 20:3 305.248 C20H33O2 -1.0 PC 38:4 848.5585 C46H84NO8PK -2.2 
FA 20:1 309.280 C20H37O2 -1.3 
22:1-Glc-
Cholesterol 
891.7043 C55H96O7Na 0.6 
FA 22:4 331.264 C22H35O2 -1.2 TG 52:3 895.7157 C55H100O6K -0.7 
MG 16:0 365.246 C19H38O4Cl -1.6 Ubiquinone 901.6481 C59H90O4K -1.1 
Cer d34:2 570.466 C34H65NO3Cl -0.7 TG 54:4 921.7289 C57H102O6K 2.1 
Cer d34:1 572.481 C34H67NO3Cl -1.2 TG 56:6 945.7295 C59H102O6K 1.4 
Cer d42:3 680.575 C42H79NO3Cl -0.6 TG 56:4 949.7595 C59H106O6K 2.7 
Cer d42:2 682.590 C42H81NO3Cl -1.5    
Cer d42:1 684.607 C42H83NO3Cl 0.1    
GlcCer d34:1 734.535 C40H77NO8Cl 0.7    
PE 36:2 742.538 C41H77NO8P -1.9    
PG 16:0/18:1 747.520 C40H76O10P 1.9    
PS 16:0/18:1 760.515 C40H75NO10P 2.0    
PG 18:1/18:1 773.533 C42H78O10P -0.9    
PG 18:0/18:1 775.548 C42H80O10P -1.7    
PS 18:1/18:1 or 
18:0/18:2 
786.528 C42H77NO10P -1.5    
PS 18:0/18:1 788.547 C42H79NO10P 2.4    
PG 20:4/18:1 795.515 C44H76O10P -3.0    
PS 18:0/20:3 812.544 C44H79NO10P -1.2    
PS 18:0/22:4 838.560 C46H81NO10P 0.5    
PI 18:0/18:2 861.552 C45H82O13P 2.1    
PI 18:0/18:1 863.567 C45H84O13P 1.5    
PI 18:0/20:4 885.552 C47H82O13P 2.1    
PI 18:0/20:3 887.563 C47H84O13P -3.4    
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Figure A1.3: Fragmentation patterns obtained by higher collisional induced dissociation 
(HCD) MS/MS analysis of gluconic acid standard (A) and m/z 195.051 from 
HGSC tissue sample (B). DESI-MS images for m/z 195.051 for four HGSC 










Figure A1.4: Tandem MS spectra in the negative ion mode for representative complex GPs 
and metabolites with significant contributions to the classification model.  
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Proposed molecular structure and fragmentation sites are shown for each species. A) [M-
H]- Glycerophosphoinositol PI 18:0/20:4 B) [M-H]- Glycerophosphoglycerol PG 18:0/18:1 
C) [M-2H]2- Cardiolipin CL  18:1/18:2/16:0/20:4. * represents doubly charged fragment 
species. D) [M-H]-Glycerophosphoserine PS 18:1/18:0 E) [M-H]- Amino acid taurine F) 




Figure A1.5: Tandem MS spectra in the positive ion mode for representative species 
contributing to the classification model.  
Proposed molecular structure and fragmentation sites are shown for each species. A) 
[M+K]+ Glycerophosphocholine PC 34:1 B) [M+Na]+ Cholesteryl Ester CE 18:2 C) 





Table A1.8: Lasso per pixel results for tumor and stroma classification for five HGSC 
patients based on negative ion mode DESI-MS data.  
Lasso models were built individually for each patient. Rows represent classification based 
on pathological reports, columns represent classification based on Lasso prediction. 
Agreements are calculated based on percentage of correctly classified pixels over total 
pixels classified.  
 
  Lasso Prediction 






Tumor 678 4 99.4 
99.5 
Stroma 2 455 99.6 
2 
Tumor 509 2 99.6 
99.6 
Stroma 4 961 99.6 
3 
Tumor 269 3 98.9 
97.9 
Stroma 10 338 97.1 
4 
Tumor 345 1 99.7 
99.4 
Stroma 6 869 99.3 
5 
Tumor 565 1 99.8 
99.8 












APPENDIX A2. INVESTIGATING THE EFFECTS OF FABP4 EXPRESSION IN OVARIAN 
CANCER METABOLISM 
Table A2.1:  Lipid and metabolites identified by SAM as differentially expressed in 
human patient samples belonging to low- and high-FABP4-expression 
groups based on DESI-MS imaging data analysis performed in the negative 
ion mode.  
Positive SAM scores represent higher relative abundance in samples with low-FABP4-
expression, negative SAM scores represent higher relative abundance in samples with 
high-FABP4-expression. Tentative molecular formulas and chemical identification were 
attributed by high mass accuracy/high mass resolution and tandem MS analyses and are 
provided in supplemental Table 2.  
 
LOW FABP4 EXPRESSION  HIGH FABP4 EXPRESSION 
Attribution  SAM Score Attribution  SAM Score 
Metabolites    Metabolites    
Fumarate 18.1 N-acetylaspartic acid -17.2 
Acetyl-glycine  11.1 Ascorbic acid  -5.9 
Succinate  31.0 Gluconic acid  -41.9 
2-Hydroxy-3-methylbutyric acid  19.1 Phosphatidic acid -6.8 
Taurine  27.3 Fatty Acids    
Pyroglutamate 8.3 FA 14:1  -23.7 
Aspartate 18.9 FA 17:0 -0.5 
3-Hydroxypicolinic acid 40.8 FA hydroxy 16:0 -13.8 
Glutamine  20.8 FA 18:3 -4.1 
Glutamic acid  26.9 FA 18:2 -11.1 
2-Hydroxyglutarate  21.0 FA 18:1 -5.4 
Xanthine 37.7 FA 18:0 -3.6 
Glycerophosphoglycerol  18.4 FA 20:5 -12.2 
Glutathione  42.8 FA 20:4 -27.4 
Fatty Acids    FA 18:2 -17.2 
FA 8:0 29.7 FA 18:1 -21.3 
FA 9:0 29.8 FA hydroxy 20:4  -18.9 
FA 15:0 4.9 FA 18:0 -22.2 
FA 16:1 3.5 FA hydroxy 20:3  -8.6 
FA 20:3 15.1 FA 22:6 -21.3 
FA 20:2 11.2 FA 22:5 -22.6 
FA 20:1 20.2 FA 22:4 -37.6 
FA 20:0 8.8 FA 22:3 -6.2 
FA 22:0 10.8 FA 20:4 -32.2 
FA 23:1 11.2 FA hydroxy 22:6  -6.0 
FA 23:0 7.6 FA 24:5 -16.6 
FA 24:1 21.3 FA 24:4 -17.5 
FA 24:0 21.7 FA 24:3 -0.9 
FA 26:3 11.4 FA 22:4 -33.4 
FA 26:2 17.7 FA hydroxy 24:0  -2.8 
FA 26:1 11.7 Glycerolipids   
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FA 26:0 29.9 MG 18:0 -7.5 
Glycerolipids   MG 22:6 -6.8 
DG 24:0/0:0 10.5 DG 32:1/0:0 -8.2 
Glycerophosphoethanolamines    DG 32:0/0:0 -3.5 
PE 18:1/1:0 11.0 DG 34:3/0:0 -2.3 
PE 20:3/1:0 21.3 DG 34:2/0:0 -6.7 
PE O-34:3 or PE P-34:2 23.0 DG 34:1/0:0 -14.2 
PE O-34:2 or PE P-34:1  21.5 DG 36:4/0:0 -13.3 
PE 34:2 25.3 DG 36:3/0:0 -4.8 
PE 34:1 21.4 DG 36:2/0:0 -15.7 
PE O-36:3 or P-36:2 15.8 DG 38:6/0:0 -18.9 
PE 35:1 9.6 DG 38:5/0:0 -16.0 
PE 36:3 27.4 DG 38:4/0:0 -15.4 
PE 36:2 18.3 DG 40:7/0:0 -2.8 
PE 38:3 27.7 DG 40:6/0:0 -15.6 
Glycerophosphoglycerols    DG 40:5/0:0 -15.1 
PG 18:0/18:1 19.9 Glycerophosphoethanolamines   
PG 18:0/18:0 13.6 LysoPE P-16:0 -3.5 
PG 38:4 6.5 LysoPE O-18:1 -30.4 
PG 38:3 14.0 LysoPE 18:1 -4.2 
PG 38:2 12.2 LysoPE 18:0 -5.8 
PG 42:7 9.5 LysoPE 20:4 -18.6 
Ceramides   PE 20:4/1:0 -36.2 
Cer d18:16:0 13.1 PE 34:0 -0.7 
Cer m18:1/22:0 7.3 PE P-18:0/18:4 -10.5 
Cer m18:1/24:1 20.0 PE O-38:5 or PE P-38:4 -35.7 
Cer m42:1 16.9 PE 38:5 -24.4 
Cer d18:1/23:0 5.7 PE 38:4 -6.4 
Cer d40:0(2OH) 16.9 PE 38:2 -4.1 
Cer d42:1 10.0 PE 38:1 -19.2 
Cer d42:0 21.9 PE 39:6 -17.6 
Cer d18:1/25:0 11.7 PE 39:5 -17.6 
Cer d18:1/26:1 11.4 PE O-40:5 or PE P-40:4 -20.1 
Cer d18:1/26:0 6.8 PE 40:5 -10.2 
PE - Cer 36:3 11.3 PE 37:1 -4.9 
GlcCer d34:1 5.9 PE 40:4 -20.8 
PE-Cer d37:1 14.7 PE 39:4 -4.4 
Monoacylglycerophosphates   PE 39:2 -12.7 
PA 32:0 17.3 PE 39:1 -16.6 
PA 24:2 17.9 PE 41:6 -14.7 
PA 24:1 22.3 PE 41:5 -26.4 
PA 36:4 11.9 PE 41:4 -25.0 
PA 36:3 12.8 PE 43:6 -7.3 
Cardiolipins   PE 43:2 -8.2 
CL 68:5 5.2 Glycerophosphoglycerols    
CL 70:7 25.3 LysoPG 16:0 -7.1 
CL 70:6 20.9 LysoPG 18:2 -20.2 
CL 70:5 11.3 LysoPG 18:1 -18.4 
CL 72:8 20.7 LysoPG 22:6 -11.5 
CL 72:7 26.9 PG 34:3 -0.7 
CL 72:6 26.0 PG 34:2 -1.2 
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CL 74:10 13.3 PG 16:0/18:1 -4.3 
CL 74:9 22.1 PG 36:4 -18.5 
CL 74:8 22.5 PG 18:2/18:1 -4.8 
CL 74:7 18.9 PG 18:1/18:1 -2.3 
CL 76:10 19.9 PG 38:6 -7.6 
CL 76:9 15.0 PG 38:5 -2.8 
CL 76:8 14.3 PG 40:8 -6.2 
CL 76:7 13.4 PG 40:7 -2.8 
CL 36:4 2.8 PG 40:6 -0.7 
Glycerophosphoinositols    PG 40:5 -0.7 
LysoPI (16:0/0:0) 4.4 PG 22:6/22:6 -8.0 
PI (32:1) 22.3 Ceramides   
PI (32:0) 25.4 Cer d32:1 -8.9 
PI (34:2) 28.1 Cer d16:1/17:0 -16.2 
PI (34:1) 25.5 Cer d34:2 -8.5 
PI (O-23:0) 7.8 Cer d34:1 -1.1 
PI (25:1) 21.5 Cer d36:2 -4.7 
PI (36:4) 2.9 Cer d36:1 -17.6 
PI (36:3) 31.7 Cer d38:1  -8.2 
PI (36:2) 45.5 Cer d41:2 -1.3 
PI (36:1) 25.7 Cer d42:0  -0.5 
PI (37:3) 17.9 Cer d42:1 -1.2 
PI (38:6) 20.6 PE-Cer d36:1 -4.1 
PI (38:3) 18.7 Monoacylglycerophosphates  
PI (40:6) 9.9 PA 36:1 -18.2 
PI (39:4) 20.0 PA O-38:2 or PA P-38:1 -11.9 
Glycerophosphoserines   Cardiolipins   
PS P-34:1 4.3 CL 72:4 -7.5 
PS 16:0/18:1 18.6 Glycerophosphoinositols    
PS P-36:2 or PS O-36:3 14.4 LysoPI 15:0 -16.3 
PS O-36:2 or PS P-36:1 4.3 LysoPI O-16:0 -5.8 
PS 36:3 28.2 LysoPI 18:0 -20.1 
PS 36:2 34.3 Lyso PI 20:4 -15.7 
PS 18:0/18:1 17.5 PI O-33:2 or PI P-33:1  -13.0 
PS O-38:4 or P-38:3 4.3 PI P-18:0/17:2 -15.2 
PS 38:3 31.9 PI O-35:2 or PI P-35:1 -1.0 
PS 38:2 30.3 PI 37:4 -3.6 
PS 38:1 23.5 PI 38:6 -15.6 
PS 40:6 13.3 PI 38:5 -15.2 
PS 40:2 17.7 PI 38:4 -27.6 
PS 40:1 21.3 PI 40:4 -18.1 
PS 42:3 15.4 PI 40:3 -8.5 
PS 42:2 17.8 Glycerophosphoserines    
PS 42:1 20.3 PS O-36:4 or PS P-36:3 -6.7 
  PS 38:4 -0.5 
  PS O-39:0 -0.5 
  PS O-40:4 or PS P-40:3 -12.3 
  PS 39:2 -4.9 
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Table A2.2:  Lipid and metabolite molecular attributions for m/z values selected by SAM 
as differentially expressed in human patient samples belonging to low- and 
high-FABP4-expression groups based on DESI-MS imaging data analysis 
performed in the negative ion mode. Tentative molecular formulas and 
chemical identification were attributed by high mass accuracy/high mass 

















Metabolites        Ceramides       
Fumarate C47H84O13P 115.004 -1.7 Cer d32:1 C32H63NO3Cl 544.452 0.9 
Acetyl-glycine  C4H6NO3 116.035 1.7 Cer d16:1/17:0 C33H65NO3Cl 558.466 0.7 




C5H9O3 117.056 -1.7 Cer d34:1 C34H67NO3Cl 572.481 0.5 
Taurine  C2H6NO3S 124.008 -0.8 Cer d18:16:0 C34H69NO3Cl 574.496 1.6 
Pyroglutamate C5H6NO3 128.036 -1.6 Cer d36:2 C36H69NO3Cl 598.496 -1.7 




C6H4NO3 138.020 -0.7 Cer m18:1/22:0 C40H79NO2Cl 640.580 1.4 
Glutamine  C5H9N2O3 145.062 -1.4 Cer d38:1  C40H79NO3Cl 656.575 -0.1 




C5H7O5 147.030 -2.0 Cer d41:2 C41H79NO3Cl 668.577 -0.4 
Xanthine C5H3N4O2 151.026 -1.3 Cer m42:1 C42H83NO2Cl 668.611 1.3 
N-acetylaspartic 
acid 
C6H8NO5 174.041 0.1 Cer d18:1/23:0 C41H81NO2Cl 670.590 2.4 
Ascorbic acid  C6H7O6 175.025 2.3 
Cer 
d40:0(2OH) 
C40H81NO4Cl 674.587 -2.1 
Gluconic acid  C6H11O7 195.051 0.5 Cer d42:0  C42H81NO3Cl 682.590 1.3 
Phosphatidic 
acid 
C6H8O7Cl 226.996 0.9 Cer d42:1 C42H83NO3Cl 684.607 1.0 
Glycerophosph
oglycerol  




306.076 2.6 Cer d42:0 C42H85NO3Cl 686.622 0.3 
Fatty Acids        PE-Cer d36:1 C38H76N2O6P 687.545 -0.4 
FA 8:0 C8H15O2 143.108 0.7 Cer d18:1/25:0 C43H85NO3Cl 698.622 0.3 
FA 9:0 C9H17O2 157.124 -0.6 Cer d18:1/26:1 C44H85NO3Cl 710.626 4.9 
FA 14:1  C14H25O2 225.186 -0.9 Cer d18:1/26:0 C44H87NO3Cl 712.637 1.5 




FA 16:1 C16H29O2 253.217 -0.8 GlcCer d34:1 C40H77NO8Cl 734.532 2.7 






C16H31O3 271.228 0.4 Cardiolipins       
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FA 18:3 C18H29O2 277.217 0.7 CL 68:5 C77H138O17P2 698.472 0.9 
FA 18:2 C18H31O2 279.233 1.1 CL 70:7 C79H138O17P2 710.470 1.8 
FA 18:1 C18H32O2 281.248 0.7 CL 70:6 C79H140O17P2 711.477 3.0 
FA 18:0 C18H35O2 283.264 1.1 CL 70:5 C79H142O17P2 712.484 4.2 
FA 20:5 C20H29O2 301.217 0.7 CL 72:8 C81H140O17P2 723.479 0.4 
FA 20:4 C20H31O2 303.233 1.0 CL 72:7 C81H142O17P2 724.484 3.6 
FA 20:3 C20H33O2 305.248 -1.0 CL 72:6 C81H144O17P2 725.494 0.6 
FA 20:2 C20H35O2 307.264 -1.6 CL 72:4 C81H148O17P2 727.507 -1.9 
FA 20:1 C20H37O2 309.280 2.3 CL 74:10 C83H140O17P2 735.478 1.2 
FA 20:0 C20H39O2 311.295 -1.3 CL 74:9 C83H142O17P2 736.485 2.0 
FA 18:2 C18H32O2Cl 315.209 1.3 CL 74:8 C83H144O17P2 737.492 3.3 
FA 18:1 C18H34O2Cl 317.225 1.3 CL 74:7 C83H146O17P2 738.501 1.1 
FA hydroxy 
20:4  
C20H31O3 319.228 -1.6 CL 76:10 C85H144O17P2 749.492 2.8 
FA 18:0 C18H36O2Cl 319.241 0.6 CL 76:9 C85H146O17P2 750.504 2.9 
FA hydroxy 
20:3  
C20H33O3 321.243 2.5 CL 76:8 C85H148O17P2 751.509 2.0 
FA 22:6 C22H31O2 327.233 1.2 CL 76:7 C85H150O17P2 752.516 2.5 




FA 22:4 C22H35O2 331.264 1.2 Glycerophosphoinositols      
FA 22:3 C22H37O2 333.279 1.5 
LysoPI 
(16:0/0:0) 
C25H48O12P 571.290 1.8 
FA 20:4 C20H32O2Cl 339.209 0.9 PI (32:1) C41H76O13P 807.502 1.6 
FA 22:0 C22H43O2 339.326 1.5 PI (32:0) C41H78O13P 809.514 5.6 
FA hydroxy 
22:6  
C22H31O3 343.230 -5.0 PI (34:2) C43H78O13P 833.517 2.4 
FA 23:1 C23H43O2 351.326 2.3 PI (34:1) C43H80O13P 835.532 2.5 
FA 23:0 C23H45O2 353.342 1.4 PI (O-23:0) C42H83O12PCl 845.532 0.2 
FA 24:5 C24H37O2 357.280 1.1 PI (25:1) C44H82O13P 849.552 -2.4 
FA 24:4 C24H39O2 359.295 0.8 PI (36:4) C45H78O13P 857.517 1.6 
FA 24:3 C24H41O2 361.311 1.7 PI (36:3) C45H80O13P 859.535 -0.6 
FA 24:1 C24H45O2 365.342 1.4 PI (36:2) C45H82O13P 861.549 1.5 
FA 22:4 C22H36O2Cl 367.242 -1.9 PI (36:1) C45H84O13P 863.565 2.8 
FA 24:0 C24H47O2 367.358 1.1 PI (37:3) C46H82O13P 873.551 -0.8 
FA hydroxy 
24:0  
C24H47O3 383.353 1.3 PI (38:6) C47H78O13P 881.520 1.1 
FA 26:3 C26H45O2 389.342 0.8 PI (38:3) C47H84O13P 887.565 -0.2 
FA 26:2 C26H47O2 391.358 1.0 PI (40:6) C49H82O13P 909.547 -3.0 
FA 26:1 C26H49O5 393.373 1.0 PI (39:4) C48H85O13PCl 935.544 2.0 
FA 26:0 C26H51O2 395.389 1.5 Glycerophosphoinositols      
Glycerolipids       LysoPI 15:0 C24H46O12P 557.273 0.5 
MG 18:0 C21H40O4Cl 391.262 1.5 LysoPI O-16:0 C25H50O11P 557.309 0.9 
MG 22:6 C25H38O4Cl 437.246 1.1 LysoPI 18:0 C27H52O12P 599.320 0.5 
DG 24:0/0:0 C27H51O5 455.376 4.0 Lyso PI 20:4 C29H48O12P 619.290 -2.4 
DG 32:1/0:0 C35H66O5Cl 601.459 1.7 
PI O-33:2 or PI 
P-33:1  
C42H79O12PCl 841.501 -1.0 
DG 32:0/0:0 C35H68O5Cl 603.476 0.5 PI P-18:0/17:2 C44H81O12PCl 867.516 0.2 
DG 34:3/0:0 C37H66O5Cl 625.459 1.6 
PI O-35:2 or PI 
P-35:1 
C44H83O12PCl 869.531 0.5 
DG 34:2/0:0 C37H68O5Cl 627.475 1.1 PI 37:4 C46H80O13P 871.534 3.3 
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DG 34:1/0:0 C37H70O5Cl 629.491 0.6 PI 38:6 C47H78O13P 881.516 3.1 
DG 36:4/0:0 C39H68O5Cl 651.475 1.2 PI 38:5 C47H80O13P 883.533 1.1 
DG 36:3/0:0 C39H70O5Cl 653.492 0.2 PI 38:4 C47H82O13P 885.548 1.8 
DG 36:2/0:0 C39H72O5Cl 655.507 0.3 PI 40:4 C49H86O13P 913.579 2.1 
DG 38:6/0:0 C41H68O5Cl 675.475 1.3 PI 40:3 C49H88O13P 915.595 1.7 
DG 38:5/0:0 C41H70O5Cl 677.493 -2.2 Glycerophosphoserines  
DG 38:4/0:0 C41H72O5Cl 679.509 -2.2 PS P-34:1 C40H75NO9P 744.518 1.1 
DG 40:7/0:0 C43H70O5Cl 701.489 3.6 PS 16:0/18:1 C40H75NO10P 760.515 2.0 
DG 40:6/0:0 C43H72O5Cl 703.506 1.6 
PS O-36:4 or 
PS P-36:3 
C42H75NO9P 768.521 -3.4 
DG 40:5/0:0 C43H74O5Cl 705.523 1.1 
PS P-36:2 or PS 
O-36:3 
C42H77NO9P 770.532 2.2 
Glycerophosphoethanolamines     
PS O-36:2 or 
PS P-36:1 
C42H79NO9P 772.549 1.0 
LysoPE P-16:0 C21H43NO6P 436.284 -2.3 PS 36:3 C42H75NO10P 784.513 0.1 
LysoPE O-18:1 C23H47NO6P 464.316 -2.8 PS 36:2 C42H77NO10P 786.528 1.5 
LysoPE 18:1 C23H45NO7P 478.295 -2.5 PS 18:0/18:1 C42H79NO10P 788.546 -2.4 
LysoPE 18:0 C23H47NO7P 480.311 -2.7 
PS O-38:4 or P-
38:3 
C44H79NO9P 796.547 3.9 
LysoPE 20:4 C23H43NO7P 500.280 -2.6 PS 38:4 C44H77NO10P 810.528 1.5 
PE 18:1/1:0 C24H45NO8P 506.288 1.2 PS 38:3 C44H79NO10P 812.544 1.2 
PE 20:4/1:0 C26H43NO8P 528.273 -0.8 PS 38:2 C44H81NO10P 814.558 3.3 
PE 20:3/1:0 C26H45NO8P 530.291 -4.5 PS 38:1 C44H83NO10P 816.574 1.8 
PE O-34:3 or 
PE P-34:2 
C39H73NO7P 698.515 3.3 PS O-39:0 C45H89NO9P  818.625 4.3 
PE O-34:2 or 
PE P-34:1  
C39H75NO7P 700.527 2.1 
PS O-40:4 or 
PS P-40:3 
C46H83NO9P 824.581 0.1 
PE 34:2 C39H73NO8P 714.505 3.8 PS 39:2 C45H83NO10P 828.572 4.3 
PE 34:1 C39H75NO8P 716.522 2.1 PS 40:6 C46H77NO10P 834.527 2.4 




722.512 1.9 PS 40:1 C46H87NO10P 844.606 2.0 
PE O-36:3 or P-
36:2 
C41H77NO7P 726.545 0.8 PS 42:3 C48H87NO10P 868.603 -5.1 
PE 35:1 C40H77NO8P 730.537 3.3 PS 42:2 C48H89NO10P 870.622 -1.1 
PE 36:3 C41H75NO8P 740.520 3.8 PS 42:1 C48H91NO10P 872.637 -1.9 
PE 36:2 C41H77NO8P 742.538 1.9 Glycerophosphoglycerols      
PE O-38:5 or 
PE P-38:4 
C43H77NO7P 750.543 -1.2 LysoPG 16:0 C22H44O9P 483.273 -2.1 
PE 38:5 C43H75NO8P 764.522 -3.2 LysoPG 18:2 C24H44O9P 507.274 -3.1 
PE 38:4 C43H77NO8P 766.538 6.2 LysoPG 18:1 C24H46O9P 509.288 -2.9 
PE 38:3 C43H79NO8P 768.557 -3.3 LysoPG 22:6 C28H44O9P 555.274 -0.7 
PE 38:2 C43H81NO8P 770.566 1.2 PG 34:3 C40H72O10P 743.489 -2.8 
PE 38:1 C43H83NO8P 772.585 1.9 PG 34:2 C40H74O10P 745.502 1.5 
PE 39:6 C44H75NO8P 776.522 1.8 PG 16:0/18:1 C40H76O10P 747.520 1.6 
PE 39:5 C44H77NO8P 778.538 -1.0 PG 36:4 C42H74O10P 769.501 2.3 
PE O-40:5 or 
PE P-40:4 
C45H81NO7P 778.576 0.5 PG 18:2/18:1 C42H76O10P 771.520 -2.5 




794.549 -0.8 PG 18:0/18:1 C42H80O10P 775.548 1.7 
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876.629 0.8 PG 40:6 C46H78O10P 821.531 3.5 
Monoacylglycerophosphates     PG 40:5 C46H80O10P 823.548 1.8 
PA 32:0 C35H68O8P 647.468 3.2 PG 42:7 C48H80O10P 847.546 3.8 
PA 24:2 C37H68O8P 671.464 2.2 PG 22:6/22:6 C50H74O10P 865.500 3.4 
PA 24:1 C37H70O8P 673.481 1.6     
PA 36:4 C39H68O8P 695.465 1.6     
PA 36:3 C39H70O8P 697.480 1.9     
PA 36:1 C39H74O8P 701.512 1.0     
PA O-38:2 or 
PA P-38:1 
C41H79O7PCl 749.528 1.3 





APPENDIX A3: SPATIALLY CONTROLLED MOLECULAR ANALYSIS OF BIOLOGICAL 
SAMPLES USING NANODROPLET ARRAYS AND DIRECT DROPLET ASPIRATION  
 
Figure A3.1: Imaging workflow with uncoupled droplet deposition and analysis, 
illustrated for a single line of 11 droplets.  
Droplets were deposited onto tissue samples at a rate of a droplet per second. The sample 
slide was transported after deposition of the droplet line and mounted on a 2D moving stage 
in approximately under 40 seconds. Time between droplet analysis was measured to be 4.1 
± 1.1 s (n=10). Note that maximum difference in t2 is 30 s between the first and last droplet. 






















Volume per drop 
(nL) 
1 5000 0.0024 0.50 
2 5000 0.0023 0.48 
3 5000 0.0024 0.50 
4 6000 0.0027 0.47 
5 6000 0.0027 0.47 
6 6000 0.0028 0.49 
 
0.0024 𝑔 × 
1.00 𝑚𝐿
0.9605 𝑔
 = 0.0024986 𝑚𝐿 
0.0024986 𝑚𝐿
5000 𝑑𝑟𝑜𝑝𝑠
= 4.9974 𝑥 10−7𝑚𝐿 𝑝𝑒𝑟 𝑑𝑟𝑜𝑝 ~ 0.50 𝑛𝐿 𝑝𝑒𝑟 𝑑𝑟𝑜𝑝 
 
Figure A3.2: Volume determination for single DMF droplets using change in mass.  
Using the picoliter dispenser, drops were dispensed into plastic Eppendorf tubes and sealed 
prior to obtaining mass of the dispensed droplets. Density of DMF was experimentally 
determined gravimetrically, and was used to determine the volume dispensed, and the 
volume per drop for each trial. Dispensed drops were determined to contain 0.49 ± 0.01 nL 
DMF per drop (avg ± st dev).  
















Figure A3.3: Optical image of the discrete droplet sampling setup coupled to a Q Exactive 
Orbitrap system.  
A cable connecting the MS voltage source and the emitter arm was used to provide a 
voltage bias to the silica emitter. A metal rod going from the voltage pin to the emitter 
grasper ensured conductivity through the arm holder. The rest of the arm material was 
made from PTFE to reduce weight and protect the user from the high voltage source (A). 
Zoom-in view of the silica emitter grasped by the arm holder and aligned with the transfer 





Table A3.1:  Properties of different solvent systems used for lipid analysis by MS.  
 
Properties DMF Water Ethanol ACN Methanol 
Vapor Pressure (Torr) 3 18 44 89 97 
Surface Tension (mN/m) 37 73 22 19 23 



















Figure A3.4: Discrete droplet sampling spectra obtained from analyzing droplets of 
different solvent composition deposited on mouse brain homogenate tissue 
sections.  
Species are color-coded according to class: metabolites, fatty acids, ceramides (Cer), 
glycerophosphoglycerol (PG), glycerophosphoserine (PS), sulfatide (ST), 







Table A3.2:  Diameters and corresponding volumes and number of drops for droplets 
dispensed as arrays onto mouse brain tissue samples.  
Standard deviations and RSDs are shown as metrics for size reproducibility of replicate 














Average RSD (%) 
50.0 100 647.0 6 6.0 0.9 1.5 
45.0 90 629.0 5 3.8 0.6 St. Dev RSD (%) 
40.0 80 610.3 10 6.7 1.1 0.7 
35.0 70 593.2 10 6.0 1.0  
32.5 65 566.1 10 6.4 1.1  
30.0 60 554.5 10 7.7 1.4  
27.5 55 546.5 10 4.9 0.9  
25.0 50 519.6 10 6.9 1.3  
22.5 45 499.1 10 15.9 3.2  
20.0 40 491.4 10 10.2 2.1  
17.5 35 474.3 10 6.3 1.3  
15.0 30 457.3 10 8.2 1.8  
12.5 25 437.1 10 8.9 2.0  
10.0 20 399.6 10 3.4 0.9  
7.5 15 370.6 10 5.7 1.5  
5.0 10 322.6 10 5.9 1.8  








Figure A3.5: Lines of droplets of 20, 15, and 10 nL volumes deposited onto mouse brain 
tissue sections.  
Optical images were taken following dispensing of the droplets and transferring the slide 























Figure A3.6: Comparison of mass spectra obtained from brain lipid extract analysis by ESI 
(top) and discrete droplet sampling (bottom).  
Lipids were extracted directly from brain tissue sections with DMF and diluted in a 1:1 
mixture of ACN:DMF. A 5 µL/min flow rate of was used for ESI experiments. Lipid 
droplets of 0.2 µL volume were analyzed. Note that the solution used for direct droplet 




Table A3.3:  Measured diameters for droplets used in MS imaging of mouse brain tissue 
samples shown in Figure 4.3.  
Measurements were obtained using a calibrated Dino Lite Microscope camera. Note that 
these values are slightly different than those reported Table S2 due to slight changes in 









 Diameter (µm) N St. Dev 
RSD 
(%) 
20 drops 386.6 10 11.9 3.1 
30 drops 424.1 7 10.8 2.6 




Figure A3.7: Total ion count versus droplet-to-surface contact time (extraction time).   
Replicate lines of 50 nL droplets (n= 7-13 droplets per extraction time) were deposited 
onto mouse brain homogenate tissue samples and analyzed by discrete droplet sampling. 
No overall trend in total ion count was observed as a function of extraction time within the 
times evaluated. An ANOVA test was also performed (p-value = 0.079) revealing a non-





















Figure A3.8: Total ion current chromatograms for eight consecutive droplet lines used for 
MS imaging of a mouse brain tissue sample at a spatial resolution of 424 ± 
11 µm.  
Each spike in ion current corresponds to the analysis of an individual droplet of ~15 nL 
volume. Note that the number of spikes/droplets changes between the lines due to changes 










Figure A3.9: Representative MS/MS spectra of lipid species detected from mouse brain 
tissue samples.  
Tandem MS measurements were performed using HCD and the orbitrap for analysis. Note 
that fatty acid chain stereochemistry, as well as double bond positions, are not determined 

















Table A3.4:  Most abundant m/z values detected from MS analysis of mouse brain tissue 
sections.  
Attributions were assigned based on high mass accuracy and tandem MS measurements. 
Lipid species are defined by number of carbons and double bonds in the fatty acid chains. 
 
Detected m/z Ion Attribution Molecular Formula Mass Error (ppm) 
255.233 M-H FA 16:1 C16H33O2 0.4 
281.249 M-H FA 18:1 C18H33O2 -0.4 
283.264 M-H FA 18:0 C18H35O2 0.4 
303.233 M-H FA 20:4 C20H31O2 -0.1 
327.233 M-H FA 22:6 C22H31O2 -0.6 
598.498 M+Cl Cer d36:2 C36H69NO3Cl -1.7 
600.513 M+Cl Cer d36:1 C36H71NO3Cl -0.8 
721.504 M-H PG 32:0 C38H74O10P -1.9 
747.519 M-H PG 34:1 C40H76O10P -1.1 
762.509 M-H PE 38:6 C43H73NO8P -1.2 
766.541 M-H PE 38:4 C43H77NO8P -1.8 
774.544 M-H PE P-18:0/22:6 C45H77NO7P -0.1 
788.546 M-H PS 34:1 C42H79NO10P -1.3 
790.540 M-H PE 40:6 C45H77NO8P -0.9 
806.546 M-H ST 18:0 C42H80NO11S -0.4 
822.545 M-H ST 18:0 (OH) C42H80NO12S -5.1 
834.530 M-H PS 40:6 C46H77NO10P -1.2 
844.645 M+Cl Gal/GluCer d24:1 C48H91NO8Cl -1.7 
857.519 M-H PI 36:4 C45H78O13P -0.8 
865.503 M-H PG 44:12 C50H74O10P -0.8 
885.550 M-H PI 38:4 C47H82O13P -0.1 




Figure A3.10: Representative mouse brain tissue mass spectra acquired using discrete 
droplet sampling and DESI from grey matter (A) and white matter (B).  
A dashed blue line is included in the grey matter spectra to show the difference in the 








Figure A3.11: Representative mouse brain tissue DESI-MS spectra acquired using DMF 







Table A3.5:  Most abundant m/z values detected from analysis of ovarian cancerous and 
normal tissue samples.  
Attributions were assigned based on high mass accuracy and tandem MS measurements. 
Lipid species are defined by number of carbons and double bonds in the fatty acid chains. 
*Species mostly found in ovarian cancer necrotic spectra. 
 
Detected m/z Ion Attribution Molecular Formula Mass Error (ppm) 
124.006 M-H Taurine C2H6NO3S 9.7 
175.024 M-H Ascorbic Acid C6H7O6 3.4 
281.249 M-H FA 18:1 C18H33O2 -1.8 
572.483 M+Cl Cer d34:1 C34H67NO3Cl -3.3 
588.478 M+Cl Cer d34:1 (2OH) C34H67NO4Cl -3.2 
600.515 M-Cl Cer d36:1 C36H71NO3Cl -4.3 
629.496 M+Cl DG 34:1 C37H70O5Cl -6.5 
656.580 M+Cl Cer d40:2 C40H79NO3Cl -6.7 
682.595 M+Cl Cer d42:2 C42H81NO3Cl -5.7 
684.608 M+Cl Cer d42:1 C42H83NO3Cl -1.5 
722.516 M-H PE P-36:4 C41H73NO7P -3.7 
*734.537 M+Cl Glu/GalCer d 34:1 C40H77NO8Cl -3.1 
742.543 M-H PE 36:2 C41H77NO8P -5.3 
744.558 M-H PE 36:1 C41H79NO8P -3.9 
747.521 M-H PG 34:1 C40H76O10P -4.1 
748.531 M-H PE P-38:5 C43H75NO7P -3.6 
750.546 M-H PE P-38:4 C43H77NO7P -2.7 
766.543 M-H PE 38:4 C43H77NO8P -4.4 
771.519 M-H PG 36:3 C42H76O10P -1.2 
773.535 M-H PG 36:2 C42H78O10P -2.1 
788.549 M-H PS 34:1 C42H79NO10P -6.0 
792.533 M+Cl PC 34:2 C42H80NO8PCl -1.3 
794.548 M+Cl PC 34:1 C42H82NO8PCl -1.1 
816.535 M+Cl PC 36:4 C44H80NO8PCl -3.8 
818.550 M+Cl PC 36:3 C44H82NO8PCl -3.4 
835.537 M-H PI 34:1 C43H80O13P -3.8 
842.551 M+Cl PC 38:4 C46H82NO8PCl -4.0 
844.567 M+Cl PC 38:3 C46H84NO8PCl -5.1 
857.522 M-H PI 36:4 C45H78O13P -3.8 
861.553 M-H PI 36:2 C45H82O13P -3.2 
865.506 M-H PG 44:12 C50H74O10P -4.3 
885.553 M-H PI 38:4 C47H82O13P -3.3 
*896.591 M+Cl PC 42:6 C50H88NO8PCl 3.7 
913.584 M-H PI 40:4 C49H86O13P -3.0 
*980.685 M+Cl LacCer(d40:1) C52H99NO13Cl -3.6 
*1004.685 M+Cl LacCer(d18:1/24:0) C54H99ClNO13 -4.1 






Figure A3.12: Representative MS profile obtained from a necrotic region of a cancerous 













Table A3.6:  Most abundant m/z values detected from MS analysis of human cancerous 
and normal brain tissue samples.  
Attributions were assigned based on high mass accuracy and tandem MS measurements. 
Lipid species are defined by number of carbons and double bonds in the fatty acid chains. 
 
Detected m/z Ion Attribution Molecular Formula Mass Error (ppm) 
124.006 M-H Taurine C2H6NO3S 12.1 
126.904 M Iodine I 11.0 
151.025 M-H Xanthine C5H3N4O2 7.9 
174.040 M-H NAA C6H8NO5 6.3 
175.024 M-H Ascorbic Acid C6H7O6 6.9 
215.032 M+Cl Hexose C6H12O6Cl 3.7 
255.233 M-H FA 16:1 C16H33O2 1.6 
281.249 M-H FA 18:1 C18H33O2 -0.4 
283.264 M-H FA 18:0 C18H35O2 1.4 
303.233 M-H FA 20:4 C20H31O2 2.0 
327.233 M-H FA 22:6 C22H31O2 0.9 
331.265 M-H FA 22:4 C22H35O2 -0.9 
572.483 M+Cl Cer d34:1 C34H67NO3Cl -3.3 
598.499 M+Cl Cer d36:2 C36H69NO3Cl -2.7 
600.515 M-Cl Cer d36:1 C36H71NO3Cl -3.2 
682.594 M+Cl Cer d42:2 C42H81NO3Cl -3.8 
700.529 M-H PE P-24:1 C39H75NO7P -0.4 
722.515 M-H PE P-36:4 C41H73NO7P -2.5 
726.545 M-H PE P-36:2 C41H77NO7P -1.2 
742.541 M-H PE 36:2 C41H77NO8P -2.8 
744.557 M-H PE 36:1 C41H79NO8P -2.4 
747.521 M-H PG 34:1 C40H76O10P -3.3 
748.530 M-H PE P-38:5 C43H75NO7P -1.5 
750.545 M-H PE P-38:4 C43H77NO7P -0.8 
766.543 M-H PE 38:4 C43H77NO8P -4.4 
774.544 M-H PE P-40:6 C45H77NO7P 0.4 
788.549 M-H PS 34:1 C42H79NO10P -6.0 
790.540 M-H PE 40:6 C45H77NO8P -0.9 
794.548 M+Cl PC 34:1 C42H82NO8PCl -1.1 
806.548 M-H ST 18:0 C42H80NO11S -2.1 
810.530 M-H PS 38:4 C44H77NO10P -0.9 
816.532 M+Cl PC 36:4 C44H80NO8PCl -0.4 
834.531 M-H PS 40:6 C46H77NO10P -2.8 
838.563 M-H PS 40:4 C46H81NO10P -2.5 
844.646 M-H PS P-41:0 C47H91NO9P -2.4 
857.520 M-H PI 36:4 C45H78O13P -1.9 
860.639 M-H PS 41:0 C47H91NO10P -0.8 
885.551 M-H PI 38:4 C47H82O13P -1.4 
888.625 M-H ST 24:1 C48H90NO11S -1.2 
904.618 M-H ST 24:1 (OH) C48H90NO12S 1.4 
906.632 M-H ST 24:0 (OH) C48H92NO12S 2.4 
909.550 M-H PI 40:6 C49H82O13P 0.1 
916.657 M-H ST 26:1 C50H94NO11S -1.9 
932.652 M-H ST 26:1 (OH) C50H94NO12S -1.5 
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Figure A3.13: Representative MS profiles detected from human ovarian cell pellets 
deposited and dried on a glass slide. Droplets of 0.2 µL volume were 












Table A3.7:  Method reproducibility.  
Cosine analyses comparing  mass spectra from the same pixels in three mouse brain tissue 
serial sections (top), and from pixels in a homogenous ovarian tumor region from two serial 
sections (bottom). Note that cosine analysis provides similarity values ranging from 0 
(dissimilar or orthogonal vectors) to 1 (identical or parallel vectors). 
 
 
 Cosine Analysis  
Mouse Brain Pixel 1 Pixel 2 Pixel 3 Pixel 4 Pixel 5 
All Pixels 
Combined 
Line 1 vs Line 
2 
0.970 0.898 0.955 0.914 0.920 - 
Line 1 vs Line 
3 
0.692 0.904 0.885 0.987 0.918 - 
Line 2 vs Line 
3 
0.721 0.983 0.892 0.944 0.800 - 
Average 0.794 0.928 0.911 0.948 0.880 0.892 
SD 0.153 0.047 0.039 0.037 0.069 0.089 
Ovarian Tumor 
Pixel 1 vs 
Pixel 1 
Pixel 2 vs 
Pixel 2 
Pixel 1 vs 
Pixel 2 
Pixel 2 vs 
Pixel 1 
- - 
Line 1 vs Line 
2 
0.902 0.829 0.897 0.881 - - 
Line 1 vs Line 
2 





















Table A3.8:  Ratio between ion abundances at m/z 834.530 and 885.550 evaluated from 




1 1 0.688 
 2 0.673 
 3 0.822 
2 1 0.688 
 2 0.904 
 3 0.784 
3 1 0.686 
 2 0.786 
 3 0.931 
4 1 0.707 
 2 0.769 
 3 0.700 
5 1 0.703 
 2 0.659 
 3 0.696 
AVG 0.746 
SD 0.084 





















Figure A3.14: Demonstrating imaging performance.  
Ion images and corresponding hematoxylin & eosin (H&E) stain of a normal human 
brain tissue sample (A). Extracted ion chromatographs for ion m/z 700.529 (top) and m/z 





APPENDIX A4: NONDESTRUCTIVE TISSUE ANALYSIS FOR EX VIVO AND IN VIVO CANCER 
DIAGNOSIS USING A HANDHELD MASS SPECTROMETRY SYSTEM 
 
 
Figure A4.1:  Effect of MasSpec Pen contact time on the mass spectra obtained.  
Representative negative ion mode mass spectra obtained from mouse brain tissue sections 











Table A4.1: Patient demographics of the 253 human tissue samples used in this study. 
 
Patient Diagnosis Median Age, Years Age Range, Years 
Number of 
Patients by Gender 
(Male, Female) 
Number of 




Normal 47 24-76 (0,29) (21,7,1,0) 
Cancer 58 41-75 (2,14) (10,2,4,0) 
Lung 
Normal 57 12-82 (33,14) (35,12,0,0) 
Cancer 66 22-84 (25,23) (35,7,0,6) 
Ovary 
Normal 50 31-80 (0,29) (22,7,0,0) 
Cancer 62 30-83 (0,28) (25,2,0,1) 
Thyroid 
Normal 40 18-80 (10,17) (18,7,0,2) 
Cancer 49 16-81 (12,17) (21,4,0,4) 
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Figure A4.2: Intraoperative analysis of tumor and normal tissues in a murine model.  
Optical and histological images of tissue during and after intraoperative MassSpec pen 
analysis in a mouse model. The H&E stained tissue section (inset) was obtained from the 






























Figure A4.3:  MasSpec Pen analysis of the same tissue sample in vivo and ex vivo.  
Representative MasSpec Pen negative ion mode mass spectra obtained in vivo and ex vivo 




APPENDIX A5: PERFORMANCE OF THE MASSPEC PEN FOR RAPID DIAGNOSIS OF 
OVARIAN CANCER  
Table A5.1:  Patient demographic information for fallopian tube and peritoneum samples 
analyzed with the MasSpec Pen.  
FT (n=7) and peritoneum (n=4) frozen tissue samples were received from the MD 
Anderson and CHTN Tissue Banks, respectively. Additional FT (n=8 samples from 6 
patients) and peritoneum samples (n=12 samples from 11 patients) were prospectively 
collected by the Seton Medical Center (Austin, TX) as fresh surgical specimens from 







Parameter Fallopian Tube Peritoneum  
Number of Patients (N) 13 16 
Tissue Origin (MD Anderson Tissue Bank, CHTN, Tissue Bank, 
Seton Medical Center) 
(7,0,6) (0,4,12) 
Median Age, Years 61 36 
Age Range, Years (31,86) (29, 74) 
Number of Patients by Race 
(9,0,0,0,6) (3, 0,0,0,13) 
(White, Black, Asian, Hispanic, Unknown) 
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Table A5.2: Ion identities and molecular formula attributed by high mass accuracy/high 
mass resolution and tandem MS measurements for species detected from 
MasSpec Pen analysis of HGSC, LGSC and normal ovarian tissue.  
Deviations from exact mass are provided as mass error in ppm. Stereochemistry or double 




















124.007 [M-H]– Taurine C2H6NO3S 5.6 
146.046 [M-H]– Glutamate C5H8NO4 2.7 




Lactate C6H10O6Na 0.5 
215.033 [M+Cl] – Hexose C6H12O6Cl -2.8 
306.077 [M-H]– Glutathione C10H16N3O6S -2.3 
701.514 [M-H]– PA 18:0_18:1 C39H74O8P -1.7 
722.514 [M-H]– PE P-16:0_20:4 C41H73NO7P -1.7 
750.546 [M-H]– PE P-18:0_20:4 C43H77NO7P -1.7 
788.546 [M-H]– PS 18:0_18:1 C42H79NO10P -1.8 
835.536 [M-H]– 




PI 18:1_18:1 or 
18:0_18:2 
C45H82O13P -1.6 
863.567 [M-H]– PI 18:1_18:0 C45H84O13P -2.2 
885.551 [M-H]– PI 18:0_20:4 C47H82O13P -1.6 
909.552 [M-H]– PI 18:0_22:6 C49H82O13P -2.3 
913.582 [M-H]– PI 18:0_22:4 C49H86O13P -0.7 
 201 
 
Figure A5.2: Tandem mass spectra obtained by higher-energy collision induced 
dissociation and MasSpec Pen analysis of ovarian tissue samples in the 
negative ion mode.  
Representative complex glycerophospholipids and metabolites were evaluated. Proposed 
molecular structure and fragmentation sites are shown for each species. [M-H]- Taurine 
(A), [M-H]- Glutamate (B), [M-H]- Ascorbate (C), [2M-2H+Na]-Lactate (D), [M-H]- PE P-




Figure A5.3: Representative MasSpec Pen mass spectra obtained from the three analyzed 







Table A5.3:  Lasso results for normal versus HGSC (top), normal versus cancer (middle), 
and normal versus HGSC versus LGSC (bottom) classification.  
Rows represent classification based on pathological evaluation, columns represent 
classification based on Lasso prediction. Results show agreements with pathology for train 
and test sets, when applicable. Performance is reported as sensitivity (true positive rate), 
specificity (true negative rate) and overall accuracy (% of correctly classified patients for 






Pathology Lasso Prediction 
Normal vs 
HGSC 









Normal 31 1 - 
100.0 96.8 98.3 
HGSC 0 28 - 
Validation 
Normal 11 0 - 
100.0 100.0 100.0 
HGSC 0 8 - 
Test 
Normal 26 2 - 
91.7 92.9 92.3 
HGSC 2 22 - 
Normal vs 
Cancer 









Normal 32 1 
93.9 96.9 95.4 
Cancer 2 31 
Validation 
Normal 9 1 
100.0 90.0 95.0 
Cancer 0 10 
Test 
Normal 26 2 
91.7 92.9 92.3 









Normal 43 0 0 100.0 
97.7 HGSC 0 36 0 100.0 









Table A5.4:  Ion identities and molecular formula attributed by high mass accuracy/high 
mass resolution and tandem MS measurements for species detected from 
MasSpec Pen analysis of fallopian tube and peritoneum tissue samples.  
Deviations from exact mass are provided as mass error in ppm. Stereochemistry or double 
bond position is not known for the identified species. 
  
Detected m/z Ion Attribution Molecular Formula Mass Error 
175.023 M-H Ascorbate C6H7O6 9.2 
215.031 M+Cl Glucose C6H12O6Cl 7.0 
267.073 M-H Inosine C10H11N4O5 3.0 
279.232 M-H FA 18:2 C18H31O2 3.9 
281.247 M-H FA 18:1 C18H33O2 4.3 
391.261 M+Cl MG 18:1 C21H40O4Cl 3.6 
537.487 M-H FA dimer 18:0 - 16:0 C34H65O4 3.5 
563.503 M-H FA dimer 18:1 - 18:0 C36H67O4 3.5 
585.485 M+Na-2H FA dimer 18:1 - 18:0 C36H66O4Na 3.1 
615.168 M-H Heme C34H31FeN4O4 3.4 
655.505 M+Cl DG 36:2 C39H72O5Cl 3.2 
700.528 M-H PE P-34:1 C39H75NO7P 1.0 
701.514 M-H PA 36:1 C39H74O8P -1.7 
722.514 M-H PE P-36:4 C41H73NO7P -1.7 
742.538 M-H PE 36:2 C41H77NO8P 2.3 
750.546 M-H PE O-38:5 C43H77NO7P -1.7 
788.546 M-H PS 36:1 C42H79NO10P -1.8 
810.527 M-H PS 38:4 C44H77NO10P 2.5 
835.536 M-H PI 34:1 C43H80O13P -1.6 
857.519 M-H PI 36:4 C45H78O13P -0.8 
861.551 M-H PI 36:2 C45H82O13P -1.6 
863.567 M-H PI 36:1 C45H84O13P -2.2 
885.551 M-H PI 38:4 C47H82O13P -1.6 
891.720 M+Cl TG 52:3 C55H100O6Cl 2.1 
909.552 M-H PI 40:6 C49H82O13P -2.3 
913.582 M-H PI 40:4 C49H86O13P -0.7 
917.735 M+Cl TG 54:4 C57H102O6Cl 2.3 
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Table A5.5:  Ion identities and molecular formula attributed by high mass accuracy/high 
mass resolution and tandem MS measurements for species detected from 
MasSpec Pen analysis of fallopian tube and peritoneum tissue samples.  
Deviations from exact mass are provided as mass error in ppm. Stereochemistry or double 
bond position is not known for the identified species. 
 
 
Detected m/z Ion Attribution Molecular Formula Mass Error 
175.023 M-H Ascorbate C6H7O6 9.2 
215.031 M+Cl Glucose C6H12O6Cl 7.0 
267.073 M-H Inosine C10H11N4O5 3.0 
279.232 M-H FA 18:2 C18H31O2 3.9 
281.247 M-H FA 18:1 C18H33O2 4.3 
391.261 M+Cl MG 18:1 C21H40O4Cl 3.6 
537.487 M-H FA dimer 18:0 - 16:0 C34H65O4 3.5 
563.503 M-H FA dimer 18:1 - 18:0 C36H67O4 3.5 
585.485 M+Na-2H FA dimer 18:1 - 18:0 C36H66O4Na 3.1 
615.168 M-H Heme C34H31FeN4O4 3.4 
655.505 M+Cl DG 36:2 C39H72O5Cl 3.2 
700.528 M-H PE P-34:1 C39H75NO7P 1.0 
701.514 M-H PA 36:1 C39H74O8P -1.7 
722.514 M-H PE P-36:4 C41H73NO7P -1.7 
742.538 M-H PE 36:2 C41H77NO8P 2.3 
750.546 M-H PE O-38:5 C43H77NO7P -1.7 
788.546 M-H PS 36:1 C42H79NO10P -1.8 
810.527 M-H PS 38:4 C44H77NO10P 2.5 
835.536 M-H PI 34:1 C43H80O13P -1.6 
857.519 M-H PI 36:4 C45H78O13P -0.8 
861.551 M-H PI 36:2 C45H82O13P -1.6 
863.567 M-H PI 36:1 C45H84O13P -2.2 
885.551 M-H PI 38:4 C47H82O13P -1.6 
891.720 M+Cl TG 52:3 C55H100O6Cl 2.1 
909.552 M-H PI 40:6 C49H82O13P -2.3 
913.582 M-H PI 40:4 C49H86O13P -0.7 
917.735 M+Cl TG 54:4 C57H102O6Cl 2.3 
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Table A5.6:  Lasso results for discrimination of HGSC and cancer samples from FT and 
peritoneum.   
Rows represent classification based on pathological evaluation, columns represent 
classification based on Lasso prediction. Results show agreements with pathology for train 
and test sets, when applicable. Performance is reported as sensitivity (true positive rate), 
specificity (true negative rate) and overall accuracy (% of correctly classified patients for 













Pathology Lasso Prediction 
 HGSC FT Sensitivity (%) Specificity (%) Overall Accuracy (%) 
HGSC 32 4 
88.9 100.0 91.5 
FT 0 11 
 Cancer FT    
Cancer 39 4 
90.7 100.0 92.6 
FT 0 11 
 HGSC Peritoneum    
HGSC 29 7 
80.6 100.0 86.3 
Peritoneum 0 15 
 Cancer Peritoneum    
Cancer 36 7 
83.7 100.0 87.9 
Peritoneum 0 15 
 207 
 
Figure A5.4: Representative metabolic profiles obtained by averaging three mass spectra 
obtained from MasSpec Pen analysis of high-grade serous carcinoma (top), 
and normal ovarian tissue (bottom) with an ion trap analyzer.  












Table A5.7:  Comparison of Lasso prediction results for normal vs HGSC using the 
MasSpec Pen coupled to an orbitrap (top) or ion trap (bottom) mass analyzer.  
Rows represent classification based on pathological evaluation, columns represent 
classification based on Lasso prediction. Results show agreements with pathology for train 
and test sets. Performance is reported as sensitivity (true positive rate), specificity (true 





Pathology Lasso Prediction 
Orbitrap 








Normal 14 1 
86.7 93.3 90.0 
HGSC 2 13 
Validation 
Normal 5 0 
80.0 100.0 90.0 
HGSC 1 4 
Ion Trap 








Normal 15 0 
100.0 100.0 100.0 
HGSC 0 15 
Validation 
Normal 5 0 
100.0 100.0 100.0 
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